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THIS ISSUE OF MEDICOGRAPHIA DEALS WITH THE CORE SYMP-toms of depression, a topic that is not only relevant for the diagnosisand treatment of depression, but also for theories about its etiopatho-genesis. This subject can be addressed from different perspectives, as
is apparent in the various contributions in this issue. The first group of articles covers a clinical
point of view, and each asks whether certain specific symptoms like depressed mood, retardation
and anhedonia, sleep disturbances, or sexual disorders belong to the core symptoms of depres-
sion. Other articles describe the assessment of core symptoms of depression and discuss the
psychometric relevance of specific symptoms for the subtyping of major depressive disorders.
Etiopathogenetic factors such as chronobiological and brain imaging aspects are also covered.
Finally, the question of how to deal with the core symptoms of depression in primary care, and
which core symptoms of depression should be addressed first, are topics of further contributions. 
All these are important issues, and different clinical and research approaches have been try-
ing for a long time to clarify them. In the following, I endeavor to show some examples of the
issues at hand in order to highlight the relevance of these questions.
It has long been a tradition, on the basis of clinical experience, to distinguish different sub-
types of depression and their associated symptom profiles. Melancholic depression, formerly
also referred to as endogenous depression, is seen to be the prototype of a “biological” depres-
sion and the type most likely to respond positively to antidepressants. This condition has been
a topic of discussion for a long time, and was recently addressed by Parker et al1 on the basis of
new research data focusing on the relevance of somatic symptoms, among others. On the basis
of results of routine care documentation, Parker and colleagues came to the conclusion that
tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) were the most effec-
tive pharmacological treatments for melancholic depression, while the newer agents (selective
serotonin reuptake inhibitors [SSRIs], reversible inhibitors of monoamine oxidase A, and anti-
psychotic drugs) were much less effective. In a subsequent publication, albeit of preliminary re-
sults, Parker found that although TCAs and SSRIs did not differ distinctly in their effectiveness
in younger patients with melancholia, SSRIs were less effective in older melancholic patients,
and that this effect was unlikely to be secondary to age of disorder onset or to the length of life-
time depressive experience.2 In the author’s view, an understanding of the impact of age on an-
tidepressant drug response across melancholic and nonmelancholic depressive subtypes may
help to clarify differential drug effectiveness patterns, and to link the underlying neuropatholog-
ical changes to clinical management, including choice of antidepressant.
The traditional concept of atypical depression, which has recently gained renewed interest,
presents, to a certain degree, quite the opposite situation. In contrast to “typical” depression,
major depression, and especially its most representative subtype, melancholic depression, is
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characterized by symptoms such as mood reactivity and increased sleep and appetite.3 Atypical
depression is not as rare as is sometimes believed: a frequency of up to 20% to 30% has been re-
ported in an outpatient setting.3 Atypical depression does not seem to respond well to classic
antidepressants like the TCAs, but to be more sensitive to MAOIs.4 Most clinical research has been
conducted on traditional MAOIs. The newer selective and reversible inhibitors of MAO-A promise
lower toxicity and better tolerance and may thus turn out to be a better alternative than the older
MAOIs. It has been hypothesized that the serotonin system may be involved in the etiopatho-
genesis of atypical depression5; in this case, SSRIs could be expected to show clinical efficacy in
this subtype of depression; however, as yet insufficient data on this question are available. 
Other subtypes of depression also seem to be of clinical relevance, for example, psychotic
depression, anxious depression, agitated depression, retarded depression, etc. All these subtypes
have implications in terms of drug treatment, for example, combination of an antidepressant and
a neuroleptic in psychotic depression, or of an antidepressant and a benzodiazepine in anxious
depression.
Besides their relevance to clinical decision-making, these subtypes may also be of interest in
neurobiological research. Although no clear associations between these different features and
any particular neurobiological parameter have been found to date, it can be expected that the de-
velopment of more sophisticated methods like molecular genetics will increase the chance of
discovering such links.
Bipolar depression is also relevant in this context. Differential diagnosis is primarily based
on aspects of the disease course (manic/hypomanic episodes). However, some experts emphasize
that there might also be some differences in the cross-sectional pattern of clinical symptoms.
This view seems primarily to stem from the existence of mixed states, during which patients
experience both depressive and (some) manic symptoms.
Besides these clinically based differentiations and subtypes, the field of psychopathometrics
developed as another line of research to try to differentiate between core and secondary/asso-
ciated symptoms. Factor analyses and other multivariate approaches were applied to data ob-
tained from measurements with depression scales in cross-sectional and longitudinal studies
in an attempt to define subdimensions of depressive symptomatology like the Hamilton De-
pression Scale (HAMD) subscores for “depressive inhibition,” “depressive agitation,” “anxiety,”
and “somatic symptoms.” The question of depressive core symptoms was also addressed in this
context6,7 as well as their relevance for response to treatment with antidepressants.7-9 Bech et al
first defined the melancholia subscale (now referred to as the “HAMD depression factor”) of the
HAMD using a probabilistic test model. They found that the original 17-item HAMD was with-
out adequate consistency as a measure of the severity of depressive states and that a subscale
consisting of the 6 items depressed mood, guilt, work and interests, retardation, psychotic anx-
iety, and general somatic symptoms delivered more reliable results.10 In later meta-analyses,
Bech and colleagues showed that the 6-item depression factor was more sensitive to detecting
antidepressive effects of fluoxetine7 and mirtazepine9 than the total 17-item HAMD. Similar
results were obtained by using another statistical approach, the facet theory in combination with
nonmetric multidimensional scaling procedures.6 In an evaluation of two sertraline-amitripty-
line studies,11,12 it was found that the efficacy of TCAs was no longer superior to that of the SSRIs
when only the core symptoms of depression were considered instead of the full HAMD scale.8
The total score of the HAMD seems to have an inherent bias toward more sedative antide-
pressants, but this bias can be avoided by considering the depression factor, while the addition-
al items of the HAMD-17 can be used to describe other characteristics of the depressive symp-
tomatology.
In recent years, extensive research has been performed to evaluate how best to screen for
and diagnose depression in primary care.13,14 The results indicate that symptoms that are tra-
ditionally not seen as being core or “specific” symptoms, but that occur very frequently in de-
pression, such as reduced well-being or sleep problems, can be used very effectively for screening
purposes. This underlines the importance of sleep disturbances—which are not only very com-
mon symptoms in primary care patients, but also one of the most frequent symptoms of depres-
sion—as a potential indicator of depression.15-18 The fact that “sleep disturbances” not only be-
long to the most frequently reported symptoms in depression, but also show some specificity in
polysomnographic sleep pattern analysis,19 indicates that these sleep disturbances might have
special neurobiological relevance in the context of depression.
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This brings us to the intriguing subject of psychopharmacological interventions that focus
primarily on symptoms such as sleep disorders,20 which are not always regarded as core symp-
toms. It was recently demonstrated using a sophisticated statistical analysis that excluded po-
tential confounders, that beyond the positive effects on sleep, treatment of depressive patients
with a hypnotic could also reduce the severity of depression.21 In this context, it is interesting to
speculate that the capacity of agomelatine to normalize the disturbed sleep pattern of depres-
sive patients might also contribute to its overall antidepressant efficacy.22-25 This allows us to hy-
pothesize that not only the classic core symptoms are of relevance for diagnosis and triggering
of depression, but also the very frequent and so-called unspecific symptoms like reduced well-
being, sadness, and, over all, sleep disorders. These symptoms are possibly more specific in terms
of neurobiological mechanisms of depression than is commonly believed on the basis of psycho-
pathological considerations, and this issue of Medicographia looks into the debate surrounding
their eligibility as “new core syndromes” of depression. 
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C E NUMÉRO DE MEDICOGRAPHIA ABORDE, SOUS DIVERSESperspectives, le sujet des symptômes majeurs de la dépression,dont les implications sont importantes non seulement pour le dia-gnostic et le traitement, mais aussi pour l’étiopathogénie de cette
maladie. Un premier groupe d’articles centrés sur les aspects cliniques cherche à déterminer
dans quelle mesure certains symptômes spécifiques comme l’humeur dépressive, l’inhibition et
l’anhédonie ou les troubles du sommeil et sexuels font partie des symptômes majeurs de la dé-
pression. Viennent ensuite des articles consacrés aux aspects psychométriques qui passent en
revue les méthodes d’évaluation de ces symptômes et examinent leur pertinence dans la classi-
fication des troubles dépressifs majeurs. D’autres articles évoquent les facteurs étiopathogé-
niques à la lumière de l’imagerie cérébrale et de la chronobiologie, tandis que le problème de
l’identification des symptômes majeurs prioritaires et comment les traiter dans le cadre de la
prise en charge primaire de la dépression est débattu par plusieurs auteurs.  
Tous ces aspects sont importants, et différentes approches cliniques et expérimentales ont
tenté de les clarifier depuis longtemps. L’exposé qui suit voudrait citer quelques exemples des
sujets qui font encore débat afin de bien faire saisir l’importance des considérations soulevées
par les articles de ce numéro. 
La différenciation de la dépression en plusieurs sous-types et profils symptomatiques asso-
ciés est une tradition ancienne, fondée sur l’expérience clinique. La dépression mélancolique,
appelée aussi autrefois dépression endogène, est considérée comme le prototype de la dépres-
sion « biologique », celle qui est la plus susceptible de répondre positivement aux antidépres-
seurs. Cette pathologie a longtemps fait l’objet de discussions, Parker et al.1 ont fait le point
récemment sur de nouvelles données de recherche portant en particulier sur l’importance des
symptômes somatiques. Se basant sur les données publiées concernant les traitements habituels,
ces auteurs conclurent à la plus grande efficacité des antidépresseurs tricycliques (ATC) et des
inhibiteurs de la monoamine oxydase (IMAO) dans la dépression mélancolique, alors que les
médicaments plus récents tels les inhibiteurs sélectifs de la recapture de la sérotonine [ISRS],
les inhibiteurs réversibles de la monoamine oxydase A, et les antipsychotiques étaient beaucoup
moins efficaces. Parker, dans une publication ultérieure, ne concernant cependant que des ré-
sultats préliminaires, constate qu’alors que l’efficacité des ATC et des ISRS diffère peu chez les
patients mélancoliques les plus jeunes, les ISRS sont moins efficaces chez les patients plus âgés,
et il est improbable que cet effet soit secondaire à la date d’installation des troubles ou à la du-
rée de la maladie dépressive 2. À mon avis, la compréhension de l’influence de l’âge sur la ré-
ponse des sous-types de dépression mélancolique ou non mélancolique aux antidépresseurs
pourrait éclaircir les différences dans l’efficacité thérapeutique, et permettre de relier les diverses
modifications neuropathologiques sous-jacentes à des modalités distinctes de prise en charge
clinique, y compris jusque dans le choix de l’antidépresseur. 
Quant au concept traditionnel de dépression atypique, qui a connu récemment un regain
d’intérêt, celui-ci se trouve, dans une certaine mesure, dans la situation opposée. Contrairement
à la dépression « typique », la dépression majeure, et en particulier son sous-type le plus repré-
É D I T O R I A L
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sentatif, la dépression mélancolique, se caractérise par des symptômes à type d’humeur réac-
tive et d’augmentation du sommeil et de l’appétit 3. La dépression atypique n’est pas aussi rare
que l’on pense : sa fréquence a été estimée entre 20 % et 30 % en ambulatoire 3. La dépression
atypique ne semble pas bien répondre aux antidépresseurs classiques comme les ATC, mais elle
est plus sensible aux IMAO4. Les IMAO traditionnels ont fait l’objet de la plupart des études cli-
niques. Il semble que les inhibiteurs sélectifs et réversibles de la MAO-A les plus récents aient une
toxicité plus faible et une meilleure tolérance et qu’ils puissent donc représenter une meilleure
alternative que les anciens IMAO. Le système de la sérotonine pourrait être impliqué dans l’étio-
pathogénie de la dépression atypique 5 avec, pour corollaire, une efficacité clinique des ISRS dans
ce sous-type de dépression ; cependant, nous ne disposons pas encore de données suffisantes
sur cette question. 
D’autres sous-types de dépression semblent cliniquement importants, par exemple la dé-
pression psychotique, la dépression anxieuse, la dépression agitée, la dépression inhibée, etc.
Tous ces sous-types ont des incidences en termes de traitement, par exemple, l’association d’un
antidépresseur et d’un neuroleptique dans la dépression psychotique, ou d’un antidépresseur
et d’une benzodiazépine dans la dépression anxieuse.
Ces sous-types peuvent aussi, en plus de leur importance face à la prise de décision clinique,
être intéressants pour la recherche neurobiologique. Bien que de nos jours aucune association
claire n’ait été retrouvée entre ces différentes caractéristiques et un paramètre neurobiologique
particulier, le développement de méthodes plus sophistiquées comme la génétique moléculaire
pourra peut-être accroître la chance de découvrir de tels liens. 
La dépression bipolaire rentre aussi dans ce cadre. Le diagnostic différentiel est principa-
lement fondé sur l’évolution de la maladie (épisodes maniaque/hypomaniaque). Certains experts
soulignent cependant qu’il peut aussi y avoir des différences transversales du profil symptoma-
tologique clinique. Cette hypothèse semble principalement provenir de l’existence de stades
mixtes, au cours desquels les patients présentent à la fois des symptômes dépressifs et (quelques)
symptômes maniaques.
À côté de ces différenciations et sous-types fondés sur la clinique, le domaine de la psycho-
pathométrie s’est développé comme une autre ligne de recherche pour essayer d’établir une
distinction entre symptômes majeurs et symptômes associés/secondaires. Au cours d’études
longitudinales et transversales, des analyses factorielles et d’autres approches multivariées
ont été appliquées aux données obtenues à partir des mesures faites avec des échelles de dépres-
sion afin de caractériser des sous-catégories de symptomatologie dépressive. C’est ainsi qu’on a
pu définir, à partir de l’échelle de dépression de Hamilton (HAMD) des sous-scores pour « l’in-
hibition dépressive », « l’agitation dépressive », « l’anxiété » et « les symptômes somatiques ».
La question des symptômes dépressifs majeurs 6,7 ainsi que de leur importance dans la réponse
aux antidépresseurs 7-9 a également été étudiée sous l’angle de la psychopathométrie. Bech et
al. ont commencé par définir une sous-échelle de mélancolie de la HAMD (maintenant appelée
«indice de dépression de la HAMD ») au moyen d’un modèle de test de probabilité. Ils ont pu éta-
blir que l’échelle originale de la HAMD à 17 items ne convenait pas comme mesure de la sévé-
rité dépressive et qu’une sous-échelle à 6 items (humeur dépressive ; culpabilité ; travail et centres
d’intérêt ; inhibition ; anxiété psychotique ; symptômes somatiques généraux) donnait des ré-
sultats plus fiables10. Dans des métaanalyses ultérieures, Bech et al. démontrèrent que l’indice
de dépression à 6 items était plus sensible pour déceler les effets antidépresseurs de la fluoxé-
tine 7 et de la mirtazapine 9 que l’échelle HAMD complète à 17 items. Des résultats similaires
ont été obtenus par une autre approche statistique associant la théorie des facettes à l’utilisa-
tion d’échelles multidimensionnelles non métriques6. L’évaluation de deux études comparant la
sertraline et l’amitriptyline11,12 a montré que l’efficacité des ATC ne dépassait pas celle des ISRS
lorsque seulement les symptômes majeurs de la dépression étaient pris en compte au lieu de
l’échelle complète de l’HAMD8. L’utilisation du score total de l’HAMD semble introduire un biais
en faveur des antidépresseurs plus sédatifs, mais ce biais peut être évité en prenant en compte
l’indice de dépression, les items supplémentaires de l’HAMD-17 pouvant être utilisés pour dé-
crire d’autres caractéristiques de la symptomatologie dépressive. 
Ces dernières années, une recherche approfondie a permis de déterminer les meilleures mé-
thodes de dépistage et de diagnostic de la dépression dans le contexte de la médecine de soins
primaires 13,14. Il a pu être montré que les symptômes qui ne sont pas habituellement considé-
rés comme des symptômes majeurs ou « spécifiques », mais qui surviennent de façon très fré-
quente dans la dépression, comme la diminution du bien-être ou les troubles du sommeil, sont
des indicateurs très efficaces pour le dépistage. Ceci souligne l’importance des troubles du som-
meil en tant qu’indicateur potentiel de dépression, ceux-ci n’étant pas seulement courants chez
les patients de soins primaires, mais aussi une des manifestations les plus fréquentes de la dé-
pression 15-18. Le fait que les « troubles du sommeil » comptent non seulement parmi les symp-
tômes les plus fréquemment rapportés dans la dépression, mais se traduisent également par
une certaine spécificité dans l’analyse du schéma polysomnographique du sommeil 19, montre
que ces troubles peuvent avoir une importance neurobiologique particulière dans le contexte
dépressif.
Ces considérations nous amènent au sujet intéressant des interventions psychopharma-
cologiques axées en priorité sur des symptômes secondaires tels que les troubles du sommeil 20
qui ne sont pas toujours considérés comme étant des symptômes majeurs. Une analyse statis-
tique sophistiquée excluant les facteurs confondants potentiels à récemment démontré, au-
delà des effets positifs sur le sommeil, que le traitement des sujets déprimés avec un hypnotique
pouvait aussi diminuer la sévérité de la dépression21. Dans ce contexte on peut émettre l’hypo-
thèse que la normalisation des troubles du sommeil sous l’action de l’agomélatine contribue
à son efficacité antidepressive globale 22-25. Ceci nous conduit à formuler l’hypothèse que ce ne
sont pas seulement les symptômes majeurs classiques qui sont importants pour le déclenche-
ment et le diagnostic de la dépression, mais également les symptômes très fréquents et soit-di-
sant non spécifiques comme la diminution du bien-être, la tristesse et surtout les troubles du
sommeil. D’un point de vue psychopathologique, ces symptômes joueraient un rôle plus spéci-
fique qu’on ne le croit communément dans les mécanismes neurobiologiques de la dépression,
et ce numéro de Medicographia fait le point sur les débats autour de leur acceptabilité en tant
que « nouveaux symptômes majeurs » de la dépression. 
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For half a century, depressive illness has beenlargely quantified using the Hamilton Depres-sion Rating Scale (HAM-D). Factor analysis is
the psychometric method most often used when
classifying depressive symptoms. Despite the many
versions of the HAM-D used (from 17 to 28 symp-
toms), and the many variants of factor analysis,
the results have consistently identified “depressed
mood” and “work and interests” as the two “big”
symptoms in depressive states. Within the major
depression syndrome, according to the Diagnos-
tic and Statistical Manual of Mental Disorders—
Fourth Edition (DSM-IV),1 the first two listed symp-
toms are “depressed mood” and “loss of interest or
pleasure in nearly all activities.” However, these two
core symptoms need to be followed by at least four
additional symptoms drawn from a list of seven cov-
ering the syndrome of DSM-IV major depression.
Depressed mood, or negative affect, and lack of
interest, or anhedonia, are components of abulia, a
term used by neurologists and neuropsychiatrists
to denote lack of spontaneous goal-directed behav-
ior.2,3 DSM-IV describes the essential feature of de-
pressed mood as being sad, hopeless, discouraged,
or “down in the dumps.” Table IA ( page 10), which
shows the “depressed mood” item in HAM-D, pro-
vides a more detailed definition. On revising the
HAM-D in 1967, Hamilton observed4:
Depressed mood is not easy to assess. One looks
for a gloomy attitude, pessimism about future,
feelings of hopelessness and a tendency to weep…
When patients are severely depressed they may
“go beyond weeping.” It is important to remem-
ber that patients interpret the word “depression”
in all sorts of strange ways. A useful common
phrase is “lowering of spirits.” It is generally be-
lieved that women weep more readily than men,
but there is little evidence that this is true in the
case of depressive illness…
The scoring instructions in Table IA were pub-
lished in 1986, when, with Hamilton’s agreement,
the HAM-D was revised to cover both men and
women.5
Unfortunately, many different versions of the
HAM-D have been published that were not approved
by Hamilton himself. Table IB (page 10) shows the
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S adness or lowered mood is the primary symptom specific to depressivestates, as shown by most studies using the Hamilton Depression RatingScale (HAM-D). In both the Diagnostic and Statistical Manual of Mental
Disorders—Fourth Edition and the International Statistical Classification of
Diseases and Health-Related Problems—10th Revision, “depressed mood” and
“loss of interests or pleasure in nearly all activities” are the two “big” symptoms
in major depression. The two items overlap in the concept of abulia, which cov-
ers both anhedonia and low spirits. The neurovegetative symptoms associated
with depressive states should be considered an interactive manifestation of the
disease process, but with a less specific symptom rating than depressed mood or
anhedonia. Lowered mood should, therefore, not be considered a consequence
of the neurovegetative symptoms. Change in lowered mood is the most appro-
priate indicator of antidepressant effect. Many of the neurovegetative symp-
toms included in the HAM-D could reflect the side effects of an antidepressant,
but the separately evaluated “depressed mood” symptom is a most sensitive
indicator of antidepressant effect. This has been confirmed in many placebo-
controlled trials. When used as an indicator of global impression of severity,
depressed mood shows satisfactory standardization between the various symp-
tom rating scales. Thus were we to go for a HAM-D1 (ie, including only one
item and not the half-a-dozen core items in the HAM-D6 within the HAM-D17),
this single item should be “depressed mood.”
Medicographia. 2008;30:9-13. (see French abstract on page 13)
Keywords: abulia; acedia; anhedonia; depressed mood; Hamilton Depression
Rating Scale; neurovegetative symptom; standardization
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SELECTED ABBREVIATIONS AND ACRONYMS
DSM-IV Diagnostic and Statistical Manual of 
Mental Disorders—Fourth Edition
GAD generalized anxiety disorder 
HAM-A Hamilton Anxiety Rating Scale
HAM-D Hamilton Depression Rating Scale
ICD-10 International Statistical Classification 
of Diseases and Health-Related Prob-
lems—10th Revision
IVRS interactive voice response system
MADRS Montgomery-Åsberg Depression Rating 
Scale
MES Melancholia Scale
PSE Present State Examination
an instrument is the interactive voice response sys-
tem (IVRS) that has been used for the HAM-D6.9
Table II shows the “depressed mood” item in the
HAM-D6 self-rating version.10
Table IC shows the HAM-D “work and interests”
item. Hamilton’s 1967 instructions for an abridged
version11 included the following:
It could be argued that the patient’s loss of in-
terest in his work and activities should be rated
separately from his decreased performance, but
it has been found too difficult to do so in prac-
tice. Care should be taken not to include fatigua-
bility and lack of energy here; the rating is con-
cerned with loss of efficiency and the extra effort
required to do anything.4
Thus “fatigability” and “lack of energy” are not
to be included under “work and interests.” Patients
often say that they no longer care. This is essential-
ly lack of interest, spiritual apathy, or intellectual
laziness, sometimes termed “acedia,” meaning “ab-
sence of caring” in the original Greek (or “sloth,” in
the context of the seven cardinal sins12). The re-
ligious historian Clebsch analyzed the first major
depressive episode experienced by William James
as follows:
Acedia is often referred to by “sloth,” ie, a gen-
eral act of laziness. However, acedia is rather an
overscrupulous wondering about what one ought
to do when faced, as James, by “a kind of expe-
rience in which intellect, feeling and will, all our
consciousness and all our subconsciousness to-
gether melt in a kind of chemical fusion.”12
Acedia is closely associated with melancholia, as
it prevents the person from doing anything, except
perhaps suicide as the only escape from the ennui
and guilt of inactivity.12 Acedia is also very closely
associated with abulia. The poet T. S. Eliot, who
also suffered recurrent depressive episodes, used
the term “aboulie” to describe his own disorder of
the will which he found to be the core symptom of
depression.13 He considered depression to be an
emotional, not a thinking disorder because it im-
paired his mood and will, but not his thought pro-
cesses.
HAM-D version most frequently used in assessing
antidepressants in randomized clinical trials of ma-
jor depression.6 It elicited the following comment
from Hamilton:
A further deficiency was that it regarded the
spontaneous mention of a symptom as indicat-
ing greater severity than if it had been elicited
by questioning. There are many reasons why pa-
tients may not mention a symptom at an inter-
view. For example, they may not find it relevant
(eg, feeling of guilt), they may be embarrassed
(eg, loss of libido) or they may be too polite to
mention to the interviewer that they believe they
are suffering from a physical illness.7
Recently, self-rating versions of the HAM-D have
been developed, because such a scale can be consid-
ered a structured patient interview. The original
Beck Depression Inventory8 was designed in such
a way that a therapy-neutral person had to read the
items aloud for the patient. A recent version of such
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HAMILTON DEPRESSION
RATING SCALE (HAM-D): 
SELF-RATING VERSION (S HAM D6)
“Depressed mood”
0. I have been in my usual good mood
1. I have felt a little more sad than usual
2. I have been clearly more sad than usual, but 
haven’t felt helpless or hopeless
3. I have been so gloomy that I briefly have felt 
overpowered by hopelessness
4. I have been so low in my moods that everything





1. It is doubtful whether the patient is more des-
pondent or sad than usual; for example, the 
patient appears vaguely  to be more depres-
sed than usual.
2. The patient is more clearly concerned with un-
pleasant experiences, although he/she still 
lacks helplessness or hopelessness.
3. The patient shows clear nonverbal signs of 
depression and/or is at times over-powered 
by helplessness or hopelessness.
4. The patient’s remarks on despondency  and 
helplessness or nonverbal signs dominate 
the interview.
B. “Depressed mood” 
(sadness, hopeless, helpless, worthless)
0. Absent
1. These feeling states only indicated on 
questioning
2. These feeling states spontaneously reported 
verbally 
3. Communicates feeling states nonverbally, 
ie, through facial expression, posture, voice, 
tendency to weep
4. Patient reports virtually only these feeling states
in his/her spontaneous verbal and nonverbal 
communication
C. “Work and interests”
0. Not present
1. The patient expresses motivation and/or is 
carrying out the usual workload. Some feeling
of incapacity.
2. The patient shows a more pronounced reduction
in motivation and/or has trouble in carrying 
out daily work activities. Some loss of interest
in hobbies; inability to feel affects the family. 
3. Difficulties in simple routine activities.
4. Unable to do anything without help.
Table I. Hamilton Depres-
sion Rating Scale (HAM-D).
A: Revised to cover men
and women, approved
by Hamilton.
From: Bech P, Kastrup M,
Rafaelsen OJ. Mini-compendium of
rating scales for states of anxiety,
depression, mania, schizophrenia
with corresponding DSM-III syn-
dromes. Acta Psychiatr Scand.
1986;73(suppl):7-37.5
B: A version not approved
by Hamilton.
From: Guy W. Early Clinical Drug
Evaluation (ECDEU) Assessment
Manual for Psychopharmacology.
Publication No. 76-338. Rockville,
MD: National Institute of Mental
Health; 1976.6
C: “Work and interests”
item with definitions
updated and approved by
Hamilton4 as an extension
of his guidelines.
Abridged and modified from:
Bech P. Rating scales for psy-
chotherapy, health states and
quality of life. Berlin, Germany:
Springer; 1993:164-165.11
Table II. Self-rating version of the Hamilton Depression
Rating Scale (HAM-D) scale for “depressed mood.”
From: Bech P. Rating scales in depression: limitations and pitfalls.
Dialogues Clin Neurosci. 2006;8:207-215.10
“lack of interests” may change. Thus a recurrent de-
pressive might have more work activity than nor-
mal between episodes. Such states of overactive
neutral mood are now considered hypomanic,22 and
the depressive episode is therefore classified as bi-
polar II depression.
Is sadness the cause 
or consequence of depressive 
neurovegetative symptoms?
The HAM-D “general somatic” symptom, which
includes tiredness, muscular tension, and pains,
shares its phenomenology with the core symptoms
of depressive states (Tables III and IV), in contrast to
the neurovegetative symptoms of sleep, appetite,
and autonomic anxiety (eg, cardiovascular, respira-
tory, and genitourinary symptoms).22 In the Hamil-
ton Anxiety Rating Scale (HAM-A), the autonomic
anxiety symptoms are not among the core items of
the symptomatic DSM-IV criteria for generalized
anxiety disorder (GAD). Dose-response studies with
selective serotonin reuptake inhibitors in patients
with major GAD23 or depression24 indicate that only
The two “big” core symptoms of depressive illness
(“depressed mood” and “work and interests”) thus
seem to have coalesced by a kind of chemical fu-
sion into abulia or acedia. According to the psychia-
trist Storr,14 William James, T. S. Eliot, and Winston
Churchill all experienced abulia in their depressive
episodes, but compensated by working hard when-
ever possible outside their episodes of depression.
In their neutral phases recurrent depressives may
thus be characterized by enormous vitality and ap-
petite for work.14
The International Statistical Classification of
Diseases and Health-Related Problems—10th Re-
vision (ICD-10)15 identifies “tiredness” as the third
core symptom of depressive illness. A general pop-
ulation study using the Present State Examination
(PSE)16 showed “depressed mood” and “lack of en-
ergy” to be among the most common symptoms,
while “guilt,” “suicide,” and “depression worst in
the morning” were among the most uncommon
(Table III).17 This study identified the hierarchical
pattern of the PSE symptoms in that the rarer the
symptom, the higher the total symptom score in-
dicated by its presence. In other words, the preva-
lence of uncommon symptoms in Table III was pre-
ceded by a higher prevalence of the most common
symptoms.17
In several studies using the HAM-D, we have
found that six items fulfil this hierarchical pattern
in depressed patients.18 The six items (HAM-D6) are
“depressed mood,” “work and interests,” “general
somatic (tiredness and pain),” “anxious mood,”
“guilt feelings,” and “psychomotor retardation”
(Table III). This sequence of symptoms reflects their
point prevalence in patients with depressive ill-
ness.18 Thus “depressed mood” and “work and in-
terests” have the highest prevalence while “guilt
feelings” and “psychomotor retardation” have the
lowest prevalence. We used item response theory
models (one-parameter Rasch analysis and non-
parametric Mokken analysis) to test the hierar-
chical pattern of these six items. The hierarchical
prevalence from “depressed mood” to “psychomo-
tor retardation” (Table III) confirms their hierar-
chical role in the constitution or measurement of
depressive states. According to item response the-
ory models, it is precisely because of this difference
in the prevalence of the six items, and the fact that
persons scoring on the less prevalent items also
score on a more prevalent item, that the sum of all
six items becomes a valid representation of depres-
sion severity.19
The separation between “lack of interests” and
“lack of energy” in the HAM-D, DSM-IV and ICD-10
is important because “lack of interests” is closer to
“depressed mood” than “lack of energy.” Table IV
shows the correlation between the “lack of energy”
item and the other items covering depression ac-
cording to DSM-IV and ICD-10 when reanalyzing
the data from the study by Olsen et al.20 The corre-
lation coefficients are highest for “depressed mood”
and “lack of interests” and lowest for “sleep prob-
lems,” which is consistent with other studies.21 In
the remission phase, after 4 to 6 weeks of therapy,
the internal balance between “depressed mood” and
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Symptom General population Depressed patients 
prevalence (PSE) (HAM-D6)
Most common Depressed mood Depressed mood/Work 
and interests
Lack of energy Tiredness and pains
Worrying/Tension Psychic anxiety
Least common Guilt feelings Guilt feelings
Depression worst Psychomotor retardation
in the morning
Suicide
DSM-IV or ICD-10 
symptoms of depression Lack of energy
Depressed mood 0.52
Lack of interests 0.60
Low self-confidence 0.51
Guilt feelings 0.46
Life not worth living 0.34





Table III. Hierarchical patterns of depression-related symptoms in a pop-
ulation study after Present State Examination (PSE), and in patients
with depressive illness after the 6-item Hamilton Depression Rating Scale
(HAM-D6). See comments in text.18,23
From: Sturt E. Hierarchical patterns in the distribution of psychiatric symptoms. Psychol
Med. 1981;11:783-794.17
Table IV. Prevalence (Spearman correlation coefficients)
of depressive symptoms over 2 weeks measured by the
Major Depression Inventory in a general population
(N=1121).
From: Olsen LR, Jensen DV, Noerholm V, Martiny K, Bech P. The
internal and external validity of the Major Depression Inventory in
measuring severity of depressive states. Psychol Med. 2003;33: 
351-356.20
course of a symptom. Diurnal variation in mood
symptoms is an indicator for depressive illness and
not for stress-related sadness. The Newcastle Diag-
nostic Depression Scale28 includes diurnal symptom
variation as an indicator of endogenous depression,
alongside the important “quality of depression”
item for which patients are asked to what extent
their sadness is qualitatively distinct from normal
despondency when under adversity or stress. In
other words, they are invited to distinguish between
“ordinary” sadness, as experienced in adverse situ-
ations (grief, ill-health etc), and the qualitatively
different experience of being “depressed for no rea-
son at all.” Both “depressed mood regularly worse
in the morning” and a distinct “quality of depres-
sion” are among the criteria for endogenous depres-
sion or “melancholic” features in DSM-IV.
In patients diagnosed with major depression and
requiring antidepressant medication, mood mod-
ification is an important indicator of early treat-
ment effect. Use of the dynamic item response the-
ory model in antidepressant trials to identify
specific improvement curves has shown that the
total score of the six HAM-D6 items is a sensitive
indicator of response. However, because the “de-
pressed mood” item has the highest prevalence
in the HAM-D6, it has most room for improve-
ment and the greatest variance in response, often
referred to as high responsiveness or sensitivity.
Most antidepressant trials consider the “depressed
mood” item (Table IA) a “global” indicator of re-
sponse and therefore show it separately.
To illustrate “depressed mood” as a “global” in-
dicator within the HAM-D, we standardized total
scores on the HAM-D17, HAM-D6, and Melancholia
Scale (MES) using data from baseline ratings as
well as weekly ratings from different studies to cov-
er the whole range of the 5-point “depressed mood”
scale (not depressed; doubtfully depressed; mildly
depressed; moderately depressed; severely depressed)
(Table V). These studies were based on 87 patients
receiving electroconvulsive therapy,29 345 inpa-
tients,30 and 102 ambulatory patients.31 Mean HAM-
D6 and MES scores fully corresponded to the con-
ventional standardization of these scales,23 whereas
agreement between HAM-D17 and the convention-
al cutoff scores was only approximate (Table V).
“Depressed mood” on the HAM-D17 has proved
quite sensitive as an outcome measure of response
in antidepressant trials. Thus a placebo-controlled
trial of paroxetine covering a fixed dose range of
10, 20, 30, and 40 mg daily found that not only was
20 mg the minimal effective dose, but that it was
also superior to 30 mg and 40 mg on the HAM-D17.32
On the HAM-D “depressed mood” item, 20 mg was
also the minimal effective dose but the dose-re-
sponse curve for 30 mg and 40 mg was flat. Paroxe-
tine showed a clear linear dose-response relation-
ship for adverse effects,which seemed to be reflected
in the nonspecific HAM-D items.32
A dose-response study with fixed doses of ven-
lafaxine (from 25 mg to 200 mg daily) versus place-
bo showed “depressed mood” on the HAM-D to be
more sensitive than the HAM-D17 or the 10-item
Montgomery-Åsberg Depression Rating Scale
the neurovegetative symptoms of tiredness and
muscular tension have a shared phenomenology.
These symptoms should not therefore be considered
a consequence of depressed mood, but rather as re-
flecting an interactive manifestation of the “psychic”
and the “somatic” items in the Hamilton scales.
In the HAM-D, the neurovegetative symptoms of
affective disorder covering autonomic symptoms
are combined into a single somatic anxiety item,
whereas in the HAM-A they are listed individually
and include cardiovascular, gastrointestinal, and
genitourinary symptoms. Benzodiazepines and
β-blockers have a specific effect on autonomic symp-
toms.25 However, in patients with affective disorders,
these classes of drugs often induce the core symp-
toms of depression once the autonomic symptoms
have been reduced. In other words, autonomic
symptoms were masking the depressive illness.
Is mood modification the appropriate 
treatment for depression?
Using the PSE to screen patients with Parkinson’s
disease, Brown and MacCarthy26 found that 25% had
depressed mood, but very few had the other symp-
toms of the depression syndrome. They concluded
that depressed mood lowered quality of life in Par-
kinson’s disease, but did not require antidepressant
medication, apart from a few exceptions. Many qual-
ity of life questionnaires include depressed mood.
The DSM-IV criteria for depressed mood can be
found in the Medical Outcome Study 36-item Short-
Form Health Survey: “Have you felt so down in the
dumps that nothing could cheer you up?” 27
Sturt’s general population study in the UK17 found
“depressed mood” to be one of the commonest
symptoms measured by the PSE; “depression worst
in the morning” was one of the least common
(Table III). However, in the PSE, “depressed mood”
is in principle a score on a categorical scale (present
versus not present), in contrast to the HAM-D,
which it is measured on the 5-point scale from 0 to
4 (Table IA). “Depressed mood worst in the morn-
ing” is, strictly speaking, not a symptom, but the
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HAM-D17
Empirically, mean (sd)
Depressed mood Conventionally HAM-D17 HAM-D6 MES
(N=689)   0 No 7 3.4 (3.1) 2.0 (1.9) 3.4 (3.1)
(N=748)   1 Doubtful 13 9.4 (3.7) 5.9 (1.8) 9.6 (3.3)
(N=1226) 2 Mild 18 16.2 (4.5) 9.6 (2.0) 16.3 (3.8)
(N=859)   3 Moderate 25 23.0 (4.7) 12.7 (1.9) 22.3 (3.7)
(N=190)   4 Severe 30 28.7 (5.0) 15.4 (2.1) 27.5 (4.8)
Table V. Standardization of the Hamilton Depression Scales HAM-D17 and
HAM-D6, and Melancholia Scale (MES), using depressed mood as a global
index (patients seen weekly: N=534; total data items: 3712).
Data sources: Lauritzen L, Odgaard K, Clemmesen L, et al. Relapse prevention by means of
paroxetine in ECT-treated patients with major depression: A comparison with imipramine
and placebo in medium-term continuation therapy. Acta Psychiatr Scand. 1996;94:241-251;29
Bech P. Quality of life in psychosomatic research. A psychometric model. Psychopathology.
1987;20:169-179;30 Martiny K, Lunde M, Undén M, Dam H, Bech P. Adjunctive bright light in
non-seasonal major depression: results from clinician-rated depression scales. Acta Psychiatr
Scand. 2005;112:117-125.31
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L’HUMEUR DÉPRESSIVE, 
SYMPTÔME MAJEUR DE LA DÉPRESSION
L a tristesse ou l’humeur dépressive représente le principal symptômespécifique de l’état dépressif, comme le montrent la plupart des étudesutilisant l’échelle HAM-D (Hamilton Depression Rating Scale). Que ce
soit dans le DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th
Edition) ou l’ICD-10 (International Statistical Classification of Diseases and
Health-Related Problems, 10th Revision), « humeur dépressive » et « perte d’in-
térêt ou de plaisir dans presque toutes les activités » sont les deux « grands »
symptômes de la dépression majeure. Ces deux items se superposent dans le
concept d’aboulie qui recouvre l’anhédonie et l’humeur dépressive. Les symp-
tômes neurovégétatifs associés aux états dépressifs doivent être considérés
comme une manifestation interactive de l’évolution de la maladie mais dont le
score est moins spécifique que l’humeur dépressive ou l’anhédonie. L’humeur
dépressive ne doit donc pas être considérée comme une conséquence des symp-
tômes neurovégétatifs. Les modifications de l’humeur dépressive sont le meilleur
indicateur de l’effet antidépresseur. Beaucoup des symptômes neurovégétatifs
présents dans l’HAM-D pourraient n’être que le reflet des effets indésirables du
traitement antidépresseur, alors que le symptôme « humeur dépressive », éva-
lué séparément, est l’indicateur le plus sensible de l’effet antidépresseur. Ceci
a été confirmé dans de nombreuses études contrôlées contre placebo. L’humeur
dépressive, lorsqu’elle est utilisée comme indicateur de sévérité globale, montre
une standardisation satisfaisante entre les différentes échelles d’évaluation des
symptômes. Ainsi, si nous devions opter pour une échelle HAM-D1 (c’est-à-dire
avec seulement un item et non une demi douzaine comme dans l’HAM-D6,
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(MADRS10),33 demonstrating a dose-response re-
lationship after only 1 week of therapy versus 3 to
4 weeks with the HAM-D17 and MADRS10. In pa-
tients with bipolar depression, lamotrigine 200 mg
daily was superior to placebo on both HAM-D “de-
pressed mood” and the global clinical improvement
scale, but not on the HAM-D17.34 Modification of
depressed mood thus appears to be an appropriate
treatment of depressive episodes in both unipolar
and bipolar disorders. If reduction of the HAM-D17
items to half-a-dozen core items (HAM-D6) no
longer appears so radical, what about a HAM-D2 ver-
sion reduced simply to “depressed mood” and “work
and interests”? We might eventually arrive at a
HAM-D1 version reduced solely to “depressed mood”
as a global impression score of depressive states. 
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Emotional deficit: anhedonia
Depression is associated with a variety of emotion-
al disturbances, and has been subgrouped on this
basis. In particular, we have defined two contrasting
emotional subgroups: depressed patients with an-
hedonia and psychomotor retardation, versus those
with anxiety, agitation, and hyperemotivity.1 This
distinction may have a pathophysiological basis:
using functional imaging, we have shown that a de-
crease in presynaptic dopamine function in the left
caudate nucleus is found only in anhedonic de-
pressives with retardation.2 During treatment of a
depressive episode, these clinical dimensions can
progress independently of other symptoms.3
Cognitive deficit: 
psychomotor retardation
More recently, several studies have revealed the cere-
bral cost of depression on the functional, anatomic,
and cognitive-emotional levels. Depression leaves
neuronal and functional scars. On the functional
level, it is associated with impaired cerebral dynam-
ics, measured by indices extracted from electroen-
cephalography (EEG) signals. During the depressive
episode, cerebral dynamics are more predictable
and rigid; they are less inclined to adapt and ad-
just by incorporating new elements. Depression is
characterized by a reduction in the variety, com-
plexity, and instability, hence richness, of neuronal
dynamics.4
Many cerebral imaging studies have shown dys-
function, in particular in the dorsolateral prefrontal
cortex, but also in the amygdala and hippocampus.
Thus, depressed patients show hypoactivation while
performing a verbal fluency task consisting of ut-
tering as many words beginning with “P” as possi-
ble within a set time.5 Morphological data confirm
the cumulative effect of depressive episodes. Stud-
ies using neuroimaging, experimental pharmacol-
The core features of depression can be observedacross several domains, including those re-lated to affective, cognitive, motor, and circa-
diansomatic function. Typical affective symptoms
are anhedonia (loss of pleasure) and emotional
blunting. These negative symptoms, in addition
to the cognitive symptoms of depression, may be
viewed as resulting from the impairment of a sys-
tem underlying volition. This impairment may re-
flect both a primary disorder of volitional operation
and deficits in processes associated with the initia-
tion of action and allocation of attentional resources
during cognitive effort. This paper emphasizes the
role of cognitive flexibility and the capacity to mo-
bilize cognitive resources to explain the cognitive
control deficits and emotional dysregulation ob-
served in depression with anhedonia and psycho-
motor retardation.
T H E C O R E O F D E P R E S S I O N
A nhedonia, a personality trait defined as a decreased capacity to expe-rience pleasure, can be viewed, together with depression, as resultingfrom specific deficits in a system underlying volition located in several
regions of the prefrontal cortex. We discuss the hypothesis that volitional and
cognitive deficits in anhedonia and depression are two facets of a same process
that consists in the failure to maintain emotional and cognitive control in times
of increased and sustained cognitive demands. According to this view, the deficits
observed in depressed patients with anhedonia and psychomotor retardation
when faced with an effortful task are preceded by an increase in the effort re-
quired to maintain a high level of performance. Such patients recruit more cog-
nitive resources than controls during cognitive effort, to an extent that may de-
plete their cognitive and brain resources. Cognitive resource exhaustion may
thus account, at least in part, for the impaired volition seen in this depressive
subgroup.
Medicographia. 2008;30:14-16. (see French abstract on page 16)
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Negative symptoms in 
depression: from anhedonia 
to retardation 
b y  R . J o u v e n t ,  F r a n c e
 Cognitive inhibition. Executive functions identi-
fy the best strategies within the behavioral spectrum
for responding to environmental stimuli. Above all
they allow rapid interplay between controlled and
automatic processes. Planning, cognitive flexibility,
and the ability to change or alternate motor and
conversational strategies all play a very important
role in this regard.21
Two facets of the same process?
There is every indication that cognitive deficits and
emotional impairment in depressives are simply
two facets of one and the same process. We can
safely hypothesize that depression is a long process
comprising a constellation of emotional and cogni-
tive adjustments and maladjustments, all of which
may account for the progressive anhedonia. The
thought machine appears rusty and less fluid, with
the result that psychic pleasure and reinforcement
are decreased. The same applies to social pleasure.
Defective interpersonal relations have long been
documented in depressives. These subclinical symp-
toms have themselves a negative impact on social
functioning, hedonism, and quality of life. Anhe-
donia and retardation thus appear to act on each
other in a vicious circle.
ogy, and postmortem observation have shown vol-
ume reductions or structural abnormalities in many
brain regions known to be involved in depression,
primarily in cortical and striatal gray matter and
hippocampus.6
These results are explained by changes in neuro-
plasticity, neurogenesis, and cell resilience in de-
pression. The effects of antidepressants on synaptic
plasticity support this hypothesis: antidepressants
increase neurotrophic factors and neurogenesis.7
For example, in the hippocampus, antidepressants
increase both the proliferation and survival of young
hippocampal cells.8,9
Recent review has suggested that these morpho-
logical and structural changes in depression are
largely responsible for the deterioration in cogni-
tive function.10 The damage is cumulative and leaves
scars between episodes. The more frequent the dys-
thymic episodes, the more the cognitive disorders
persist and intensify.11
Memory is the most frequently impaired func-
tion, usually in correlation with episode severity or
frequency.12 Memory impairment suggests a strat-
egy disorder, with difficulties in generating cogni-
tive and behavioral diversity.13
Signs and symptoms may serve as a guide, but are
inadequate for describing the cognitive deficit. Loss
of memory and impaired concentration are famil-
iar depressive symptoms for psychiatrists. An array
of experimental data suggests that negative symp-
toms (anhedonia, blunted affect, retardation) in de-
pression are associated with more profound cog-
nitive deficits. The manifestations of depression are
extremely heterogeneous. Decreased activation in
the dorsolateral region of the prefrontal cortex is as-
sociated more with the presence of psychomotor
retardation than with depression severity.14 Further
evidence is that the most retarded depressives are
those with the severest attention deficit, whereas
moderately retarded depressives have less severe
attention deficits.15
The most consistently observed feature of depres-
sion-related cognitive deficit is the preservation of
performance in relatively simple tests, in contrast
to a deterioration in performance when tasks be-
come more complex (Figure 1).16,17 This is explained
by the coexistence of three types of executive dys-
function:
 Sustained attention deficit. Attention is a fluc-
tuating state, exercised in space and time. Its tem-
poral aspect involves the processes of orientation
reaction, reflex capture, and maintenance of atten-
tion over time. Decrease in attention represents the
degree of decline in performance over time.18 A fea-
ture specific to depressives is that they can begin
a task normally, but very soon become exhausted:
they can play table tennis or chess for only 20 or 30
seconds at their normal level before their perfor-
mance declines.
 Impaired memory. Deficits are observed in ver-
bal, working, visuospatial, and autobiographic mem-
ory, with a consistency that varies between tests and
the patient populations used.19,20 The feature com-
mon to each memory deficit appears to be the ef-
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Figure 1. Mean reaction times (RTs) according to time-on-task. Subjects completed
six blocks of 100 trials each. Each block lasted about 5 minutes. Blocks were separated
by a 2-minute pause. The whole task lasted about 40 minutes.
Reproduced from reference 16: Dubal S, Jouvent R. Time-on-task effect in trait anhedonia. Eur Psychiatry.
2004;19:285-291. Copyright © 2004, Elsevier Masson SAS. 
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 Extending to transnological approach
This combination of emotional and cognitive ap-
proaches may lead to a dimensional, transnoso-
graphic view of negative symptoms. Indeed,negative
symptoms can be found across various nosograph-
ic categories. However, in each pathological setting,
negative symptoms are “indexed,” or “colored,” by
nosological specificities (Figure 2, page 15).22
Conclusion
Cognitive impairment is characteristic of both de-
pressives and anhedonic healthy subjects. Depres-
sives and anhedonic patients recruit more cogni-
tive resources than controls during cognitive effort.
Repeating such cognitive effort may consume the
requisite brain resources. Volitional deficit in de-
pression and loss of pleasure in anhedonia may par-
tially reflect this exhaustion of cognitive resources.
Going a step further, we can hypothesize that both
retarded anhedonic depressives have two important
reasons for developing a specific negative pattern.
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SYMPTÔMES NÉGATIFS DANS LA DÉPRESSION :
DE L’ANHÉDONIE AU RALENTISSEMENT PSYCHOMOTEUR
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In the brain, foci of network dysfunction identified
in the baseline depressed state should be consid-
ered as etiological abnormalities as well as sites of
adaptive intrinsic compensatory processes. A given
metabolic or brain activation pattern (assessed by
positron emission tomography or functional mag-
netic resonance imaging) is a combination of a func-
tional lesion and an ongoing process of attempted
self-correction or adaptation. 
From this perspective, net regional activity is
what accounts for the observed clinical symptoms.
For instance, frontal hyperactivity could be seen as
an exaggerated and maladaptive compensatory pro-
cess, manifesting clinically as psychomotor agita-
tion and rumination, the purpose of which is to
override, at cortical level, a persistent negative
mood generated by abnormal chronic activity of
limbic subcortical structures. In turn, frontal hy-
pometabolism might reflect the failure to initiate
or to maintain such a compensatory state with re-
sulting apathy, anhedonia, and impaired executive
functioning. 
may also represent a risk factor or prodromal symp-
tom of a new depressive episode or a residual symp-
tom after successful treatment. This article reviews
current knowledge of sleep disturbance in depres-
sion, discusses its biological background, and ex-
amines its response to antidepressant drugs.
Sleep disturbance in depression
Depression-related insomnia comprises subjective
sleep disturbance but also abnormal sleep architec-
ture, as first shown by Kupfer and colleagues1,9 in
the early 1970s. Polysomnography reveals impaired
sleep continuity and duration, reduced slow-wave
sleep (SWS), shortened rapid eye movement (REM)
sleep latency, an increased proportion of REM sleep
in the early part of the night, a prolonged first REM
period, increased total REM sleep, and increased
eye movement counts during REM periods (REM
density). Shortening of the interval between sleep
onset and first REM period from 90 min in normal
subjects to between 20 min and 30 min (decreased
REM sleep latency) was initially proposed as a bio-
logical marker of primary depression, unrelated to
any other mental or organic disorder.10 Reanalysis
Sleep pattern changes were first associated withdepression over 30 years ago.1 Between 50%and 90% of diagnosed depressives complain of
sleep disturbance,2-4 typically sleep-onset insomnia,
frequent nocturnal awakening, and early morning
awakening. Although none of these complaints are
pathognomonic of depression, sleep onset insom-
nia is usually viewed as the least specific, and early
morning awakening as the most specific. Hyper-
somnia is less typical, although it may occur in cer-
tain subtypes, such as bipolar depression, seasonal
affective disorder, and atypical depression;5-7 it is
more common in younger depressives, especially
women.8 Sleep disturbance is such a fundamental
aspect of depression that the Diagnostic and Statis-
tical Manual of Mental Disorders—Fourth Edition
(DSM-IV) criteria for major depressive episode in-
clude “insomnia or hypersomnia nearly every day.”
Insomnia, in particular, is one of the most frequent
and prominent symptoms, and often the presenting
complaint in depression. Not only is it typical, but it
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S ubjective sleep disturbance, typically sleep-onset insomnia, frequent noc-turnal awakening, early morning awakening and, less typically, hyper-somnia, is common in major depression. It also includes structural poly-
somnographic changes, mainly increased “pressure” of rapid eye movement
sleep and decreased slow-wave sleep. Although none of these changes appear
specific to depression, some persist after remission, representing a putative
marker of vulnerability. Epidemiological data suggest that sleep disturbance
is not only a core symptom of depression, but also represents a risk factor or
prodromal symptom of a new depressive episode, or a residual symptom after
successful treatment. Management of insomnia is thus an important compo-
nent in the prevention and treatment of depression. Antidepressants differ both
between and within drug classes in their effects on subjective sleep and sleep
architecture. Clinicians need to take these effects into account when choosing
the most appropriate antidepressant for a given patient.
Medicographia. 2008;30:17-23. (see French abstract on page 23)
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graphic changes represent a marker of “vulnerabil-
ity” to depression. In support of this view, healthy
subjects with no personal history, but a heavy fam-
ily history of depression, were found to exhibit in-
creased REM density and decreased SWS,30 while
relatives of depressed probands with short REM la-
tency were found to have a lifetime risk of depres-
sion almost double that of relatives of depressed pro-
bands with normal REM latency.31 Increased REM
density in healthy relatives of depressed patients was
recently reported to be predictive of a psychiatric
disorder,32 suggesting that this polysomnographic
alteration may constitute a vulnerability marker.
Although DSM-IV includes hypersomnia in the
criteria for major depressive episode, it is a less
common feature. It is mostly related to subtypes
such as bipolar depression, atypical depression, and
seasonal affective disorder (SAD).6,33,34 Polysomno-
graphic studies in depressives with hypersomnia are
relatively scanty. Patients with atypical depression
exhibit completely normal polysomnograms if
wakened relatively early in the morning. But if al-
lowed to sleep to satiety, they show long total sleep
time, with a normal amount of SWS and more REM
sleep than normal, probably because their longer
sleep time results in one or two more REM sleep
episodes.35 Length of sleep in SAD does not differ
greatly from that in the general population, but
sleep patterns differ from those of other patients
with major depression since they exhibit signifi-
cantly longer NREM episodes and greater slow-wave
activity during NREM sleep.36,37 Hypersomnia in de-
pression remains difficult to quantify, and com-
plaints of hypersomnolence often involve excessive
daytime sleepiness as a consequence of depression-
or treatment-related nocturnal insomnia. Drug
strategy should be careful to take its presence into
account.
The incidence and severity of sleep disturbance
in depression appear strongly influenced by age,
gender, and depression severity. In healthy subjects,
age is itself a well-recognized cause of sleep changes,
in particular increased nocturnal awakening, de-
creased SWS, early morning awakening, and short-
er REM latency.38,39 Most studies in depression have
shown negative correlations between REM latency
and age, whereas REM density appears unrelated to
age.14,40,41 Differences between patients and controls
may be more prevalent among younger adults and
diminish with increasing age.42,43 As for gender, de-
pressed men appear to have less SWS than their
female counterparts44; the regulation of slow-wave
activity was impaired in depressive men, but not
women.42,43 Some studies have claimed correlations
between sleep abnormalities and depression sever-
ity, measured by psychometric scales,17,22,45 but these
remain unconfirmed.16,46
Sleep disturbance  
and the risk of depression
Individuals with sleep disturbance may be at high
risk for depression over the subsequent 1-3 years. Of
7900 participants in the Epidemiologic Catchment
Area study, 40% of those with insomnia and 46%
of the original data by the same group,11 however,
showed that patients with secondary depression,
due to other disease, also had REM latencies within
the range seen in primary depression. They con-
cluded that the initial differences had been an ar-
tifact of the differing age distribution between the
two patient groups.
Subsequent studies addressed the differential di-
agnostic value of short REM latency and/or other
REM sleep abnormalities for a specific subtype of
depression. Some found no significant differences
in REM sleep changes between endogenous/melan-
cholic depression (a subtype with more somatic fea-
tures and a biological substrate) and nonendoge-
nous depression.12-14 Others found reduced REM
sleep latency specific for endogenous depression.15-17
However, since the latter compared less severely
nonendogenously depressed patients with more
severely depressed endogenous patients, the dis-
crepancy could be explained by the impact of de-
pression severity on sleep. Similarly, the greater
severity of depression with psychotic features could
account for the reportedly greater REM sleep abnor-
malities in psychotic versus nonpsychotic depres-
sion.1,18,19 Studies of unipolar versus bipolar depres-
sion have found no significant polysomnographic
differences.17,20 Thus the burden of present evidence
is that REM sleep changes are not specific to de-
pression subtypes. Decreases in REM sleep latency
and SWS also occur in other psychiatric disorders.
Meta-analysis of 177 sleep laboratory studies in var-
ious psychiatric syndromes found that the reduced
sleep efficiency and total sleep time accounted for by
the decreases in REM sleep disinhibition and SWS
were not highly specific to affective disorders. They
also occurred in other psychiatric conditions, such
as schizophrenia, alcoholism, obsessive-compulsive
disorder, and dementia.21
A key point is whether sleep abnormalities in de-
pression are “state-” or “trait-dependent.” Longitu-
dinal studies of EEG sleep profiles in depression de-
scribed a tendency for REM sleep abnormalities to
resolve with remission,22,23 and total normalization
was even reported after successful treatment.24 This
was consistent with the assumption that polysom-
nographic abnormalities were a state-dependent
phenomenon. However, other studies reported per-
sistence of REM sleep abnormalities during remis-
sion,25,26 and found an association between short
REM latency during remission and an increased
risk of relapse.27 Persistence of reduced SWS was
similarly associated with more rapid and frequent
recurrence.28
Since antidepressants modify sleep architecture,
these results could be biased by the inclusion of
drug-treated patients. To control for such an effect,
sleep profiles were longitudinally assessed in de-
pressed patients undergoing cognitive-behavioral
therapy. Decreased REM sleep latency, decreased
delta sleep ratio (the ratio of delta wave counts in
the first and second non-REM [NREM] sleep peri-
ods), and decreased SWS were found to be stable
over time, whereas REM density and sleep efficien-
cy improved significantly with remission.29 These
findings suggest that at least some polysomno-
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had had sleep disturbance on starting treatment,
thus making it unlikely that the disturbance was
treatment-emergent.60 Residual sleep disturbance
predicts relapse61: residual symptoms confer a 3-  to
6-fold higher risk of relapse than full remission.55
Clinicians thus need to be vigilant in identifying and
treating residual sleep disturbance in the manage-
ment of depression.
Persistent sleep disturbance appears associated
with increased suicide risk, although few studies
have addressed this issue. Reduced sleep for 4 weeks
was highly predictive of further suicidal episodes
in 58 high-risk patients with multiple acts of suici-
dal behavior.62 In adolescents, suicidal ideation was
linked to nonspecific somatic complaints, includ-
ing sleep difficulties,63 while depression and sleep
difficulties in adolescent suicide attempters admit-
ted to pediatric units were more frequent than in
other inpatient settings.64 The relationship between
sleep disturbance and suicide risk in depression de-
serves further investigation.
Psychobiology of 
sleep disturbance in depression
The two most prominent explanations for the sleep
abnormalities in depression are the reciprocal in-
teraction model of NREM and REM sleep regula-
tion65 and the chronobiological paradigm based on
the two-process Borbély model.66
The reciprocal interaction model assumes that
sleep disturbance in depression is due to dysfunc-
tion of the central neurotransmitter systems—
acetylcholine (Ach), norepinephrine (NE), and sero-
tonin (5-HT)—that modulate mood and sleep/
wakefulness. 5-HT neuron activity in the dorsal
raphe nucleus and 5-HT release at serotonergic ter-
minals are maximal during wakefulness, decreased
during SWS, and minimal during REM sleep.67,68 In
animal studies, 5-HT neurons in the dorsal raphe
(and noradrenergic neurons in the locus coeruleus)
inhibit REM sleep (REM “off” neurons), whereas
Ach neurons in the pontine tegmentum stimulate
REM sleep (REM “on” neurons).69 Thus, REM sleep
regulation depends on a balance between the 5-HT/
NE and Ach systems at the pontine level. Since de-
pression has been strongly associated with increased
central Ach tone and decreased 5-HT and NE trans-
mission,70 this imbalance has been held responsible
for disinhibiting REM sleep in depressed individu-
als. The model was subsequently modified on the
grounds that the neurotransmitter network in-
volved in modulating REM sleep is not confined to
the mesencephalon, but spread widely throughout
the nervous system.71
There is evidence of cholinergic supersensitivi-
ty in depression, resulting in enhanced REM sleep
pressure. Even in healthy humans, potentiation of
brain Ach transmission shortens REM sleep laten-
cy and decreases SWS.12 Compared with healthy
controls, depressed patients exhibit shorter onset
of REM sleep periods following cholinergic stim-
ulation, although this effect does not appear de-
pression-specific; great interindividual variability
within both depressed and control groups is also
of those with hypersomnia in the previous 6 months
met criteria for a psychiatric disorder, with major
depression showing the strongest association with
sleep disturbance.47 At reinterview a year later, 14%
of those with persistent insomnia had a new episode
of major depression, representing a near 40-fold
greater risk than in those without sleep complaints.
Conversely, individuals whose insomnia had re-
solved before the 1 year follow-up had much less
chance of developing depression. In a subsequent
analysis of the same data set, insomnia at a given
time point identified 47% of new cases of major
depression in the following year, thus having the
strongest predictive value of all the symptoms con-
sidered.48
Epidemiological data from primary care show a
quadruple increase in the likelihood of depression
in patients with severe insomnia.49,50 A similar anal-
ysis of 1000 adults followed for 3 years in a man-
aged care organization confirmed that a history of
insomnia at baseline conferred a relative risk of 4.0
for new onset major depression.51 Of eight epidemi-
ological studies of baseline primary insomnia as a
predictor of depression, all but one suggested that
isolated insomnia predicted an increased risk of de-
pression in the following1-3 years.52 Similarly, meta-
analysis of 20 prospective studies of risk factors for
depression among community elderly showed that
sleep disturbance was one of the strongest predic-
tors of depression over a mean 2-year follow-up.53
Studies confined to 1-3–year follow-up cannot ex-
clude baseline insomnia as just an early prodrome
of ensuing depression. However, preliminary epi-
demiological data suggest that the elevated risk for
mood disorders associated with disturbed sleep is
not limited to 1 to 3 years, but may persist for a life-
time. In a prospective 40-year study of the relation-
ship between self-reported sleep disturbance and
subsequent depression in 1053 medical students,
12% reported clinical depression at some time in
adulthood; those reporting insomnia in medical
school had twice the risk of clinical depression.54
Although these findings require replication, they
suggest that insomnia in young adults remains a
predictorof depression over at least 30 years. Indeed,
chronic insomnia itself may trigger depression: in-
ability to sleep as desired may cause helplessness-
hopelessness feelings leading to depression. These
data emphasize the need for appropriate early treat-
ment of sleep disorders to prevent subsequent de-
pression.
Even today, only one third of patients remit ful-
ly from drug therapy. Another third are partial re-
sponders, and the remaining third nonresponders.55
Partial responders still have residual symptoms.
These are associated with poor outcomes such as re-
lapse, work impairment, and emotional distress.56-59
Sleep disturbance persists in many partial respon-
ders: early insomnia in 48%, middle insomnia in
53%, and late insomnia in 16%.58 However, because
many drugs interfere with sleep,35 assessment of
residual sleep disturbance must control for treat-
ment-emergent disturbance. In a study where 44%
of patients meeting the criteria for remission con-
tinued to complain of sleep disturbances, almost all
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evidence of a correlation between the clinical re-
sponse to amitriptyline and clomipramine and the
degree of REM sleep suppression.78,79 Furthermore, a
study using selective REM sleep deprivation showed
a significant correlation between improvement in
depressive symptoms and REM sleep suppression.80
However, not all antidepressants suppress REM
sleep.4,81 Atypical antidepressants, eg, the reversible
MAOI moclobemide, nefazodone, and bupropion,
may actually enhance REM sleep despite proven
antidepressant efficacy.82-84 This invalidates the hy-
pothesis that antidepressants act by suppressing
REM sleep. Antidepressants have less evident and
consistent effects on NREM sleep parameters, with
some drugs increasing SWS and others decreasing
it.77
Antidepressant effects on sleep are clinically im-
portant. TCAs, for example, have very varied effects
on subjective sleep. Amitriptyline, trimipramine,
nortriptyline, and doxepin improve insomnia,
whereas imipramine and desipramine are associ-
ated with insomnia; the evidence is less clear for
clomipramine.85 SSRIs have varied effects, with 10%
to 15% of patients complaining initially of insom-
nia; as a result, a significant minority receive con-
comitant hypnotics. In a retrospective study of the
Texas Medicaid database, 35% of 30 000 patients
receiving SSRIs also received anxiolytic hypnotics.86
Nevertheless, many patients report improved sleep
during SSRI therapy.87 The two SNRIs now avail-
able, venlafaxine and duloxetine, resemble SSRIs in
their effects on sleep, with insomnia rates higher
than placebo.89,90
Bupropion is generally considered an activating
antidepressant, with 5% more patients reporting
treatment-emergent insomnia than on placebo.91
Mirtazapine significantly shortens time to sleep on-
set, improves sleep efficiency, and increases total
sleep time by reducing nocturnal awakening, part-
ly because of its prominent antihistaminic effects.92
Trazodone increased total sleep time and de-
creased nocturnal awakening.93 It  also improved
insomnia when coprescribed with another antide-
pressantdrug.94,95 Nefazodone tends to improvesleep
continuity and maintenance: in two double-blind
studies it was more effective than fluoxetine in im-
proving sleep quality and efficiency and in reduc-
ing nocturnal awakening.96,97
Agomelatine, an antidepressant with an innova-
tive pharmacological profile combining melatonin
receptor agonism and 5-HT2C receptor antagonism,
has peculiar effects on sleep architecture and sub-
jective sleep in major depression. It increases SWS
and normalizes the distribution of both SWS and
REM sleep throughout the night, improving sleep
continuity.98 It was more effective than venlafaxine
in terms of shorter sleep onset and greater sleep
quality, without diurnal drowsiness.99
Antidepressants thus vary between and within
classes in their effects on the sleep profile. Clinicians
should allow for these effects when prescribing. Pa-
tients reporting sleep onset insomnia are more like-
ly to benefit from a sedating antidepressant, where-
as those complaining of hypersomnolence would
benefit from a nonsedating compound.
common.72,73 Moreover, cholinergic stimulation
with arecoline provoked faster REM sleep induction
in remitted depressed patients than in healthy sub-
jects,74 while euthymic subjects with a family his-
tory of affective disorders showed an enhanced
response of the REM sleep system to cholinergic
stimulation.75 These findings suggest that cholin-
ergic supersensitivity leading to disinhibition of
REM sleep may represent a trait or vulnerability
marker of depression.
The chronobiological model focuses on NREM
sleep rather than on REM-sleep disinhibition to ex-
plain sleep disturbance in depression. In the two-
process model,76 the amount of SWS at night is de-
termined by the amount of prior wakefulness, the
level of sleep propensity during the day, and the
depth of sleep at night (“process S” [“sleep”]). Pro-
cess S accumulates during waking hours as SWS
propensity rises, and dissipates during the night,
leading to an exponential decline in SWS. The sec-
ond process (“process C” [“circadian”]) reflects the
circadian control of sleep propensity, which is high-
est between 3 and 5 AM and lowest at 4 PM. The ten-
dency to fall asleep depends on the difference be-
tween S and C; awakening occurs when S and C fall
together. In healthy humans, the propensity for
REM sleep is assumed to increase as SWS dissipates,
thus explaining the short duration of the first REM
period, when SWS is high (first part of the night),
and the increase in REM sleep in the second part of
the night, when SWS dissipates. In depression, the
theory is that an impaired process S decreases SWS,
with diminished accumulation of sleep pressure
during the day and reduced dissipation of SWS at
night.66 The decrease in SWS in the initial NREM
sleep period allows early onset of the first REM pe-
riod.
The reciprocal interaction model of NREM and
REM sleep regulation accounts for REM sleep tim-
ing abnormalities, but does not address NREM sleep
disturbance per se, except as a consequence of REM
disinhibition. The chronobiological impaired pro-
cess S model, on the other hand, accounts for ab-
normal timing of sleep onset, intermittent noctur-
nal awakening, decreased SWS, and abnormal REM
timing. It also accounts for the antidepressant ef-
fects of sleep deprivation by proposing that pro-
longing wakefulness increases process S and SWS,
thereby ameliorating mood. Although each model
has limitations, they remain possible explanations
for abnormal sleep architecture in depression.
Effects of antidepressants  
on sleep in depression
Most antidepressants, whether tricyclic antidepres-
sant (TCA), monoamine oxidase inhibitor (MAOI),
selective serotonin reuptake inhibitor (SSRI), or
the serotonin norepinephrine reuptake inhibitor
(SNRI) venlafaxine, suppress REM sleep, prolong
REM latency, and decrease total REM sleep time.77
Due to the connection between increased REM
sleep pressure and depression, antidepressant sup-
pression of REM sleep was initially considered a pre-
condition of efficacy.77 This belief was backed by
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derstanding of the biological background to those
abnormalities. Despite the absence of hard evidence
for a causal relationship with depression, sleep dis-
turbance deserve clinical attention. Nondepressed
individuals with persistent insomnia appear at high
risk for depression in the subsequent 1 to 3 years
and for up to 30 years. Moreover, the persistence of
sleep abnormalities in responders and remitters
appears associated with increased risk of relapse,
recurrence, and suicide. Optimized management of
insomnia may thus play an important part in the
prevention and treatment of depression. 
Conclusion
Sleep disturbance is frequent in depression, but
whether as cause or effect remains unknown. Nor
is it yet clear whether sleep abnormalities are state
or trait markers of major depression. At least some
polysomnographic changes probably reflect “vul-
nerability,” since not only do they fail to resolve on
remission, but they are also present in never-de-
pressed healthy subjects with a heavy family history
of depression and in the healthy relatives of de-
pressed probands. Genetic studies should aid un-
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SOMMEIL PERTURBÉ, UN SYMPTÔME MAJEUR
DE LA DÉPRESSION
L es troubles subjectifs du sommeil, qu’ils soient typiques, comme l’in-somnie d’endormissement, les réveils nocturnes fréquents, les réveils ma-tinaux précoces, ou moins typiques, comme l’hypersomnie, sont fréquents
dans la dépression majeure. Y sont également rattachées les variations poly-
somnographiques structurales, principalement l’augmentation de la « pres-
sion » de sommeil à mouvements oculaires rapides et la diminution du som-
meil à ondes lentes. Certaines de ces modifications, sans qu’aucune ne soit
spécifique de la dépression, persistent après la rémission et constituent ainsi
un marqueur potentiel de vulnérabilité. Des données épidémiologiques sug-
gèrent que les troubles du sommeil, au-delà de leur signification en tant que
symptôme majeur de la dépression, seraient aussi un facteur de risque ou un
symptôme prodromal d’un nouvel épisode dépressif ou encore un symptôme
résiduel après un traitement efficace. La prise en charge de l’insomnie est donc
essentielle dans la prévention et le traitement de la dépression. Les effets des
antidépresseurs sur le sommeil subjectif et l’architecture du sommeil diffèrent
à la fois entre les classes d’antidépresseurs et au sein d’une même classe. Les
médecins doivent prendre ces effets en considération dans leur choix de l’anti-
dépresseur le plus adapté pour un patient donné. 

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A questionnaire relating to the month before diag-
nosis of major depression showed that 40% of men
and 50% of women had decreased libido and sexual
arousal; specifically orgasmic problems were less
common (15% to 20%).
Because SD is such a frequent presenting com-
plaint and may persist as a side effect of antidepres-
sant treatment, it must be identified at diagnosis
and monitored during therapy. The purpose of treat-
ing depression is to achieve complete remission
without impairing quality of life. Treatment of a first
episode may take several months, but may need to
be maintained for years in recurrent depression and
other chronic disease, such as anxiety or dysthymia.
Long-term sexual side effects thus become a key as-
pect of tolerability, and hence treatment compli-
ance. At worst, SD can be responsible for nonremis-
sion and recurrence. 
Clinicians must take a careful sexual history be-
fore initiating antidepressant therapy. Sexual per-
formance parameters should include libido, erectile
function, vaginal lubrication, and ejaculation/or-
gasm. They should be periodically reviewed during
follow-up. This will ensure early recognition of
treatment-related SD.
A ccording to the National Health and SocialLife Survey in a demographically represen-tative cohort of US adults in 1992, sexual
dysfunction (SD) is common, and more prevalent
in women (43%) than men (31%).1 In depressives,
SD is a classic symptom. Depression is character-
ized by loss of interest and energy, low self-esteem,
disturbed sleep, and anhedonia. A major conse-
quence is a collapse in communication skills that
impairs personal relationships. Many patients, due
to lack of insight, take months or even years before
seeking help. Such a scenario makes it difficult to
lead a satisfactory sexual life. SD may actually be the
problem that induces the patient and/or partner to
seek help. SD is twice as common in depressed pa-
tients than in normal controls (50% versus 24%).2
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S exual dysfunction may be the commonest side effect of antidepressanttherapy. The prime culprits—selective serotonin reuptake inhibitors,serotonin norepinephrine reuptake inhibitors, and tricyclic antidepres-
sants—impair sexual function in up to 60% of patients, due to their seroto-
nergic mechanism of action. Other antidepressants, however, with a different
mechanism of action—bupropion, moclobemide, mirtazapine, and the recent-
ly introduced melatonergic antidepressant agomelatine—have many fewer
sexual side effects. Quality of life is a major challenge for compliance with long-
term treatment. Clinicians often underestimate sexual side effects and spon-
taneous reports by patients are few (14% to 24%). Brief, practical, and specific
questionnaires can be helpful. Coping strategies include waiting for sponta-
neous remission, decreasing the dose, antidotes, and weekend drug holidays,
but none are satisfactory for all patients. Probably the most effective method is
to switch to a drug without sexual side effects. Primary prevention in sexually
active patients begins with selecting a sexually nonincapacitating antidepres-
sant. Clinicians should then systematically monitor the sexual effects of their
treatment.
Medicographia. 2008;30:24-29. (see French abstract on page 29)
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core symptoms of depression? 
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SELECTED ABBREVIATIONS AND ACRONYMS
ASEX Arizona Sexual Experiences Scale
CSFQ Changes in Sexual Functioning Ques-
tionnaire 
ED erectile dysfunction
GABA γ aminobutyric acid
GAD generalized anxiety disorder 
MAOI monoamine oxidase inhibitor  
PRSexDQ Psychotropic-Related Sexual Dysfunction
Questionnaire
SD sexual dysfunction
SexFX Sexual Effects (scale)
SNRI serotonin norepinephrine reuptake 
inhibitor 
SSRI selective serotonin reuptake inhibitor
tion, while serotonin, via postsynaptic 5-HT2 recep-
tors, inhibits desire, and ejaculation/orgasm.25,26
Noradrenergic influence is unclear, but appears to
modulate the onset and maintenance of copulato-
ry behavior in male rats.27 Blockade of peripheral
α-adrenergic and cholinergic receptors in the gen-
itourinary tract impairs sexual function.28 Potent
anticholinergic agents and/or α1-blockers (such as
antidepressants and some antipsychotic agents) are
strong inhibitors of sexual arousal.
Antidepressants may induce SD via an effect on
nitric oxide.29 Sildenafil, an effective treatment for
erectile dysfunction (ED) of variable etiology, stim-
ulates the action of nitric oxide. At the same time,
many other drug classes are associated with SD,
including cardiovascular agents (antihypertensives,
digoxin), H2 receptor antagonists, hormones, cyto-
toxics, and lipid-lowering agents, although such ef-
fects tend to be rarely reported to pharmacovigilance
systems other than by manufacturers.30 Adrenergic
inhibition may mediate the effect of antihyperten-
sives, eg, methyldopa, reserpine, clonidine, and pro-
pranolol, on erectile function and ejaculation. 
 The importance of specific questionnaires in
eliciting sexual problems
Several validated SD questionnaires have been de-
veloped in recent years (Table II), eg, the Psycho-
tropic-Related Sexual Dysfunction Questionnaire
(PRSexDQ),31 the Sex Effects (SexFX) scale,32 the
Changes in Sexual Functioning Questionnaire
(CSFQ),33 and the Arizona Sexual Experiences Scale
(ASEX).34
The PRSexDQ has been used in several groups of
depressed and schizophrenic patients on medica-
tion,35 and in direct clinical interviews by the Span-
Antidepressant effects on 
sexual function and dysfunction
There are many causes of SD in major depression:
the disease itself, the collapse in social and inter-
personal relationships, and the medication, to name
a few. The clinician’s task is complicated by the fact
that depression also makes it difficult for patients to
communicate their complaints, in particular those
concerning sexual function. As a result, this aspect
is often underestimated. 
Fortunately, however, SD has become increasing-
ly recognized in recent years.3-5 It is the common-
est side effect of the antidepressants that increase
serotonin levels: selective serotonin reuptake in-
hibitors (SSRIs), venlafaxine, and clomipramine.6,7
The resulting impact on quality of life leads to
noncompliance with long-term treatments. SD is
among the commonest side effects leading to drop-
out (50.8%).8 The incidence of iatrogenic SD differs
between antidepressants. It is more common with
monoamine oxidase inhibitors (MAOIs), SSRIs, sero-
tonin norepinephrine reuptake inhibitors (SNRIs)
such as venlafaxine, and tricyclic antidepressants,
in particular those with a high serotonin reuptake
inhibitor profile, eg, clomipramine.9,10 Bupropion,11
mirtazapine, moclobemide,12 and tianeptine are
much less frequently involved, being nonseroton-
ergic.
Antidepressants impair function across all sexual
activity phases: desire, arousal, and orgasm/ejacu-
lation. Among the less frequent changes, there are
anecdotal reports of penile and clitoral anesthe-
sia,13,14 painful orgasm,15 orgasm associated with
yawning,16,17 priapism associated with paroxetine18
and trazodone,19 increased libido,20 spontaneous or-
gasm,21 and decreased ejaculation volume.
The true incidence of such effects is unlikely to
come to light unless explicitly elicited. Spontaneous
report is uncommon, despite the potentially ma-
jor impact of such side effects on treatment com-
pliance. In a specific study, SD was volunteered by
14% of patients, but elicited in 58% by question-
naire.22 Patients are not only embarrassed to men-
tion SD, but also unhopeful of receiving help.23
Reports on secondary SD have significantly in-
creased since the 1980s, and comparison with
placebo-treated patients and healthy volunteers has
shown a close relationship between SD and antide-
pressant use. Clinicians should therefore be well
prepared for managing such effects.
 Mechanisms of antidepressant-related sexual
dysfunction
The normal sexual response includes a combination
of neurogenic, psychogenic, vascular, and hormon-
al factors coordinated by higher centers (Table I)
via multiple neurotransmitters, including dopamine,
serotonin, norepinephrine, acetylcholine, γ-amino-
butyric acid (GABA), oxytocin, arginine-vasopressin,
angiotensin II, gonadotropin-releasing hormone,
substance P, neuropeptide Y, and cholecystokinin-8.24
Hormones are particularly important: estrogen,
testosterone, and progesterone in women, and tes-
tosterone in men. Dopamine enhances sexual func-
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 Increased serotonin activity
 Anticholinergic effect
 D2 blockade
 Nitric oxide inhibition









Scale ASEX CSFQ SexFX PRSexDQ
McGahuey Clayton Kennedy Montejo
Author/country USA USA Canada Spain
Questions 5 14 13 29
<10 minutes yes yes yes yes
Measures change yes yes yes yes
Intrusive no no no yes
Likert scale yes yes yes 5 items
Specific drug–related no no no no
With interview no no yes no
Table II. Comparison of sexual dysfunction assessment instruments.
Abbreviations: ASEX, Arizona Sexual Experiences Scale; CSF-Q, Changes in Sexual Function-
ing Questionnaire; DISFSR, Derogatis Interview for Sexual Functioning Short Report; RSI,
Rush Sexual Inventory; PRSexDQ, Psychotropic Related Sexual Dysfunction Questionnaire;
SexFx, Sex Effects (scale).
tidepressant monotherapy revealed significant SD
in 37%. Highest SD rates among SSRI and SNRI
users belong to citalopram, paroxetine (the most
potent SSRIs), and venlafaxine. Reports of male SD
to the Committee on Safety of Medicines during the
first 2 years of SSRI use in the UK were 10-fold high-
er for paroxetine than for remaining SSRIs. Meta-
analysis also showed higher rates of SD and seda-
tion with paroxetine over other SSRIs.36 In our own
patients, SD rates were slightly lower with fluoxe-
tine than with other SSRIs. There is a clear relation-
ship between serotonergic activity, lowered libido,
and delay and/or absence of ejaculation/orgasm. 
The reversible MAO-A inhibitor moclobemide
has very little effect on sexual function, probably
because it is dopaminergic and nonserotonergic.
Bupropion, as a selective norepinephrine and dopa-
mine reuptake inhibitor devoid of serotonergic ac-
tivity, has similarly few effects, with SD rates no
different from those on placebo in 6300 patients re-
ceiving a variety of newer antidepressants, includ-
ing SSRIs and venlafaxine37; orgasmic dysfunction
is less common than on SSRIs, and SD much less
common than on venlafaxine.38 Bupropion is sim-
ilarly devoid of other common antidepressant-as-
sociated side effects, such as weight gain and se-
dation.
SSRIs may be the major culprits with regard to
SD, but there are important differences between
them. A prospective multicenter study in 1010 pa-
tients showed that decreased libido and delayed
ejaculation/orgasm were the most frequent effects
with SSRIs and venlafaxine (Table III). ED was sig-
nificantly less common than ejaculation problems,
suggesting a different mechanism of action related
not to serotonin, but rather to peripheral adrener-
gic and cholinergic pathways combined with other
factors. The differences between paroxetine, citalo-
pram, and venlafaxine were significant since ED
rates approached 30% to 40%. Paroxetine was asso-
ciated with significantly higher rates of ED or in-
adequate vaginal lubrication. This effect has been
turned to advantage as a coadjuvant in the treat-
ment of compulsive sexual behavior, premature
ejaculation, and paraphilia. 
SSRIs did not differ from venlafaxine in depress-
ing libido, but paroxetine, for example, caused
greater ED, possibly because it is a 5 to 160 times
more potent cholinergic blocker than other SSRIs.
ish Working Group for the Study of Psychotropic-
Related Sexual Dysfunction. It has shown satisfac-
tory feasibility and good psychometric properties.
It consists of 7 items assessing 5 dimensions of SD
according to severity or frequency: loss of libido,
delayed or absent orgasm/ejaculation, ED (men)/
vaginal lubrication dysfunction (women), and pa-
tient acceptance of SD. In addition to individual
item scores, it provides a summated scale score with
items 3 to 7 ranging from 0 to 15 (severe SD). 
The SexFX scale has been used in previous stud-
ies to compare sexual side effects associated with
various antidepressants.32 It is a brief scale devel-
oped to capture changes in the frequency of desire,
arousal, and orgasm, which can be summed to pro-
vide a total SexFX score. Scale items are gender-spe-
cific where necessary. Two additional lines provide
a global satisfaction score.
 Frequency of antidepressant-related sexual
dysfunction
The PRSexDQ scale elicited a frequency of SD
among antidepressant users that was significantly
higher than volunteered SD (59.1% versus 24%)
(Figure 1). This confirmed studies reporting fre-
quencies between 30% and 70%, and revealed the
extent of a problem that would otherwise have gone
undetected. A cross-sectional observational study
using the CSFQ in 8312 US patients receiving an-
26 Are sexual disorders core symptoms of depression? – MontejoMEDICOGRAPHIA, VOL 30, No. 1, 2008
T H E C O R E O F D E P R E S S I O N
Fluoxetine Paroxetine Fluvoxamine Sertraline Citalopram Venlafaxine Mirtazapine
N=279 N=208 N=77 N=159 N=66 N=55 N=49
Decreased libido 50.2 63.9 48.1 54.7 62.1 60.0 20.4
Delayed orgasm 49.5 63.9 54.5 56.6 63.6 61.9 18.4
Anorgasmia 39.1 52.8 37.6 47.1 51.5 41.8 8.2
Erectile/ 
lubrication 21.8 41.4* 20.8 28.9 34.8 40.0 14.2 
dysfunction
Table III. Specific sexual side effect rates (%) with individual antidepressants in a multicenter study in 1010 evalu-
able patients. (*P<0.05 paroxetine versus other antidepressants.) 
From reference 6: Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with different antidepressant
agents. A prospective and multicenter study in 1022 patients. J Clin Psychiatry. 2001;62(suppl 3):10-21. Copyright © 2001, Physicians
Postgraduate Press, Inc.
Figure 1. Prevalence of sexual dysfunction with selective serotonin reuptake
inhibitors (SSRIs).
From reference 6: Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction
associated with different antidepressant agents. A prospective and multicenter study in 1022



























treatment. Perhaps surprisingly, the older the pa-
tient, the less likely he or she is to tolerate SD. Length
of treatment may be an important variable in this
regard. The presence of SD could be secondary to a
months-long history of impaired libido and ejacu-
lation/orgasm.
 Patient and/or partner acceptance of sexual
dysfunction
SD acceptance influences the rate of treatment drop-
out. We recently found SD well accepted by 27.2%
of patients, accepted with reservations by 34.5%,
and not accepted at all by 38.3%, in which case non-
compliance rates were high (Table IV). Paroxetine
was the least tolerated drug by patients with SD
when compared with fluoxetine. Large-scale sur-
veys have shown that between 41.7% and 50.8% of
all withdrawals are due to side effects. Hence the
importance of using alternative treatments to de-
crease the frequency and intensity of SD. 
Management strategies 
Several strategies are available for managing an-
tidepressant-induced SD, including awaiting spon-
taneous remission, adjusting the dose, taking drug
holidays, switching drugs, administering antidotes,
and deploying nonpharmacologic strategies, al-
though their efficacy remains mostly unknown or
unproven (Table V).49,50
Although spontaneous remission may occur af-
ter a while and for a while, at least 80% of patients
with SD will have symptoms at 6 months. Differ-
ences between antidepressants in this regard are
unknown, but durable spontaneous remission may
prove more achievable with the newer dual-action
agents such as SNRIs.
Tapered dose reduction is especially useful in pa-
tients who are also experiencing other side effects.
However, it should only be attempted in good re-
sponders. Clinician and patient should be alert for
any signs of relapse or discontinuation symptoms.
Drug holidays, in which patients skip treatment
for a day or two, can be effective, but can also under-
mine treatment compliance. Even if instructed to
take their treatment every day except at weekends,
patients may still decide to skip other days as well.
In addition, with short-acting SSRIs, drug holidays
However, the recent discovery that it is a potent ni-
tric oxide synthase inhibitor, both in vitro and in
vivo, offers an alternative explanation. 
With mirtazapine, SD is much less common
(24.4%) and much less intense (delayed orgasm
and milder anorgasmia) than with SSRIs and ven-
lafaxine. However, ED is as severe as with the other
drugs, due to the different mechanisms involved in
erectile and orgasmic function. In several studies,
SD improved markedly in patients switched to mir-
tazapine from other antidepressants. Mirtazapine
has been reported to reverse SD when added to an
SSRI. It also appears to improve SD in depressed
men and women. However, this needs to be bal-
anced against side effects such as weight gain and
somnolence. A reported global improvement of
64.7% suggests that mirtazapine is a good thera-
peutic alternative in patients with severe SD, es-
pecially orgasmic problems, secondary to other
drugs.39
The first case of SD reversal was recently de-
scribed in a patient switched from one SSRI to an-
other, escitalopram. The SNRI duloxetine appears
to cause less SD than paroxetine or escitalopram.40
However, there are too few controlled studies to
conclude that SD is significantly less common with
either escitalopram or duloxetine.
Agomelatine, a recent antidepressant with novel
properties (a melatonin MT1 and MT2 receptor ag-
onist, and a 5-HT2C antagonist), preserves SD.41-43
Agomelatine 50 mg/day was superior in both or-
gasm and preorgasm measures to venlafaxine XR
150 mg in remitted patients after 12 weeks, and was
similar in antidepressant efficacy.43 Agomelatine also
caused significantly less SD than paroxetine (<10%
versus >80%) in a sample of 90 healthy volunteers,
and was indistinguishable in this regard from place-
bo.44 Agomelatine resets circadian rhythms in de-
pressed patients, significantly improves individual
sleep phases and overall sleep quality, and does not
cause daytime drowsiness.45 Experience across a
range of studies suggests that agomelatine offers a
novel approach to the treatment of depression com-
bining efficacy, even in severe disease, with an ex-
tremely favorable side-effect profile, with particular
regard to sexual function.45-48
 Effect of gender and age on sexual dysfunction
in depression
SD is slightly more common in men than women
(62.4% versus 56.9%), but decreased libido, delayed
orgasm, and anorgasmia are all more severe in
women. Since women are generally more reluctant
to report SD than men, it is especially important to
monitor this aspect after initiating antidepressant
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 Switch to bupropion and mirtazapine C
 Switch to moclobemide, trazodone, 
reboxetine, maprotiline, escitalopram, 
tianeptine NC
 Antidotes, buspirone, amantadine, 
selegiline, and Ginkgo biloba are NO  
better than placebo C
 Sildenafil useful in erectile dysfunction C
 Weekend holidays useful in anorgasmia NC
Table V. Levels of evidence for management strategy in
sexual dysfunction.
Abbreviations: C, controlled trials; NC, noncontrolled trials, small
group or individual case reports.
Good Fair Nil*
27.2% 34.5% 38.3% 
*High dropout risk. 
Table IV. Patient acceptance of sexual dysfunction.
From reference 42: Montejo AL. Beyond efficacy on the core symp-
toms of depression: sex and sleep benefits. Eur Psychiatry. 2007;
22(suppl 1):S92. Abstract. Copyright © 2007, Elsevier Masson SAS. 
techniques. Patients should also be warned against
avoiding sexual activity, since maintaining a sex life
helps to enhance improve sexual desire.
Conclusions
The incidence of antidepressant-related SD is un-
derestimated. It occurs mainly with serotonergic
agents such as SSRIs and venlafaxine. It is impor-
tant because it impairs quality of life and increases
the risk of noncompliance with a treatment that is
often long-term and in some cases life-long. SD can
only be effectively detected and managed during
treatment if a detailed psychosexual history, includ-
ing with the use of scales, has been taken before
treatment. Alternative options are needed in pa-
tients in whom SD does not spontaneously remit
and/or who find SD unacceptable. SD is not explic-
itly mentioned among the diagnostic criteria for
Major Depressive Episode according to the Diag-
nostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV). However, “markedly dimin-
ished interest or pleasure in all, or almost all activ-
ities most of the day, nearly every day” could also be
interpreted as loss in sexual interest. 
This paper provides strong scientific evidence that
sexual dysfunction should be considered as one of
the core symptoms of depression, as is the case for
depression, anhedonia, and disturbed sleep in de-
pressed patients. New treatments that preserve sex-
ual function could, in future, contribute to a better
overall outcome of the treatment in terms of re-
mission. In sexually active patients, the risk of SD
must be a major consideration when selecting an
antidepressant for long-term use. The best strategy
is from the outset to use a drug with a known low
SD potential. 
can cause relapse or discontinuation symptoms.
Replacing one SSRI with another may alleviate SD,
but only in 10% of cases. Replacing SSRIs with
drugs having a different mechanism of action, eg,
bupropion51 and mirtazapine,52 appears more effec-
tive. Patients with GAD have also been successful-
ly switched to the selective GABA reuptake inhibitor
tiagabine with no further complaints of SD.53 Ago-
melatine opens up interesting perspectives in this
context, as it combines antidepressant efficacy and
preservation of sexual function, making it particu-
larly valuable in patients suffering from moderate-
to-severe SD.
Antidotes may be an effective option for manag-
ing antidepressant-induced SD, but more data are
required. Most of the available evidence derives from
case reports, case series, and open-label trials. Anti-
dotal therapy is claimed to alleviate SD and encour-
age compliance with the antidepressant regimen.54
Antidotes commonly used in placebo-controlled tri-
als have included drugs approved for treating ED,
eg, sildenafil and tadalafil.55
Duloxetine and agomelatine are among the new-
er candidate antidotes. Sexual function was assessed
using the ASEX in 4 double-blind placebo- and
paroxetine-controlled trials of duloxetine in patients
with major depression.56 The incidence of treatment-
emergent SD was significantly lower on duloxetine
than on paroxetine, although both rates were high-
er than on placebo. In healthy volunteers, SD rates
on agomelatine were similar to those on placebo
and lower than on paroxetine. It appears a good al-
ternative treatment for patients with moderate to
severe SD on another antidepressant. A nonphar-
macologic approach may also help. Simply talking
may be enough in some patients, while others may
benefit from sex therapy or trying different sexual
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LES TROUBLES SEXUELS SONT-ILS
DES SYMPTÔMES MAJEURS DE LA DÉPRESSION ?
L es troubles sexuels semblent être l’effet indésirable le plus fréquent dutraitement antidépresseur. Les premiers coupables, les inhibiteurs sélec-tifs de la recapture de la sérotonine, les inhibiteurs de la recapture de la
sérotonine et de la noradrénaline et les antidépresseurs tricycliques, altèrent
la fonction sexuelle de près de 60 % des patients en raison de leur mécanisme
d’action sérotoninergique. D’autres antidépresseurs, tels que le bupropion, le
moclobémide, la mirtazapine et un nouvel antidépresseur mélatoninergique,
l’agomélatine, ont cependant beaucoup moins d’effets sexuels indésirables de
par leur mode d’action différent. La qualité de vie est le principal critère d’ob-
servance d’un traitement au long cours. Les effets sexuels indésirables sont sou-
vent sous-estimés par les médecins et rarement évoqués spontanément par les
patients (14 % à 24 %). Des questionnaires brefs, pratiques et spécifiques peu-
vent être utiles. Aucune des stratégies d’ajustement n’est satisfaisante pour la
totalité des patients, qu’il s’agisse de l’attente d’une rémission spontanée, de la
diminution de posologie, d’antidotes et de fenêtre thérapeutique du week-end.
La méthode la plus efficace est probablement celle du changement de classe
thérapeutique vers un médicament sans effets secondaires sexuels. Outre la pré-
vention primaire pour les patients sexuellement actifs, qui passe par le choix
d’un antidépresseur n’inhibant pas la fonction sexuelle, le médecin se doit d’éva-
luer systématiquement les effets sexuels des traitements prescrits.

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and social stimuli entrain the circadian pacemaker
to the 24-hour cycle. In humans, circadian varia-
tions characterize multiple physiological and psy-
chological functions, including core body temper-
ature, endocrine and autonomic functions, sleep,
mood, alertness, and cognitive performance.1-4 Core
body temperature peaks during the day, and drops
during the night. Melatonin levels peak during the
night, and are lowest during the day. Cortisol levels
reach a low at bedtime and rise again in the morn-
ing. Thyroid stimulating hormone peaks prior to
sleep onset, wanes during the night, and rises again
during the day.4
Sleep and wakefulness are the most obvious man-
ifestations of the mammalian circadian system. The
drive to sleep is determined by two processes, one
homeostatic (process S), and the other circadian
(process C).5,6 Process S increases sleep propensity
with increasing duration of prior wakefulness. Pro-
cess C is a SCN-dependent circadian mechanism,5,6
which integrates and reinforces endogenous and
exogenous zeitgebers to enhance the maintenance
of wakefulness during the circadian day, and to en-
hance the maintenance of sleep during the night.
Healthy subjects typically report mood deteriora-
tion in the evening compared with the morning.7,8
Mood variation across the 24-hour cycle depends
on the interaction between circadian phase and the
duration of prior wakefulness.1 Mood, alertness, and
cognitive performance decline during the day, and
are worst during the night.4,9
A ll species exhibit marked endogenous vari-ations in several physiological and behav-ioral rhythms. Rhythms that approximate
the 24-hour light-dark cycle are termed circadian
(from the Latin circa diem, “about a day”), whereas
those that are shorter or longer than the 24-hour
cycle are termed ultradian and infradian, respective-
ly. These cyclic processes are endogenously gener-
ated, maintained, and regularized. Synchronization
of multiple endogenous processes enhances survival.
A central homeostatic pacemaker, the suprachias-
matic nucleus (SCN) of the hypothalamus, orches-
trates the multiple oscillator systems. To further
enhance survival, the pacemaker is adaptable. It can
be entrained to respond directly or indirectly to ex-
ternal time givers, or zeitgebers. Stimuli from the
environment (light/dark), behavior (meals, sleep),
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D epression is characterized by disturbances in multiple physiological,neuroendocrine, neurobiological, behavioral, and social rhythms. Anumber of depressive symptoms vary in severity over a 24-hour period.
Diurnal mood variations and sleep disturbances are the most commonly ob-
served circadian disturbances in depressed patients. Circadian disturbances
affect treatment response and clinical outcome. Similarly, regularizing and
stabilizing behavioral and social rhythms in patients with mood disorders di-
rectly benefits mood symptoms and clinical outcome. We briefly describe some
of the ultradian and circadian disturbances reported in major depression before
discussing the relationship between sleep disturbance and the course and out-
come of depression. We then present an alternative to the  pharmacotherapeu-
tic approach, namely social rhythm therapy, which is designed to regularize so-
cial rhythms in patients with mood disorders. Recognizing circadian variations
in symptoms and aiming to regularize circadian and sleep disturbance may en-
hance treatment outcome in depression.
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maintenance insomnia, and early morning awak-
enings,24 while a minority (6% to 29%) report hy-
persomnia.25 Objective sleep measures are also dis-
turbed.26 The latency between sleep onset and the
first episode of rapid eye movement (REM) sleep is
typically shortened. Depressed patients exhibit long-
er REM sleep, more eye movements during REM
sleep, and shorter slow-wave sleep than healthy
subjects.24 Depressed patients also differ in alertness
over the 24-hour cycle compared with normals.
Sustained alertness across the 24-hour cycle in de-
pressed patients may relate to heightened neuronal
activity in the brainstem and hypothalamic regions
involved in maintaining daytime wakefulness. In
healthy subjects, brain glucose metabolism is in-
creased in the brainstem and hypothalamic regions
involved in maintaining wakefulness in the evening
relative to the morning. This may reflect an in-
creased circadian drive to remain alert as sleep
propensity increases in the evening.27
Diurnal patterns of motor activity tend to differ
between patients with major depression and healthy
subjects.28 Continuous activity measurement using
actigraphs (wristwatch-like devices) that detect and
store information on wrist movement have consis-
tently shown greater between-patient variability
and reduced activity levels across the 24-hour cycle
in depressed patients.29,30 Speech pause time is also
increased.31,32 Differences inpatternsof reaction time
and cognitive performance have also been reported.
Specifically, depressed patients are slower in deci-
sion time and motor performance in morning test-
ing, but not evening testing.33-35
While some evidence suggests that diurnal vari-
ation in depressive symptoms parallels diurnal vari-
ation in neurobiological and neuroendocrine activ-
ity, the specific underlying mechanisms remain
largely unelucidated. Recent advances in molecular
biology suggest that polymorphisms in circadian
(or clock) genes constitute a critical mechanism by
which circadian and sleep disturbances predispose
to depressive illness33 and underlie diurnal symptom
variation. Additionally, the role of disrupted social
rhythms as mediators of the relationships between
diurnal symptom variation and physiological circa-
dian disturbances remains unknown. Several stud-
ies have now shown that social rhythms are disrupt-
ed and less regular in patients with mood disorders
and individuals undergoing stressful life events.36-40
Disrupted social rhythms may be directly responsi-
ble for diurnal depressive symptom variation. The
association between increased regularity of social
rhythms and reduced depression severity41-43 sug-
gests that irregular social rhythms may mediate the
relationship between diurnal symptom variation
and physiological circadian disturbances.
Relationship between  
sleep disturbances and depression
There is clinical and epidemiological evidence that
sleep disturbance in depression is a risk factor for
poor clinical outcomes. Insomnia complaints pre-
cede the onset and recurrence of depression44 in up
to 40% of cases.45 The risk of developing major de-
Circadian disturbances have been reported in
multiple physiological systems in patients with ma-
jor depression. Increased mean core temperature
and decreased period amplitude are well document-
ed.10 Circadian oscillations in plasma cortisol and
norepinephrine occur earlier in the 24-hour period,
or are phase-advanced, compared with healthy sub-
jects;11 24-hour cortisol secretion is more variable12
and less closely related to social zeitgebers.13 Ab-
normal levels and patterns of melatonin secretion
have also been observed in some,14 but not all stud-
ies.15 Sleep disruption is a particularly well-docu-
mented circadian disturbance in depression, as dis-
cussed in more detail below.
Circadian disturbances in depression may relate
to impaired generation of circadian rhythms, desyn-
chronization of multiple circadian rhythms, and
blunted responsiveness of the circadian system to
entrainment cues, or to reduced exposure to, fre-
quency of, these entrainment cues due to the re-
duced activity levels, anhedonia, and social isolation
that characterize depressive episodes. In sum, com-
plex disturbances in multiple circadian mechanisms
may account for the heterogeneity of symptoms in
mood disorders and their diurnal variation. For in-
stance, reduced amplitude of 24-hour cortisol lev-
els is apparent in nonpsychotic depressed patients,




Some depressive symptoms show considerable di-
urnal disturbance in major depression. Many pa-
tients with nonseasonal depression show a regular
daily pattern of symptoms, usually more severe in
the morning, whereas healthy subjects typically re-
port mood deterioration in the evening compared
with the morning. Diurnal mood variation (with
improved mood in the evening) in depressed pa-
tients predicts an antidepressant response to sleep
deprivation.17-19 A minority of depressed patients
show the opposite pattern (reversed diurnal varia-
tion20), with mood deterioration in the evening rel-
ative to the morning.
A recent study compared the neuroanatomical
correlates of diurnal mood variation between de-
pressed and healthy subjects.21 Depressed patients
exhibited different patterns of variation in regional
brain glucose metabolism across times of day com-
pared with healthy subjects. Specifically, during the
morning, they showed more activity in brain re-
gions involved in affect production. In the evening,
when mood ratings improved in depressed subjects
andworsened in healthy subjects, depressed patients
showed increased activity in brain regions involved
in affect regulation. These findings suggest that
evening mood improvement in depressed patients
may be related to normalization of the mechanisms
underlying affect production and regulation.22,23
Among circadian disturbances associated with
depression, those affecting sleep are by far the most
common and well documented. Up to 90% of de-
pressed patients report sleep onset insomnia, sleep
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rhythms refer to nonphotic environmental stim-
uli, or social zeitgebers, such as social interaction,
meals, and other routines that entrain the central
and peripheral pacemakers. Depression clearly dis-
rupts daily occupational and social routines. Simi-
larly, changes in appetite affect the regularity and
frequency of meals. In vulnerable individuals, social
rhythm disruption may trigger mood episodes by
reducing exposure to, and the frequency of, social
zeitgebers. Life events that directly change daytime
routines, eg, retirement and bereavement,42,52 birth
of a child, jet lag, and shift work, are especially like-
ly to trigger a depressive episode.38,53
Frank and colleagues36,54 developed the interper-
sonal and social rhythm therapy (IPSRT) inter-
vention program to restore and consolidate social
rhythm regularity as a protective strategy against
relapse. Their rationale was that mood disorders
result from complex interaction between genetic
vulnerability, psychosocial stressors, and circadian
rhythmicity that can have positive or negative af-
fects on adherence to pharmacotherapy.
The first step in IPSRT is to identify the disrupt-
ed and/or irregular social rhythms (eg, sleep-wake
schedules, meal times, exercise times, and irregu-
lar occupational schedules such as shift work and
unemployment). A validated instrument for mea-
suring social rhythm regularity is the Social Rhythm
Metric (SRM, Figure 1),55 a self-reported measure
completed over a predetermined period (14 days to
1 month), on which patients prospectively log the
timing of different social rhythm components (time
out of bed, time in bed, meal times, time of first so-
cial contact, time of exercise sessions, time of first
outdoor light exposure, and start time of occupa-
tional activities). The SRM also includes items to
specify whether the different components are per-
formed alone, or in the presence of another person
(whether actively involved or not).
Based on the data derived from this first step, sta-
bilization goals can then be identified and imple-
mented. Typical goals include establishing regular
bed, wake, and meal times, switching to a more reg-
ular work schedule, and incorporating a regular dai-
ly exercise session. Strategies should be individual-
ly tailored. Reinforcement by regular activity is a
critical element of IPSRT. Consolidation is provid-
ed by devising specific protective strategies to min-
imize dysregulation of social rhythms by expected
predictable and unexpected stressors.36,56
IPSRT has been most widely used in bipolar pa-
tients, in whom it reduces the risk of recurrence;
emerging evidence suggests that it also effectively
regularizes social rhythms, accelerates remission
in depressed patients, and lowers relapse rates com-
pared with intensive pharmacotherapy.57 These ob-
servations warrant more direct investigation of
IPTSRT as an adjunctive or stand-alone treatment
in major depression.
Conclusion
Disruption of circadian and ultradian physiological
and social rhythms characterizes depression, and
may directly contribute to its pathophysiology.
pression is significantly increased in individuals
complaining of insomnia.46-48 Insomnia and hyper-
somnia complaints are associated with increased
suicidality.49 Furthermore, sleep disturbances in de-
pression predict treatment outcome. Specifically,
poor sleep quality predicts poor response to non-
pharmacological treatments.50,51 Persistent REM
sleep abnormalities and poor sleep quality post-psy-
chotherapy are associated with nonresponse50 and
recurrence.51 Subjective reports of better sleep qual-
ity post-treatment are associated with less recurrent
depression. Together, these observations suggest a
critical role for sleep disturbances in the pathophys-
iology of depression.
Modification of social rhythms 
as a treatment of depression 
Disruption of the physiological indices of circadian
rhythms is associated with mood symptoms in de-
pression. Disruption of social rhythms is also paral-
leled by changes in physiological rhythms, and may





























































Sample activity (for reference only)
Out of bed
First contact (in person or by phone)
   with another person
Have morning beverage
Have breakfast
Go outside for the first time
Start work, school, housework, volunteer
   activities, child or family care
Have lunch
Take an afternoon nap
Have dinner
Physical exercise
Have an evening snack/drink
Watch evening TV news program
Watch another TV program
Activity A ........................................
Activity B ........................................




Please fill this out at the end of the day
2 1
ACTIVITY
TIME         PEOPLE
1 = just present
2 = actively involved
Check
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Figure 1. The Social Rhythm Metric.
Modified from reference 55: Monk TH, Flaherty JF, Frank E, Hoskinson K, Kupfer DJ. The Social Rhythm
Metric. An instrument to quantify the daily rhythms of life. J Nerv Ment Dis. 1990;178:120-126. 
Copyright © 1990, Lippincott Williams & Wilkins.
sion can also offer promising clinical perspec-
tives.58,59 Further investigation of the molecular,
physiological, and social mechanisms that con-
tribute to the relationship between circadian dis-
turbances and mood disorders is required to guide
the development of new and effective strategies that
directly normalize the circadian abnormalities un-
derlying depression and hence enhance treatment
outcome. 
Mood variation and sleep disturbance are robust
manifestations of circadian disruption in depressed
patients, and both predict treatment response and
outcomes. Circadian disturbances in social and
sleep rhythms are risks for mood disorders that
can be attenuated by behavioral interventions that
target the regularization and consolidation of sta-
ble rhythms. Innovative pharmacological approach-
es that can normalize circadian rhythms in depres-
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CHRONOBIOLOGIE DES SYMPTÔMES MAJEURS
DE LA DÉPRESSION
L a dépression est caractérisée par des troubles affectant de nombreuxrythmes physiologiques, neuroendocriniens, neurobiologiques, compor-tementaux et sociaux. Un certain nombre de symptômes dépressifs pré-
sentent des variations de la sévérité au cours du nycthémère. Les troubles circa-
diens les plus couramment observés chez les patients déprimés sont des variations
diurnes de l’humeur et des troubles du sommeil. Ces perturbations compro-
mettent l’évolution clinique et la réponse au traitement. À l’inverse, la régulari-
sation et la stabilisation des rythmes sociaux et comportementaux des patients
ayant des troubles de l’humeur améliorent directement l’évolution clinique et
les symptômes thymiques. Cet article décrit brièvement certains troubles ultra-
diens ou circadiens observés dans la dépression majeure avant d’étudier les
liens entre les troubles du sommeil et l’évolution et l’issue de la dépression. Une
alternative au traitement pharmacologique, basée sur la régularisation des
rythmes sociaux chez les patients dysthymiques (social rhythm therapy), est
décrite. La reconnaissance des variations circadiennes des symptômes et la ré-
gularisation des troubles circadiens et du sommeil peut améliorer les résultats
du traitement dans la dépression. 

iar. Thus, in neuroscience applied to mood disorder,
it has acquired a more particular meaning. To use
the term “cognitive” is, therefore, rather too broad
in the present context, but it is given credibility by
use. It might also be more sensible to talk about
neuropsychological function since that has the im-
plication of a more laboratory-based investigation
of how the brain, or traditionally the mind, actually
works. The key finding is that neuropsychological
function, estimated experimentally, is manifestly
abnormal when patients become mood disordered,
be they depressed or manic.
Performance in tests of particular domains of ac-
tivity has long been a subject of scientific enquiry.
Such functions are essentially the emergent prop-
erties of the brain itself. How they go wrong in key
illnesses may be important for how we understand
the illness itself and its basis in brain. Moreover,
they may provide biomarkers for how new drugs
can be developed. This is increasingly the current
interest in the field and why it is developing as it is.
The investigation of cognition divides into two
broad approaches, depending upon how explicitly
we include emotional valence as a key experimen-
tal variable. The best known approach to attention,
memory, and executive function has traditionally
tested such functions independently of emotion.
Thus one may ask whether mood disorder is asso-
ciated with abnormal orientation or allocation of
attention to stimuli and whether attention can be
normally sustained. In relation to memory and ex-
ecutive function, it is possible to investigate how
well depressed or manic patients perform relevant
tasks and, moreover, whether having been depressed
impairs performance independent of current mood.
Words limit how we think. Some words, likedepression, are tired and pale expressionsof what they purport to describe. Depres-
sion is “a wimp of a word,” according to William
Styron, describing his own experience in Darkness
Visible: A Memoir of Madness. We may also be too
familiar with the idea that depression is a constel-
lation of symptoms rather than a profound distur-
bance of cognition. The word cognition (or cog-
nitive) refers to the action or faculty of knowing,
a fundamental human activity. At its simplest it
equates to thinking. Its disturbance in depression
is what most bothers patients and their families,
even if the concepts used to capture it are unfamil-
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C ognition is the word often used to describe the fundamental human ca-pacity to think. Its disturbance in depression is probably what most both-ers patients and their families, and not the symptoms that are usually
used to measure and diagnose the condition. There is an increasing interest in
applying to depressive illness the experimental methods developed in neuro-
science for understanding cognitive function. These initially focused on mem-
ory, attention and executive function, all of which are domains influenced by
depression and its severity. It has also become clear that depression has an en-
during impact on memory function, with major implications for neurobiolog-
ical explanations of depression and its sequelae. Direct investigation of how
emotion is represented in the brain is also of great emergent interest and rele-
vance. Cognitive function has thus become an increasingly central target for
the investigation of drug action and the development of compounds that selec-
tively target the most important cognitions affected in depression. These devel-
opments have also reignited interest in patient experience and the possibility
that emotions may be blunted in depression, but also as a consequence of its
treatment.
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we could show very convincingly that the mood
swing in the patients with depression was related to
changes in neuropsychological function.1 Thus, at
baseline, patients studied in the early morning
showed clear lengthening of reaction time, impaired
function on list learning (the auditory/verbal learn-
ing test) and the delayed matched sample test from
the Cambridge Neuropsychological Test Automat-
ed Battery, and poor performance on the digit sym-
bol substitution test which taps executive function
(Figure 1). When examined and compared 12 hours
later, depressed patients showed a significant mood
upswing, accompanied by improved performance
on all measures. Performance in nondepressed con-
trols, on the other hand, actually declined as the
day went on, presumably from fatigue. The study
design controlled for the effects of concomitant
medications in severely ill patients.
At that time, we also compared patients with dif-
ferent severities of depression, specifically those
showing endogenous features with those showing
neurotic features, and controls. In this study2 we
were able to compare performance in memory, at-
tention and executive tasks. Both clinical groups
showed impairments of episodic memory, which did
not differ dramatically with the presence or absence
of endogenous features. Executive function was sig-
nificantly more impaired in patients with endoge-
nous symptoms, while functional impairment was
of course greater. But we were unable to demon-
strate convincingly that this represented a simple
difference of types. It could have been a relation be-
tween cognitive function and symptom severity.
This issue has been addressed using reaction time
measures by Gordon Parker’s group at the Universi-
ty of New South Wales.3 When plotted independent-
ly, results in a large group of patients that followed a
unimodal distribution when compared using symp-
toms showed a bimodal distribution when com-
pared using retardation as a measure. This bimodal-
ity loosely corresponds to the endogenous/neurotic
distinction. In other words, we have clear evidence
that episodic memory and executive function are
always more impaired in endogenous depression
and that the impairment is related to symptom
severity. Moreover, retardation, which predicts im-
pairment on speed tests, is indeed a potential defin-
ing characteristic of the more severe syndrome we
refer to as endogenous depression.
Although cognitive impairments showed diurnal
variation over 24 hours, the patients continued to
be depressed. The question then is whether cogni-
tive function recovers with complete symptom re-
mission. The basic answer is “Yes, but incompletely.”
While some studies, particularly in older patients,
have suggested enduring residual deficits in mem-
ory and executive function,4-6 no such deficits are
present in younger patients, or at least they have
not been detected in small samples. This recovery
of function has a potential utility for clinical trials
that has never been realized, either as a marker of
severity or as an index of change. Since, arguably,
neuropsychological measures are more objective
and less susceptible to bias than traditional rating
scales, this is both surprising and regrettable. Sever-
Does depression leave a scar? The more recent ap-
proach introduces emotion into these domains. We
can increasingly study emotional processing direct-
ly using behavior and imaging. We are also return-
ing to actual patient experience, which is not always
well served by symptom scales.
The elements of cognitive function
that co-vary with mood 
The starting point for this field has been the iden-
tification of elements of cognitive function that co-
vary with mood. The core features of acute depres-
sion include the way in which thoughts and actions
are slowed, memory is subjectively disturbed, and
work and concentration are impaired. It is these
features of the acutely depressed state, rather than
simply sadness itself, that define the illness that we
describe as a major depressive episode.
It turns out that these symptoms can easily be
measured. Slowing of thoughts and actions can be
captured as reaction times to appropriate stimuli;
memory, while subjectively disturbed, can also be
objectively investigated by looking at how well we
learn and remember lists; and impairment of work
and concentration can be modeled by looking at
tests of how we organize our attentional capacity to
execute executive tasks in a laboratory setting. So-
called tests of executive function are all impaired
in patients with mood disorder, and they reflect, in
all probability, valid experimental correlatesof symp-
toms that are important in the disease.
The way in which these symptoms vary in time
with mood itself is perhaps best illustrated by study-
ing the spontaneous variation in mood that takes
place in many patients from morning to evening.
When my group studied this about 15 years ago,
36 Cognitive symptoms of depression as major targets for antidepressants – GoodwinMEDICOGRAPHIA, VOL 30, No. 1, 2008
T H E C O R E O F D E P R E S S I O N
Mood
Diurnal change (08.00-20.00 h)















Figure 1. Changes in mood and reaction time (RT). Delayed match to sample
(DMS), list learning (AVLT) and digit symbol substitution between 08.00 and
20.00 hours in depressed patients compared with controls. Change expressed as
standard deviation units (SDs) on the vertical axis.
Modified from reference 1: Moffoot AP, O’Carroll RE, Bennie J, et al. Diurnal variation of mood
and neuropsychological function in major depression with melancholia. J Affect Disord.1994;32:
257-269. Copyright © 1994, Elsevier B. V.
probably not have made sense had we not been able
to detect functional impairments related to these
areas of interest. Further, polymorphism in the gene
encoding brain-derived neurotrophic factor15 ap-
pears to modulate memory function in healthy vol-
unteers,16 and can be expected to do so in patients
with depression.
A final point, following this presentation of the
key findings specifically related to memory func-
tion and the hippocampus, is that the same neu-
ronal mechanisms may operate less detectably in
other neuronal systems. The far-reaching impact of
mood on cognitive function and the emotional life
of the depressed individual is likely to reflect this.
The neurobiology 
of emotional processing
As the preceding paragraphs illustrate, neuropsy-
chological investigation proceeded from tests of
nonemotional processing, eg, the ability to remem-
ber a list of neutral words. The relevance of the find-
ings followed from the way in which such tests
assayed function in brain areas, such as the hippo-
campus, that appear particularly vulnerable to the
effects of mood change. In recent years, experimen-
tal approaches to the direct neural representations
of emotional experience have become possible, at
the stages of perception, recollection, experience,
and expression. Many different methods have been
used to characterize the changes in these dimen-
sions caused by mood disorder. It will only be pos-
sible to give a few examples.
The most obvious approach to mood is to induce
it directly. There are traditional problems with the
authenticity of such experimentation (do subjects
tell the truth when they know what the experi-
menter expects of them?), but brain imaging goes
some way to validate it. Mood induction procedures
have shown changes in frontal and limbic areas that
have been implicated for other reasons in mood
disorder. With induced sadness and in depression,
positron emission tomography identifies increased
blood flow in the anterior insula and subgenual re-
gion of the ventral anterior cingulate gyrus accom-
panied by decreases in the neocortical (right dor-
solateral prefrontal and inferior parietal) regions.
With recovery from depression, the reverse pattern,
involving the same regions, is observed. Thus, re-
ciprocal changes involving subgenual cingulate and
right prefrontal cortex occur with both transient
and chronic changes in negative mood.17 The region
of the subgenual orbital frontal cortex (Brodmann’s
area 25) is overactive in resistant depression.18 This
lack of reactivity gave rise to the hypothesis that
stimulation of white matter adjacent to the area
would be an effective treatment for depression. The
technique of deep brain stimulation focused in or
adjacent to the area which is least reactive in pa-
tients is already widely and successfully used to treat
movement disorders. Preliminary results have been
encouraging in highly refractory depressed patients.
This is one of the first examples of modern clinical
neuroscience research leading to a translational ad-
vance in treatment.
ity is an important criterion for entry into drug stud-
ies, which could be indexed by impaired mnemonic
function. Moreover, cognitive function might serve
as a potentially more specific target for particular
drug effects. For example, it might be the case that
some drugs have a more convincing effect on cog-
nitive symptoms than others. We simply have no
knowledge in this area as far as most psychotrop-
ic drugs are concerned. However, our group has
shown in healthy volunteers that the selective sero-
tonin reuptake inhibitor (SSRI) citalopram has the
potential to improve memory function. In a way this
is quite a surprising result because it is uncommon
to see drugs improving function in healthy young
people.7
Complete recovery of memory function depends
on the duration of lifetime depression (P. Gorwood
et al, submitted). Because the impairment is slight,
it is only detectable in a very large patient sample.
The major group of patients in whom cognitive
function more detectably fails to recover fully on
symptom remission is bipolar disorder. Bipolar I
patients have been studied many times while eu-
thymic and the consistent finding is impaired list
learning. The cause remains unelucidated. It may
well be related to residual depressive symptoms,
which are actually subsyndromal, but nevertheless
have an impact on memory. It could also be a drug
effect. Perhaps most interestingly, it could be the
consequence of repeated episodes of illness.4,8-10 This
also appears to be the case for sustained attention,
where patients show substantialdecrements of func-
tion.4,5 It does not appear to be a simple working
memory effect, but more likely related to a true
deficit in the accuracy of signal detection. In gener-
al, bipolar patients may show bigger deficits because
they usually have more intense illness courses than
unipolar cases.
The neural substrate of 
enduring cognitive impairment
If depression is associated with impaired memory,
what is the likely mechanism? The structural cor-
relates of impaired brain function in depression are
interesting. The original finding11 in chronically re-
fractory depression was that hippocampal volume
was bilaterally reduced with correlated impairments
of memory function. The hippocampus is an area of
the brain in which synaptic changes and neurogen-
esis are most readily demonstrated. It may be more
sensitive to apparently functional changes of many
kinds than other areas. Other studies in clinic sam-
ples suggest that hippocampal size correlates with
duration of depression,12 as if depression itself were
a toxic exposure for the brain. It is possible, but un-
proven, that this is mediated by hypercortisolemia,
which has proved toxic in animal experiments.6,13
Other circumstantial findings strengthen the link
between depression and impaired neurogenesis. An-
tidepressants and electroconvulsive therapy increase
neurogenesis in animal models, supporting the hy-
pothesis that antidepressants work at least in part
by restoring neurogenesis and synaptic density in
depression-critical brain areas.14 This idea would
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Change begins immediately, however.23 A possible
explanation is that the actions of antidepressants
are indeed acute and immediate, but the necessary
adaptive changes, the relearning of different con-
tingencies with different emotional biases both in
perception and memory, are the basis for the actual
antidepressant response. On this basis, antidepres-
sants should be developed and screened for their
acute capacity to modify emotional representations.
This would clearly have implications for how we de-
velop new compounds. The alternative view is that
such effects are of interest, but they may really con-
stitute side effects of the drugs. There is a current
vogue to favor a more downstream effect, eg, on
growth factors with a more direct impact on hip-
pocampal and amygdalar plasticity.24 If this indeed
forms the basis of antidepressant action, then clear-
ly one should be trying to speed that process up,
independently of whether or not there are imme-
diate effects on the perception of affect and its rec-
ollection.
Subjective emotional 
experience in patients taking 
psychotropic drugs
Just as measures of cognition may tell us how to
detect the wanted effects of treatment, they may also
guide us in avoiding its unwanted effects. The in-
vestigation of emotional experience under antide-
pressants suggested a further interesting interpre-
tation of the findings. Patients appear to perceive
fearful facial expressions less readily while taking
an SSRI (citalopram). While this could correct a sys-
tem over reactive to fear stimuli, it might overcom-
pensate some individuals and make them less emo-
tionally connected with their surroundings. Could
this sometimes be an unwanted effect of SSRI treat-
ment? This possibility is supported by the most sub-
jective and unscientific evidence: clinical anecdote.
Some patients who have taken SSRIs are clearly
aware of “emotional blunting” on these drugs. The
most voluminous evidence comes from the spon-
taneous patient reports widely available on the in-
ternet. Such informal networks of experience are
potentially very useful when harnessed to more con-
trolled studies. This is now required for emotional
experience.
A potentially related side effect is impaired sexual
responsiveness, a relatively common and well doc-
umented side effect of SSRIs. A small group of pa-
tients with SSRI-induced sexual dysfunction were
investigated using the Laukes Emotional Intensity
Scale (LEIS). This includes items such as reduced
ability to cry, reduced ability to care about others,
lack of creativity, and inability to express feelings.
While this is confounded in such a study by depres-
sion itself, total LEIS scores did not correlate with
total scores on the Hamilton Depression Rating
Scale in this study. This patient subgroup appeared
to have impaired emotional reactivity in a variety
of areas, not just sexual response.25 The absence of
sexual side effects may nevertheless be an impor-
tant marker of a more benign effect on emotional
response generally. 
The recognition of emotions expressed by others
is, in some ways, a less contentious way in which to
get at emotional representation within the brain.
The basic emotions of sadness, happiness, anger,
surprise, disgust, and fear are expressed on the faces
of others. How we recognize them must tell us
something about the way in which we represent
these emotions. The parsimony of brain represen-
tation suggests that this may also be relevant to
how we experience them. Our group has examined
the effects of medication on a variety of tests ad-
dressing the quality of emotional expression. The
recognition of fearful or happy faces, for example,
can be examined by morphing exemplars of fear or
happiness between a clear and unequivocal expres-
sion to an expression of neutrality using digital
methods. When one then looks at the detectabili-
ty of the expression across the range, one sees in-
creased accuracy as one would expect when moving
from a neutral to a fully fearful face. Treatment with
citalopram or reboxetine reduces this facilitation.
Subjects become less sensitive to fearful expressions
on the faces of others.19
There is no corresponding impact on the ability
to detect happiness in the faces of others. The im-
plication may be that one way in which antide-
pressants work, or at least one property that some
antidepressants may have, is to reduce the process-
ing of fear in central structures. In the case of citalo-
pram, we have confirmed that this is likely to be at
the levelof the amygdala, since changes in thatbrain
area occur over the same time scale as the behav-
ioral change just described.20 Indeed, effects are dis-
cernible in other experiments within as little as
20 minutes after infusion of citalopram.21 It there-
fore represents an action that is extremely quick
and potentially relevant to how patients subsequent-
ly perceive the world.
Any effect that was confined simply to fear would
potentially reflect only the actions of an anxiolytic,
such as lorazepam.22 There are further effects asso-
ciated with antidepressants which suggest that they
regulate how we access positive and negative mem-
ory items. This is clearly closer to the ideal proper-
ties that might be required of an antidepressant. We
can ask subjects or patients to categorize words on
the basis of whether or not they regard them as in-
sulting or generous: would they like to be described
personally by adjectives such as obnoxious, original,
ugly, etc? One can then measure, firstly, the speed
at which patients respond, and, secondly, the ease
with which they spontaneously recall different words
after a 30-minute delay. Citalopram and reboxetine
both speed the acute response to positive words and
facilitate the recall of positive words after a fixed
delay. In simple terms, the positive words are better
encoded and more easily retrieved under the actions
of citalopram or reboxetine than placebo.
Our hypothesis is that such effects may not just
be incidental properties of antidepressants, but have
the potential to explain their antidepressant effects.
It is notable that these effects are extremely acute
and yet the overall speed of response to antidepres-
sants such as citalopram and reboxetine is relatively
slow, taking 4 to 6 weeks to be clinically significant.
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to further understanding of cognitive and executive
function, memory, and attention. These are all do-
mains that are influenced by depression and its
severity. Depression has an enduring impact on
memory function that has important implications
for neurobiological explanations of depression and
its sequelae. Direct investigation of how emotion
is represented in the brain is of great emergent rel-
evance. Cognitive function has become a central
target for investigating drug action and developing
new compounds that selectively target the most im-
portant cognitions affected in depression.  
The challenge is now to devise a systematic way of
measuring the experience of emotional blunting
that captures qualitative patient experience and can
be validated quantitatively in larger groups of rep-
resentative patient samples. It should also be possi-
ble to compare different treatments head to head.
We are currently involved in the necessary qualita-
tive work to tailor a scale to patient experience. The
first formalcomparisonwill bebetweenescitalopram
and agomelatine, since the latter should have an
advantage from the point of view of such side ef-
fects.26 In conclusion, neuroscience has been used
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LES SYMPTÔMES COGNITIFS DE LA DÉPRESSION: 
CIBLES PRIORITAIRES POUR LES ANTIDÉPRESSEURS
«C ognition » est un mot souvent utilisé pour désigner l’aptitude hu-maine fondamentale à penser. Les troubles cognitifs sont probable-ment ceux qui gênent le plus les patients déprimés et leur famille
et non les symptômes habituellement utilisés pour mesurer et diagnostiquer la
maladie. L’application à la maladie dépressive des méthodes expérimentales
développées en neurosciences pour comprendre la fonction cognitive rencontre
un intérêt croissant. À l’origine, ces méthodes étaient déstinées à étudier la
mémoire, l’attention et la fonction exécutive, tous domaines influencés par la
dépression et sa sévérité. Il est également devenu clair que la dépression a un
impact durable sur la mémoire, ce qui a de nombreuses implications pour la
compréhension neurobiologique de la dépression et de ses séquelles. L’explora-
tion directe de la représentation de l’émotion dans le cerveau a également dé-
montré son intérêt et sa pertinence. La fonction cognitive a ainsi acquis une
place de plus en plus centrale dans la recherche sur le mode d’action des médi-
caments et le développement de produits ciblant sélectivement les fonctions co-
gnitives les plus importantes affectées par la dépression. Ces développements
ont aussi renouvelé l’intérêt pour l’expérience des patients et la possibilité que
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Most papers in this issue focus on clinicalquestions concerning core symptoms indepression. This paper concentrates on
methodology, beginning with the hoary problem:
should the definition of core symptoms be categor-
ical or dimensional? It then discusses a clear trend
in psychiatric measurement away from the clinical
and towards the field of psychoexperimental re-
search. Thirdly, it addresses the much debated is-
sue of who is the most appropriate assessor of these
core symptoms: clinician or patient? The concluding
and most important question discussed is whether,
and under what conditions, a formal psychometric
definition of the core symptoms of depression is
possible.
Category versus dimension
Is psychiatric disease, such as depression, categor-
ical or dimensional in nature? This question in-
evitably relates to another: what is the definition of
a psychiatric disease? The answer is not so simple, as
shown by a recent symposium on the subject at the
American Psychiatric Association’s annual meeting.
Psychiatric disease can be viewed in various lights,
including as a historical semiological construct, a
specific physiological or psychological weakness in
human beings, a legal tool, or a simple word used in
the media.
Although the issue may be theoretically complex,
routine clinical experience favors a dimensional view
of psychiatric phenotypes, especially depression.
Thus a patient may be “more or less” depressed. So
why use a categorical construct such as major de-
pressive disorder? One answer is that therapeutics
is basically categorical. Prescribing an antidepres-
sant, electroconvulsive therapy, or psychotherapy,
or recommending hospitalization, is usually a bina-
ry decision, and thus categorical by essence. Since
clinicians are nothing if not therapists, it is likely
that they have forced diagnoses to be categorical to
help them optimize their treatment choices.
However, the optimal way to deal with patients
is not necessarily the optimal way to deal with re-
search. Clinical trials in depression, for instance,
require outcome measures that are sensitive to
change. Categorical measures are generally less ef-
ficient in this regard than dimensional measures.
Hence even if categorical outcomes, such as treat-
ment response or remission, are often valued be-
cause they are close to clinical practice and because
differences are easier to interpret, dimensional out-
comes have the advantage of being statistically more
efficient and perhaps closer to a natural representa-
tion of what we call “depression.”
Clinical versus 
psychoexperimental assessment
As clinical trials with antidepressants increasingly
fail to differentiate placebo from active comparators,
there is a temptation to identify outcome measures
that are highly sensitive to change. A solution some-
times proposed is to abandon clinical measures for
the currently more fashionable field of psychoex-
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H ow the core symptoms of depression should be assessed depends onhow they are defined. Physiological and/or psychopathological consid-erations may be essential to the definition, but statistical considerations
are also important, notably with respect to the crucial notion of unidimension-
ality. By definition, a set of items is unidimensional if there is a variable that
alone “explains” all the inter-item correlations. With quantitative measures,
factor analysis is potentially a good statistical technique for assessing unidi-
mensionality. Goodness-of-fit tests, however, are less appropriate. Scree plots
of the eigenvalues for the correlation matrix of the items are an interesting
alternative to factor analysis, especially when using simulated data, as in par-
allel analysis. Other methodological considerations in assessing the core symp-
toms of depression include the question of categorical versus dimensional mea-
surement. Each has its advantages: clinical relevance for categories, sensitivity
to change, and conceptual relevance for dimensions. Also important is the ques-
tion of who is the most appropriate assessor of the core symptoms of depres-
sion: the patient, or the physician after clinical interview? In psychiatry, unlike
in most other areas of subjective measurement, the clinician has always been
considered more reliable—a tradition currently under challenge.
Medicographia. 2008;30:40-44. (see French abstract on page 44)
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How should the core
symptoms of depression
be assessed? 
b y  B .  F a l i s s a r d ,  F r a n c e
could be methodological in origin5: clinicians in
placebo-controlled randomized trials may detect
subtle cues that help them identify the patients on
active medication, and they may then unconscious-
ly overestimate the improvement of patients under
active treatment.
Some arguments favor patient-reported depres-
sion questionnaires. One is their lower cost, anoth-
er is their greater ecological validity. Thus by using
interactive voice response systems, patients can ex-
perience these questionnaires in their everyday con-
text rather than in a medical setting.
In summary, there is no conclusive evidence for
the superiority of either clinician or patient assess-
ment in depression. In practice, this is a strong ar-
gument for developing both types of instrument and
using them in clinical trials.
Identifying core symptoms 
in depression: 
the statistical viewpoint
This paper proposes a purely statistical definition of
core symptoms: they should correspond to the sub-
set of traditional symptoms of depression that con-
stitute a unidimensional family. The question now
is: why and how? Unidimensionality is a central con-
cept in psychometrics. Firstly, psychometricians
postulate that a measure should only concern a
single attribute. The most classic illustration of
this point of view was by McNemar6:
Measurement implies that one characteristic at
a time is being quantified. The scores on an atti-
tude scale are most meaningful when it is known
that only one continuum is involved. Only then
can it be claimed that two individuals with the
same score or rank can be quantitatively and,
within limits, qualitatively similar in their atti-
tude towards a given issue. As an example sup-
pose a test of liberalism consists of two general
sorts of items, one concerned with economic and
the other with religious issues. Two individuals
could thus arrive at the same numerical score by
quite different routes. Now it may be true that
economic and religious liberalism are correlat-
ed, but unless highly correlated, the meaning of
scores on a such a composite is questionable.
More formally, in some measurement models de-
veloped for instruments comprising several items
(item response models, in particular), unidimen-
sionality of the items composing the instrument is
a prerequisite. We shall begin by defining the prop-
erty of unidimensionality in a set of items. For this
we will turn to factor analysis, and we shall discov-
er that, in this context, principal component anal-
ysis is an essential tool.
 Definition
For a number of years the very definition of uni-
dimensionality varied noticeably from one author
to another. Since the McDonald’s 1981 paper,7 a
consensus has gradually emerged: a set of items is
unidimensional if there is a variable, which, on its
own, “explains” all the correlations observed be-
perimental measures, which may, one day, acquire
valuable advantages, such as improved measure-
ment properties or objectively robust validity. At
the moment, however, they suffer from a lack of
clinical relevance: with the type of outcome they
offer, it is impossible to tell whether or to what ex-
tent patients are improved in their daily lives. This
is totally unacceptable in clinical trials that are de-
signed to obtain drug approval and even more so
for insurers needing to price a medication.
Core symptom rating by 
clinician or patient?
Depression is a subjective concept, defining sub-
jective as “belonging to the thinking subject rather
than to the object of thought.”1 Subjective entities
include pain, quality of life, fatigue, satisfaction, de-
pression, and anxiety. Psychiatric measures are an
exception among subjective measures: clinician rat-
ing scales are implicitly considered as the gold stan-
dard, whereas in other areas things are quite the
reverse. There are many reasons for this, none of
which are wholly evidence-based:
 Psychiatric measures are older than other sub-
jective measures that were developed in a specific
political context. In the 1970s, there was a move
for patients to liberate themselves from the “yoke”
of physicians. This required outcome measures
sourced more directly from the patient than from
the clinician, as illustrated by the emergence of pa-
tient-reported outcome. The frequent preference in
subjective measurement for patient-reported out-
come over clinician-reported outcome is not based
on solid scientific argument.
 Self-report depression questionnaires may be
biased in that depression may alter the patient’s
ability to assess himself sensibly, in particular at the
start of a depressive episode, when symptoms are
most severe.
 Regulatory agencies, such as the Food and Drug
Administration or European Medicines Agency, fa-
vor clinician rating scales.
 Most double-blind randomized controlled stud-
ies lead to smaller effect sizes with self-report ques-
tionnaires than with clinician rating scales. Clini-
cian scales tend to be more sensitive to change and
thus more efficient in both economical and ethical
terms.
However, all these reasons are debatable 2:
 The view that patient-reported outcome is non-
scientific is an opinion, or at most a hypothesis.
 There is, to our knowledge, no scientific evidence
that psychiatric patients’ assessment of themselves
is any more biased than that of other patients, eg,
cancer patients. Even in schizophrenia, many self-
rated questionnaires have shown good reliability.3
 Regulatory agencies may revise their position on
self-rated questionnaires in depression.4
 The effect-sizes argument against self-report
questionnaires stumbles against the finding that
effect sizes have not differed in some studies using
twin instruments in a patient-reported version and
a clinician-reported version.2 Also, any differences
41How should the core symptoms of depression be assessed? – Falissard MEDICOGRAPHIA, VOL 30, No. 1, 2008
T H E C O R E O F D E P R E S S I O N
kind is often used. This method considers the per-
centage of variance represented by the first prin-
cipal component. But why is principal component
analysis associated with the concept of unidimen-
sionality?
 Principal component analysis
Principal component analysis is a multivariate tech-
nique for reducing the number of dimensions in a
set of variables, while preserving the “information”
contained in these variables as much as possible.
In statistics, “information” is classically assimilat-
ed to variance. Thus, if the first principal component
represents, on its own, a large part of the variance
of the variables, it is tempting to conclude that a
single dimension suffices to resume the variables
overall. It is then possible to consider that they form
a unidimensional whole.
Of course, this is not in line with the definition
of unidimensionality given above, for at least two
reasons. Firstly, principal component analysis and
factor analysis are two different methods. In prac-
tice, however, the numerical results yielded by these
two techniques are generally very close 10: the per-
centage of variance represented by the first princi-
pal component approximates to the shareof variance
represented by the common factor in a one-factor
analysis model.
But this does not get us very far. The share of vari-
ance represented by the common factor does not
enter into the definition of unidimensionality. Ei-
ther the model fits, or it doesn’t. The fact that the
common factor has high variance is not relevant.
Nevertheless, this sort of attitude is not very prag-
matic: a unidimensional set of items in which the
common factor represents only a very small per-
centage of the variance leads to an instrument that
is practically useless. In a frequently quoted article,
Cronbach11 explained:
For a test to be interpretable […] what is required
is that a large proportion of the test variance
be attributable to the principal factor running
though the test. […] The proportion of the test
variance due to the first factor among the items
is the essential determinant of the interpretabil-
ity of the scores.
In practice, therefore, two stages are required:
 The first determines whether or not the first
principal component emerges in isolation from
among the components as a whole (are the items,
qualitatively, uni- or multi-dimensional?).
 The second assesses the weight of this first prin-
cipal component in the overall variance of the in-
strument (is the first component strong or not?).
The statistical tool that can be used in each of
these stages is theeigenvaluediagramorscree plot,12
an essential instrument for determining unidimen-
sionality in a set of items.13 An extremely simple
example illustrates how results can be interpreted
from a set of geometrical representations. Let us
consider a 3 item instrument administered to 27
subjects. As each subject undergoes three evalua-
tions, the data can be represented geometrically by
27 dots in a three-dimensional space (Figure 1).
tween items. In formal terms, if this variable is main-
tained at a constant level in a sample of subjects,
then items in this sample are independent of each
other. This reflects the existence of a “single core”
common to all the items: once this core is estab-
lished, the items behave independently of each
other.
It was Spearman who originated this definition
in 1904, setting it out in as yet sketchy form in a
celebrated article8 that examined the unidimension-
ality of a set of cognitive items relating to the con-
cept of intelligence:
All branches of intellectual activity have in com-
mon one fundamental function (ie, intelligence),
whereas the remaining or specific elements of the
activity seem in every case to be wholly different
from that in all the others.
Spearman developed a statistical technique to bear
out a property of this sort: factor analysis, namely
(in its one-factor version), a model in which the re-
sponse to an item is the summation of a linear func-
tion of a characteristic common to all items and a
term which groups together measurement error
and a part specific to each item.
However, if a set of items fitting a one-factor anal-
ysis model is indeed unidimensional, the reverse is
not true, in particular because the one-factor anal-
ysis model is linear in the common characteristic.
However, in practice, this sort of situation is rare.7
A one-factor analysis model is thus, as a first ap-
proximation, a necessary but insufficient condition
of unidimensionality, at least when responses to
items may be considered as numerical random
variables.
Moving on from this conclusion, the question of
the unidimensionality of a set of items looks quite
simple. It is sufficient, in theory, to statistically test
the fit of the data to a one-factor analysis model.
Some software enables this sort of test, but the re-
sults are not easy to interpret. Indeed, whatever the
characteristic to be measured, we can be sure that
the items used in the instrument are never truly
unidimensional. Furthermore, if a validation study
is conducted on a large number of subjects, the
goodness-of-fit test will be very powerful, and the
chances of the unidimensionality hypothesis be-
ing rejected will inevitably be high. This ends us up
in the paradoxical situation in which, by studying
a large sample, we reduce the chance of demon-
strating what we intend to demonstrate—in other
words, we would be better off carrying out the study
in a small sample, which would be absurd.
To get round this paradox that in fact bedevils all
the model-fitting issues, we have fit indices and
parsimony criteria, such as the root mean square
error of approximation, normed fit index, Akaike
information criterion, and Bozdogan index of in-
formation complexity.9 They have the advantage of
flexibility, but the drawback of frequently reaching
different conclusions. They are also based on un-
clear heuristics, which makes the interpretation of
results somewhat arbitrary. In practice, possibly
in reaction to this methodological vacuum, a uni-
dimensionality indicator of a completely different
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graphic representation of eigenvalues λ1, λ2 and λ3
(Figure 3). The principle remains the same when
applied to actual examples exceeding three items:
136 patients hospitalised for depression were as-
sessed on admission using the Hamilton depression
rating scale (unpublished data). Is this instrument
unidimensional in this patient sample? The scree
plot is given in Figure 4. How should this result be
viewed? The hypothesis of unidimensionality can
be rejected outright: there is no marked break after
the first component. But how many dimensions can
be distinguished? None? Possibly two? It is not easy
to answer this question from this diagram alone.
Some simulations, such as parallel analysis,14 of-
fer partial answers to these questions. Implemen-
tation involves simulating measures for 17 items
in 136 patients using random numbers, followed
by principal component analysis of the simulated
items, and finally comparison with the scree plot in
Figure 4. This procedure produces the result shown
in Figure 5. Compared with the plots obtained by
simulation, the first two dimensions of the Hamil-
ton scale appear to stand out from the rest. Thus,
the instrument is not unidimensional in this pop-
ulation.
Principal component analysis of the data looks
for the three directions in which the scatter of dots
spreads (Figure 2). The scatter spreads more or less
along the principal components. Numerically, the
square root of the eigenvalue λ1 associated with the
first principal component indicates how closely the
dots are dispersed along this component. The same
is true for λ2 and λ3 in relation to the second and
third principal components. If λ1 is very much high-
er than λ2 and λ3, the dots will be situated more or
less along a straight line: this means that they form
a unidimensional whole. A scree plot is the simple
Figure 1. Geometrical representation of three items
(x, y, and z) measured in 27 subjects.
Figure 2. Principal components of preceding data.
Figure 3. Construction of a scree plot.
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Figure 4. Scree plot for 17 items in Hamilton’s depression rating
scale.
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core symptoms should be assessed depends on how
they are defined. In this regard, statistical consid-
erations are as important as physiology and psy-
chopathology, with the notion of unidimensionality
being particularly crucial. With quantitative mea-
sures, factor analysis successfully operationalizes
the definition of unidimensionality. However, good-
ness-of-fit tests are of a questionable value. Scree
plots of the eigenvalues of the correlation matrix of
the items offer an interesting alternative to factor
analysis, especially when using simulated data, as
in parallel analysis. 
Conclusion
Practical assessment of core symptoms in depres-
sion raises classic methodological considerations,
such as the identity of the ideal assessor (patient or
clinician, or both), and the omnipresent choice in
psychiatric research between categorical and di-
mensional measures (and the possible calculation
of a cutoff). 
Each is potentially useful: categories are clinical-
ly relevant, while dimensions are sensitive to change
and conceptually relevant. More profoundly, how
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COMMENT ÉVALUER LES SYMPTÔMES MAJEURS
DE LA DÉPRESSION ?
L’ évaluation des symptômes majeurs de la dépression dépend de leur dé-finition. Cette dernière peut reposer sur des critères physiologiques et/oupsychopathologiques, mais les critères statistiques, en particulier la no-
tion essentielle d’unidimensionnalité, sont également importants. Par défini-
tion, un ensemble d’items est unidimensionnel si une seule variable « explique »
toutes les corrélations inter-items. L’analyse factorielle, avec des items quanti-
tatifs, est potentiellement une bonne technique statistique pour évaluer l’uni-
dimensionnalité. Les tests d’adéquation sont toutefois moins appropriés. L’ana-
lyse factorielle peut être remplacée de façon intéressante par un diagramme
des valeurs propres de la matrice de corrélation des items, particulièrement
lorsque l’on utilise des données simulées comme dans l’analyse parallèle. L’éva-
luation des symptômes majeurs de la dépression peut faire l’objet de diverses
approches, par exemple l’approche dimensionnelle face à l’approche catégo-
rielle. Chacune a ses avantages : pertinence clinique pour les catégories, sensibi-
lité au changement et pertinence conceptuelle pour les dimensions. La question
de savoir qui du patient ou du médecin après l’interrogatoire clinique évalue
le mieux les symptômes majeurs de la dépression est également importante.
Contrairement à la plupart des autres domaines de mesure subjective, en psy-
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What symptom should be 
the primary treatment target 
in depression?
patients’ two main complaints, namely anxiety
and sleep disturbance. However, the combination
of anxiolytics and hypnotics is invaluable for this
purpose. Depressed mood will lift at a later stage,
followed by the recovery of interest and pleasure.
Damaged brain needs time to recover. The more
complex the psychological function, the longer
it takes to improve. Even recovered depressives
remain psychologically different from healthy
controls, in terms of negativity and hesitation.
We still don’t know whether this represents the
residue of a depressive episode or a preexisting
personality trait that predisposes to depression.
Placebo can achieve improvements rates of up to
35% in depression. Since antidepressant efficacy
averages no more than 50%, the margin of phar-
macology over placebo is only 15%. Although
placebo may be able to relieve all symptoms of
depression, there is no evidence that it works bet-
ter on some symptoms rather than others. True
remission rates are much lower on placebo, by a
difference well in excess of 15%. In other words,
placebo may improve symptoms, but it tends not
to eradicate them. Placebo appears particularly
effective for somatoform symptoms that are often
hard to classify as psychological, cognitive, or
physical. But it has no place in long-term strat-
egy, probably because depression is a systemic
disease encompassing a constellation of symp-
toms that can only be cured once the depressive
disease is itself cured. Applying the results of sci-
entific research to clinical practice is a constant
challenge. A well-designed clinical trial may gen-
erate statistically significant data packaged in a
beautifully written paper. But the research set-
ting is often too abstracted from clinical reality.
It is thus no surprise that some costly studies
should have failed to impact clinical behavior. 
T he treatment of depression remains a mys-terious combination of science and art. Itis a science insofar as we know plenty about
the neurobiology of depression in terms of genet-
ic predisposition, neuroimaging changes, and
the biochemical and neuroprotective effects of
antidepressants. But it is an art in that we don’t
really know which therapeutic strategy will work
for which individual. Patients’ prioritization of
their depressive symptoms varies with age, gender,
occupation, and other sociodemographic vari-
ables. The elderly may emphasize the “meaning-
less of life,” while younger adults identify fatigue
or loss of energy as their primary concern. Cul-
ture is also important. In Asian societies, somatic
symptoms such as headache and poor appetite
are perceived as particularly distressing. They
occupy much the same position as anhedonia 
or depressed mood for Western patients. An in-
teresting study in white and Chinese elderly
showed that Chinese elderly had a more positive
attitude toward weight gain than their white
counterparts. In Chinese society, weight gain in
the elderly is perceived as “fa-foo” (literally, gain-
ing happiness, ie, a marker of wealth and a happy
family). Such people may be fat, but they are
“happy fat.” Generally speaking, anxiety and sleep
disturbance are the most distressing symptoms
of depression across all groups and they need to
be prioritized in the treatment strategy. However,
wise clinicians will always ask their patients
which symptom matters to them most. Patients
usually list several. The doctor can then work
with the patient to identify which comes first. The
order of symptom improvement is not only a
relevant clinical factor, but also a window onto
neural recovery by a depressed brain. No current-
ly available antidepressant offers rapid relief for
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be targeted with benzodiazepines and/or anti-
psychotics.
 Anxiety is common in depressive episodes and
contributes to the suicidal phenotype. Panic dis-
order in particular increases the risk of suicidal
behavior.1,2 Depending on acuteness and severity,
benzodiazepines and antidepressants are indi-
cated in combination with psychotherapy.
 Rapid relief of sustained insomnia stress en-
hances mood and provides resources for recovery.
Standard options are sedating antidepressants, eg,
amitriptyline or mirtazapine, or antipsychotics
and short-term benzodiazepines.
Outside the well-recognized influence of demog-
raphy, disease history, and somatic/psychiatric
comorbidity, antidepressant response has not been
clearly shown to differ with psychopathological
symptom profile. However, evidence suggests that
tricyclic antidepressants are more potent than
selective serotonin reuptake inhibitors (SSRIs) in
severely depressed inpatients.3 Indirect meta-anal-
ysis showed the dual-action serotonin-norepi-
nephrine reuptake inhibitor venlafaxine, intro-
duced in 1993, to be more effective than the SSRI
fluoxetine.4 Monoamine oxidase inhibitors may
be preferable for atypical features, eg, mood re-
activity, overeating and hypersomnia.5 Electro-
convulsive therapy is an option in life-threatening
situations or when otherwise appropriate drugs
are contraindicated. Depressive symptoms do not
respond to treatment at the same rate or to the
same degree. With some drugs, eg, the SSRI ser-
traline,6 this can be explained by individual phar-
macodynamics. Whether the order of symptom
improvement is relevant to episode outcome is
currently unknown. Recent review suggests that
residual symptoms (eg, subthreshold depressive
symptoms, cognitive impairment, and sexual dys-
function) influence long-term outcome: they in-
crease the risk of relapse, impede the return to
psychosocial and occupational functioning, favor
chronification, and increase suicide risk.7 As such,
they are major targets of long-term treatment
in depressive disorders. Thus, symptoms that are
life-threatening to the patient and/or others must
be the primary target of depressive episode treat-
ment, bearing in mind that not all symptoms
respond at the same rate or to the same degree.
Residual symptoms are common and must not
be overlooked in long-term treatment.8 
M ajor depressive episode is defined as aperiod of at least 2 weeks of depressedmood with suicidal ideation and abnor-
malities of neurovegetative function (altered 
appetite, weight loss, sleep disturbance [early
awakening]), psychomotor activity (loss of energy
and interest, agitation, retardation), and cogni-
tion (feelings of worthlessness, hopelessness, and
inappropriate guilt). A frequent additional fea-
ture is diurnal variation (morning depression).
While emotional symptoms such as depressed
mood and loss of interest have traditionally been
viewed as the core symptoms, the prevalence
and importance of anxiety and physical symp-
toms such as pain and fatigue are attracting in-
creasing attention. Antidepressant treatment
should be considered for patients meeting diag-
nostic criteria for depressive episode (ICD-10) or
major depressive episode (DSM-IV). Treatment
choice depends on the concurrent symptom pro-
file, the disease and treatment history, and pa-
tient preference. It should always target the most
severe symptoms, ie, those that most endanger
the patient and/or others.
 Suicidality and extreme malnutrition/dehy-
dration are life-threatening conditions requiring
priority acute treatment. Suicidality, whether
passive (the feeling that life is no longer worth
living) or active (ideation, planning, or attempted
implementation), is generally an indication for
inpatient treatment, in an intensive care unit if
acute. Fast-acting benzodiazepines are indicated.
Antidepressants that increase activation should
be used with caution and the response closely
monitored. Hospitalization is mandatory for ex-
treme malnutrition/dehydration since force-feed-
ing may be needed.
 Psychotic features, particularly delusions of
guilt and nihilistic thinking, are a major threat to
the patient and others. As such, they require im-
mediate targeting, usually with antipsychotics
(including benzodiazepines in the acute state) in
an inpatient setting.
 Anhedonia, a core feature of depression, is a
mandatory treatment target since the prolonged
inability to experience pleasure substantially in-
creases suicide risk. It requires antidepressants
and/or psychotherapy on an inpatient or outpa-
tient basis, depending on severity.
 Severe agitation stresses the patient and must
2 A. Pfennig and M. Bauer, Germany
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changes,4 and the Mini International Neuropsy-
chiatric Interview. A major obstacle when assess-
ing the efficacy of antidepressants against their
primary targets is the remarkably high placebo
response rate in clinical trials. This has been as-
cribed to the intrinsic therapeutic effect of the
intensive monitoring involved.5 Placebo response
is inversely related to depression severity, being
more marked in the case of noncore symptoms
or milder, nonmelancholic disease. Although no
consistent difference has been found between
melancholic and nonmelancholic patients, most
studies record that only 20% to 30% of melan-
cholic patients respond to placebo. Low mood re-
activity is closely related to other core symptoms
in melancholia, and may thus be regarded as the
primary treatment target. In some studies, tri-
cyclic antidepressants are more effective in this
regard than selective serotonin reuptake inhib-
itors, but this is not a consistent finding.3 Total
remission should be the treatment target, as par-
tial response carries a high risk of relapse. 
D epression is a prevalent and devastatingdisorder with a complex etiology involvinga variety of neurobiological and socio-
economic factors.1 It is also multifaceted in its
phenomenology, manifested in shifting constella-
tions of symptoms and severities. High recurrence
rates and comorbid anxiety often impair function-
al capacity and quality of life. Melancholia has
been recognized since the fourth century BC. Its
key symptoms were long regarded as the core of
clinical depression, although they have recently
been portrayed as aligned more closely with bipo-
lar states.2 Melancholic symptoms have classi-
cally been the primary target for antidepressants
and electroconvulsive therapy. They show a sig-
nificantly lower placebo response, and may also
be less responsive to various forms of psychother-
apy.3 They have been widely tested using instru-
ments such as the Beck Depression Inventory,
via such items as sadness, past failure, loss of
pleasure, guilty feelings, punishment feelings, loss
of interest, irritability, and sleep and appetite
3 H. J. Koponen, Finland
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or most important symptoms of depression. Few
studies have addressed the effects of drugs on
individual depressive symptoms, since the vast
majority of clinical trials have used total rating
scale scores as outcome variables. Analysis of the
outcome of each and every item on a depression
rating scale in a single trial would be subject to
statistical limitations associated with the issue
of multiple comparisons. Even when symptoms
are clustered, comparisons are still too many for
meaningful statistical analysis. Received wisdom
holds that antidepressants only begin to act after
2 or more weeks, with the corollary that any ear-
lier response is evidence of placebo rather than
pharmacological effect.4 Recent contrary data,
however, suggest that improvement in major de-
pression may occur much earlier, by the end of
the first week.5 This paradigm shift may encour-
age more studies on the sequential improvement
of depressive symptoms in clinical trials. The
therapeutic effects of antidepressants have been
differentiated from those of placebo on the basis
of the pattern of response over time rather than
of individual symptom response.4 An exception is
the depressive subtype melancholia, where symp-
toms such as lack of reactivity, morning depres-
M ajor depression, defined accordingto Diagnostic and Statistical Manual of Mental Disorders Fourth Revision
(DSM-IV) criteria, comprises at least five of the
following nine symptoms: depressed mood; loss
of interest or pleasure; weight loss; insomnia or
hypersomnia; psychomotor agitation or retarda-
tion; fatigue; feelings of worthlessness or guilt;
difficulty to concentrate; and suicidal ideation.1
These symptoms have been deemed most specific
of the disorder and hence most useful for making
valid and reliable diagnoses. Patients diagnosed
with depression, however, have many other symp-
toms, in particular anxiety. This explains why
scales designed to rate treatment response, eg, the
Hamilton Rating Scale for Depression (HAMD),
contain anxiety-related items. To aid differential
diagnosis between depressive subtypes and anxi-
ety disorders, studies have attempted to identify
the core signs and symptoms of depression, eg,
Parker’s work on motor retardation2 or the devel-
opment of the Newcastle Scales.3 However, with-
out hard biological markers to validate symptom
profiles derived from clinical studies, it is difficult
to establish borders between depressive, anxiety
and bipolar disorders, or even to identify the true
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son why bupropion is less prescribed than other
second-generation antidepressants appears to be
its lack of anxiolytic effect.12 Insomnia often fails
to respond to antidepressants in clinical trials
and may even worsen.13 Cotreatments targeted at
insomnia have therefore been proposed to aug-
ment response, remission, and adherence.14 Novel
antidepressants such as agomelatine, which target
underlying biorhythm disruption, are more effec-
tive in sleep disturbance and may have an impor-
tant impact in the clinical management of major
depression.15 Antidepressants that differ in their
mechanisms of action may differ in the degree and
timing of their effects on individual symptoms.
Thus, the first symptoms to respond to the nor-
epinephrine reuptake inhibitor desipramine and
the selective serotonin reuptake inhibitor paroxe-
tine were psychomotor retardation and anxiety,
respectively, while placebo showed no pattern of
improvement in association with subsequent re-
mission and response in a clinical trial.16 In sum-
mary, limited evidence suggests that the symptom
to be prioritized in the treatment of major depres-
sion is not one conventionally classified as depres-
sive, but anxiety, in particular psychic anxiety. 
sion, terminal insomnia, marked retardation,
significant weight loss, and excessive guilt have
been shown to predict poor placebo response.6 In
theory there is an urgent practical need to pri-
oritize certain symptoms, in particular suicidal
ideation. However, there is disputed evidence that
antidepressants are associated with treatment-
emergent suicidal ideation and suicide-related
behavior, although not with completed suicide, in
children, adolescents and adults; on this basis,
current antidepressants may be ineffective for se-
curing rapid control of suicidal ideation or suicide
attempts.7 A good case for prioritized treatment
could also be made for any symptom whose ini-
tial improvement is associated with better sub-
sequent outcome. The few studies of sequential
improvement in depressive symptoms suggest that
early decreases in anxiety—HAMD 17 anxiety-
somatization factor and psychic anxiety—are as-
sociated with subsequently higher responder and
remitter rates.8-10 Interestingly, these findings are
consistent with current practice in that the effect
of antidepressants on anxiety symptoms is the
main feature that doctors consider when choos-
ing one drug over another.11 Thus the main rea-
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development of depression as shown in several
epidemiological studies2 and borne out in clinical
experience. Antidepressants that relieve certain
symptoms without correcting sleep disturbance
will not achieve a significant response and will
incur a high rate of relapse. Patients feel better
if their sleep disturbance improves early during
treatment. They are otherwise likely to feel worse.
The risk that selective serotonin reuptake inhib-
itors may initially worsen sleep should be coun-
teracted by the addition of hypnotics. The ideal
antidepressant is a drug that rapidly improves
sleep and resets the circadian system. Sleep dis-
turbance should thus be the primary target in
treating depression. This recommendation may
appear to conflict with the rapidly positive effect
that sleep deprivation may have in melancholia.
However, sleep deprivation works by resetting the
disrupted circadian system. Other methods that
act on the circadian pacemaker can be equally
effective. In order to improve sleep as a basis for
mood reversal, there are thus sound scientific as
well as clinical grounds for prioritizing circadian
rhythm in the treatment of depression. 
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I nsomnia is both a symptom and cause of de-pression. It may even be the worst symptom:to lie awake unable to rest while a prey to
pessimistic thoughts is torment. Insomnia is a
proven marker for increased suicidality. We re-
cently showed a correlation between sleep distur-
bance, in particular nightmares, and suicidality
and suicide attempts.1 Sleep disturbance in de-
pression—sleep-onset insomnia, frequent noctur-
nal awakening, and early morning awakening—
reflects underlying circadian dysregulation,
mediated by the suprachiasmatic pacemaker. Dys-
functional circadian input may also influence
monoaminergic activity, lowering serotonin ac-
tivity and melatonin levels, with effects on time-
keeping and hence sleep. Stress has a major role
in the development of depression. Some degree
of stress is tolerable, but overload is harmful.
Disturbed sleep is the best clinical sign of exces-
sive stress. Stress can be tolerated as long as sleep
function is normal. But insomnia is evidence of
an overactive hypothalamo-pituitary-adrenal axis.
The regulatory peptide corticotropin-releasing
factor not only influences the release of adreno-
corticotropic hormone, but also the limbic sys-
tem, inhibiting delta sleep. This dysregulation
may also feed back onto the circadian pacemaker.
Disruptions in the biological clock mechanism
may be both a cause and a consequence of de-
pression. Insomnia is itself a risk factor for the
6 J. Hetta, Sweden






that these symptoms, in some unknown way, play
a central role in the pathophysiology of the disor-
der. They must therefore be considered as treat-
ment priorities. Clinical experience also teaches
us that cognitive symptoms are important for
informing treatment strategy in depression. They
respond quite independently from other symptom
clusters. When patients improve in their mood
and associated physical symptoms, they often
retain the same cognitive disturbance as in the
acute phase of the disorder. Clinical experience
teaches us that treating cognitive symptoms first
has practically no effect on relieving depression,
except in its milder forms. The implication is that
we must first treat the core symptoms, at least in
severe depression, if we are to achieve any glob-
al improvement that allows intervention against
cognitive symptoms. The conclusion informed
by clinical experience is that the core symptoms
of depressed mood and anhedonia must be treat-
ed first, at least in severe depression, and that
cognitive symptoms should be targeted in the
second phase of treatment. Clinical experience
has shown that improvement in depressive mood
is a precondition for obtaining significant bene-
fit from cognitive remediation therapy. 
W hy should we need to prioritize targetsymptoms in the treatment of depres-sion? The question presupposes that
some symptoms are more life-threatening or sig-
nificant than others. Our first task is therefore to
hierarchize symptoms along these lines. Depres-
sion is commonly viewed as comprising core
symptoms (depressed mood and anhedonia) asso-
ciated with three (emotional, physical, and cog-
nitive) symptom clusters. However, this view is
unsupported by any pathophysiological mecha-
nism or mechanisms common to all forms of
depression. Until such mechanisms are identified,
we have no option but to base our definition of
depression, and our resulting treatment options,
on the phenomenology of the disorder. If we now
analyze the structure of these phenomenological
symptom clusters, can we hierarchize certain
symptoms in terms of risk or their potential im-
pact on other symptoms, such that successful
treatment of one symptom could encompass a
spectrum of others? In the absence of hard phys-
ical data, we can only base our answer on clini-
cal experience. What that experience teaches us
is that if we first treat the core symptoms, we
achieve global clinical improvement. This suggests
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sion were the first to improve.5 As no biological
markers for antidepressant treatment have been
found and as current practice relies on rating
scales, assessment of a patient’s treatment has to
be based on improvement in the core symptoms,
especially during the early treatment period.1,2,5
Clinically, the degree of symptom response is
more relevant than its order, although there does
appear to be a characteristic order of symptom
response to antidepressants. Residual symptoms
are less sensitive to antidepressants and may be
more clinically relevant in that they heighten
the risk of relapse.6 Our (unpublished) finding in
nonpsychotic major depressive disorder is that
the negative self-concept factor in the BDI (items
such as feeling of guilt, sense of punishment,
self-hate, and self-accusation) is relatively less
sensitive to change than observer ratings. This
factor may therefore be clinically relevant in
treating depression.
Is the placebo effect more important for some
noncore symptoms?
Recent neurobiological studies suggest that place-
bo effects are not as simple as previously thought
and that they may be clinically relevant by en-
hancing the effect of specific treatments.7,8 In
the hierarchy of classes of personal illness model
proposed in 1975 by Foulds and Bedford,9 depres-
sion occupies a lower hierarchical class. Endoge-
nous depression, on the other hand, especially
melancholia and psychotic depression, appears
more biologically determined,10 and does not oc-
cupy a lower hierarchical class. Studies from the
1970s suggest that the frequency of placebo effects
increases from anxiety disorder, through depres-
sive disorder, to schizophrenia. If we assume that
core symptoms are the final common pathway in
the pathogenesis of depression and that placebo
effects are salient solutions to given stimuli in
an individual,7,8 the noncore symptoms that could
be classified in the lowest hierarchical class9 may
be more likely to respond via a placebo effect. 
I would nominate as the priority treatmenttarget one of the so-called core symptoms,such as depressed mood, lack of interest,
lack of energy, guilt, psychic anxiety, or somatic
anxiety.1,2 This is because improvement in core
symptoms tends to benefit other symptoms and
eventually lead to full remission. However, it is
difficult to identify the core symptom(s) in an
individual patient because depression is hetero-
geneous in its pathogenesis. Since psychiatric
symptoms can be clinically differentiated at mul-
tiple levels, phenomenological similarity does not
reflect similarity of origin or structure.3 A further
complication is that the symptoms that appear
as priorities for the patient may not be those that
require priority treatment: our (unpublished)
observations indicate that the Beck Depression
Inventory (BDI) is less sensitive than clinician
rating at identifying responders and remitters,
especially in the early treatment period. Thus, at
present, clinicians are obliged to choose a core
symptom as their priority treatment target be-
cause antidepressants have shown no specific
differences in their mechanism of action on tar-
get symptoms.2
Is the order of symptom improvement a relevant
clinical factor?
The order of symptom response to antidepres-
sants appears to depend on the drug receptor
profile. For example, duloxetine, a serotonin-nor-
epinephrine reuptake inhibitor, improved de-
pressed mood, guilt, suicidal ideation, work/ac-
tivity, and anxiety in the first week, motor
retardation in the second week, motor retardation
and hypochondriasis in the third week, and gen-
eral somatic symptoms, insomnia, and insight
after the fifth week.4 With desipramine, a tricyclic
antidepressant that inhibits the reuptake of nor-
epinephrine, early response was shown by motor
retardation and depressed mood, while with the
selective serotonin reuptake inhibitor paroxetine,
anxiety, depressed mood, and distressed expres-
7 Y. S. Kim, Republic of Korea
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first or recurrent depressive episode.3 Current
pharmacological classes of antidepressants allow
clinicians to choose the most appropriate agent
in light of specific symptom patterns. Certain
drugs show symptom specificity. Serotonin nor-
epinephrine reuptake inhibitors (SNRIs), for ex-
ample, are most effective in cognitive disturbance
and/or somatic complaints such as pain.4 Mir-
tazapine and trazodone may be particularly
useful in sleep disturbance,5 along with melaton-
ergic agents such as agomelatine.6 The holy grail
of pharmacotherapy is to develop rapid-onset
agents that accelerate symptom response and
remission. Recent examples include escitalopram,
a selective serotonin reuptake inhibitor (SSRI),
and the SNRIs venlafaxine and duloxetine. How-
ever, rapid onset of effect is not the only factor
to consider in a treatment plan, even in severe
disease. Tolerability is a critical consideration
when efficacy depends on treatment compliance.
Therapeutic strategy must therefore be based 
on a combination of disease factors (symptom
severity, profile, and duration, and pattern of 
recurrence 7) and pharmacotherapeutic factors
(efficacy, tolerability, and time to effect). In pri-
oritizing treatment targets, consideration should
be given to the most urgent symptoms, especially
if somatic, suicidal, and/or psychotic, followed
by the patient’s own symptom hierarchy. But
the restoration of the fundamental biological
rhythms governing sleep, appetite, and other
functions must never be neglected. Biorhythm
normalization is essential for breaking the vicious
cycle of dysregulated affective brain circuits and
dysfunctional hypothalamus that can underlie
the core biological symptoms of depression.
Dysfunctional biorhythms maintain cortical and
subcortical circuit imbalance and vice-versa.
Drugs designed to normalize biorhythm disrup-
tion may be the most promising additions to the
pharmaceutical armamentarium against major
depression. 
P rioritizing symptoms in order to optimizetreatment strategy is a crucial and com-plex issue in managing major depression.
Depressed patients often overemphasize specific
symptoms (eg, cognitive disturbance, loss of 
interest, sleep difficulties). This may be useful in
establishing the diagnosis, but it can be mislead-
ing in informing treatment choice. Patients may
stress certain persistent symptoms (eg, insom-
nia, somatic symptoms) at the expense of others
that appear less severe, but are more meaningful
in terms of drug response. In addition, there are
specific populations, such as the elderly, with
their own clinical patterns, which tend to be more
severe and to carry a poorer prognosis than in
nonelderly adult depressives:1 elderly depres-
sives have more somatization, hypochondriasis,
anxiety/retardation, and delusionality, but less
guilt, loss of libido, and family history of depres-
sion, as well as a less predictable therapeutic
response; despite much lower medication doses,
side effects are also more troublesome in this
age group.2 Given the symptom heterogeneity, it
is mandatory to use standardized rating scales,
such as the Hamilton Depression Rating Scale
and Montgomery-Asberg Depression Rating Scale,
for qualitative and quantitative assessment and
for optimizing intervention. In choosing an initial
treatment modality, the first consideration is
the setting: the choice between hospitalization
and outpatient care depends on suicidal ideation
and symptom severity, in particular the presence
or absence of psychotic features. The second con-
sideration is the choice between pharmacology
and electroconvulsive therapy, and if pharmacol-
ogy, the choice of agent. Life-threatening situa-
tions must be addressed as rapidly as possible for
the safety of patients and those around them. Less
urgently, in order to minimize the development
of antidepressant resistance, it is important to
consider the duration of certain symptoms and
of untreated illness in patients experiencing a
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evolving disorder and is one of the most
frequent patient complaints that should
draw the attention of the vigilant physi-
cian to probe further. 
There is general agreement that the
symptoms that form the basis of a diag-
nosis of MDD are the core symptoms of
depression. These core symptoms are
considered to be those that occur most
frequently and increase in severity with
increasing levels of severity of the disor-
der. The large number of studies in the
extensive and rich literature on antide-
pressant treatments has shown consis-
tency in the identification of the core
symptoms of depression, which are part
of the diagnostic process and which are
used to measure severity of depression.
What are the main diagnostic criteria
that can be the target for antidepres-
sants?  
The Diagnostic and StatisticalManual of Mental Disorders,
4th Edition (DSM-IV) 2 diagnostic criteria
set out a list of symptoms that have to
be probed before a diagnosis of MDD can
be made, with the requirement that a
sive symptoms as they do not recognize
depression in themselves, or they may
perceive depression as having a low pri-
ority for general practitioners, or they
may have a perception that antidepres-
sant therapies have poor efficacy or have
unwanted side effects. The physician, who
can be constrained for time, may have
poor recognition of depressive illness,
may overdiagnose physical complaints
that are manifestations of depression, or
may interpret depressive symptoms as
“understandable” reactions to circum-
stances. Patients and physicians alike are
affected by the baleful influence of neg-
ative media comment and the stigma
attached to mental health problems. 
Diagnosing depression in clinical prac-
tice therefore requires that the physician
elicit answers to specific questions in
much the same way that the diagnosis
of hypertension or diabetes requires in-
trusive tests. Patients with depression
often present complaining of poor sleep,
anxiety, and loss of energy and where
these symptoms are present the patient
should be closely questioned about the
other core symptoms of depression. With
depression, poor sleep is a good marker of
What is the easiest way to assess core
symptoms of depression in clinical
practice?
Depression is a serious disorderthat is underrecognized and
undertreated. A large-scale survey carried
out in European countries showed that in
a cohort of 78 000 adults in which 17%
were suffering from depression, 69%
were not receiving medical treatment,
and in those who were receiving treat-
ment only 7.1% of patients with major
depressive disorder (MDD) received an
antidepressant.1 In primary care, where
depressed patients form a substantial pro-
portion of the attendees, both patient-
related and physician-related factors con-
tribute to the frequent failure to detect
or acknowledge the presence of depres-
sion. Patients may not mention depres-
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D epression is serious, underrecognized and undertreated.A survey in 78 000 European adults demonstrated itspresence in 17%, of whom 69% were untreated; only
7.1% of those with major depressive disorder were receiving an
antidepressant. Both patient and physician factors are respon-
sible for this failure to detect and treat depression in primary
care. Negative media comment has a baleful influence and stig-
ma remains attached to mental disorders. Yet depression can be
diagnosed by eliciting answers to specific questions, much like
hypertension or diabetes, and just as reliably and rapidly, even
over the telephone. Physicians must be alert to complaints of poor
sleep, anxiety and loss of energy. The Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition (DSM-IV) requires de-
pressed mood or loss of interest to have been associated for at
least 2 weeks at a distressing or dysfunctional level with at least
five core symptoms (appetite disturbance, sleep disturbance, psy-
chomotor disturbance, fatigue or low energy, feelings of worth-
lessness or guilt, reduced concentration, and suicidal thoughts or
attempts). There is substantial agreement between these items
and the Montgomery & Asberg Depression Rating Scale, despite
the radically different methods of construction involved. Treat-
ment response is assessed using the same core items as for diag-
nosis. Effective treatment is defined by multi-item improvement
sustained for 6 to 8 weeks. The fact that placebo response meets
this definition in some patients complicates the conduct of clin-
ical trials and should alert primary care practitioners to the psy-
chotherapeutic benefit of constant evaluation and the reassur-
ance inherent in sympathetic follow-up.
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part of their pharmaceutical action, and
these effects may impact on anxiety
symptoms of depression or impair sleep.
SSRIs and SNRIs have been shown to
impair sexual function, and some anti-
depressants with prolonged antihis-
taminic effects, although they improve
sleep, do so at the expense of day time
concentration and psychomotor func-
tion. Tricyclic antidepressants (TCAs),
which have anticholinergic and histamin-
ergic effects, reduce the ability to con-
centrate, function, drive a car, or operate
machinery.
Scales, interviews, self- or hetero-evalu-
ation—which is the most appropriate
method?  
It is rare for patients to volunteerthe core symptoms. They need
to be systematically evaluated. This is
most easily done using a well-known
depression rating scale. In Norway, for
example, physicians are reimbursed for
completing an MADRS interview as an
incentive to recognize the presence of
depression and therefore encourage its
treatment. Physicians may have an un-
derstandable resistance to asking system-
atically after core symptoms, a reluc-
tance that may be driven partly by the
stigma attaching to the disorder. They
are also often unaware of how quickly
core symptoms may be assessed. The
presence or absence of the core symp-
toms is easy to establish with very few
questions. The quantification of severity
may take a little longer. 
The Hamilton rating scale4 is very
widely used for assessing depression,
though it has the disadvantage of con-
taining some items covering symptoms
and behaviors, which, though part of
depression, are uncommon and relative-
ly insensitive to change. The scale has
been subjected to several revisions by
other investigators, but whether you use
the 17-, 21-, 24-, or 28-item version,
there are too many redundant items
that are insensitive to change. There 
are also self-rating scales derived from
the Hamilton scale, though these tend
to be cumbersome and have not been
shown to be particularly useful in rou-
tine practice.
Some scales to measure depression
have deliberately excluded certain core
symptoms such as poor appetite or poor
sleep. For example, the Bech Melancholia
Scale5 excludes sleep disturbance despite
the fact that early morning wakening is
a well-recognized symptom of melan-
cholia. The exclusion of disturbed sleep
and disturbed appetite may tend to make
Do different antidepressant treatments
(pharmacological, sleep deprivation,
etc) act on different core symptoms?  
Treatment effective on one symp-tom alone, eg, hypnotics, which
improve sleep latency (getting off to
sleep), have not been shown to be effec-
tive as antidepressants because they lack
the ability to produce a response on the
other core symptoms. Similarly, benzo-
diazepines, which have been shown to be
effective in treating anxiety symptoms
and sleep disturbance, are not looked
upon as antidepressants in their own
right. The idea that a treatment may be
focused on a single core symptom is not
regarded as sufficient to establish efficacy
as an antidepressant. Unless there are
significantly more responders treated
with an antidepressant based on a com-
posite score compared with placebo, ex-
perts do not consider that treatment to
be effective. In general, treatments rec-
ognized as effective in MDD seem to
have an overall beneficial effect on most
of the symptoms.  
A treatment is also only regarded as
being effective in MDD if the beneficial
effects are sustained for a period 6 to 8
weeks. For this reason, sleep deprivation,
which has been shown in some studies
to have some beneficial transient effect
on a range of symptoms for a few days,
cannot be regarded as adequate treat-
ment of depression.
Placebo has been shown to have an
effect on core symptoms that may be sus-
tained for 6 to 8 weeks in some patients,
reflecting to some extent the fluctuating
nature of depression, with a proportion
of patients showing spontaneous im-
provement. This apparent efficacy also
reflects the beneficial psychotherapeutic
effects of constant evaluation of the de-
pression and the reassurance inherent
in attending a clinic under sympathetic
supervision. To qualify as an antidepres-
sant, a treatment of depression is re-
quired to be more effective than placebo
given under these reassuring conditions
and this is the rationale for conducting
carefully managed randomly assigned
placebo-controlled investigations. 
As depression improves, the symptoms
tend to improve together so that any
treatment of depression, if it is effective,
will have some beneficial effect on all of
the core symptoms.  However, many anti-
depressants have side effects that impact
negatively on some of the core symptoms.
Selective serotonin and norepinephrine
reuptake inhibitors (SSRIs, SNRIs) pro-
duce nausea and problems with appetite,
increased nervousness, or agitation as
patient has to suffer from depressed mood
or loss of interest with at least 5 other
symptoms from the list. These core symp-
toms are depressed mood, loss of inter-
est, appetite disturbance, sleep distur-
bance, psychomotor disturbance, fatigue
or low energy, feelings of worthlessness
or guilt, reduced concentration, and
suicidal thoughts or attempts. There is
substantial agreement between items
identified in DSM-IV and the Montgomery
& Asberg Depression Rating Scale
(MADRS),3 a scale for the assessment of
severity of depression. This is of particu-
lar note given the different construction
methods used for the two instruments.
The MADRS was constructed, based on
data in the field, as a scale sensitive to
change with treatment, whereas the
DSM-IV criteria were based on the con-
sensus of opinion from a committee of
experts as to which were the most rele-
vant symptoms of depression.  
The core symptoms of depression were
identified for the MADRS on the basis of
frequency (present in at least 70% of the
test population), sensitivity to changes
with treatment, and the items had also
to be well understood by people from dif-
ferent cultures. The preliminary identi-
fication of the most frequently occurring
items found that two items, worrying
over trifles and observed muscular ten-
sion, while occurring frequently, were
not in the first rank of sensitivity to
change. Two items, reduced sleep and
reduced appetite, were marginally less
frequent, but were more sensitive to
change. The final selection of 10 items
based on sensitivity and frequency, which
represent the core symptoms, were sad-
ness, both observed and reported, in-
ability to feel, inner tension, suicidal
thoughts, lassitude, concentration diffi-
culties, reduced sleep, reduced appetite,
and pessimistic thoughts. The results of
two different methods of construction
arrived at very similar conclusions on the
core symptoms of depression, with one
item, inner tension, which was both fre-
quent and sensitive, occurring in the
MADRS, but not the DSM-IV.
To diagnose depression, a range of core
symptoms needs to be elicited; to track
the improvement in the disorder it is
obviously necessary to assess change in
the same symptoms that established the
diagnosis. For a treatment of depression
to be considered effective improvement
on these core symptoms would be ex-
pected. In general, treatments that are
effective in depression have been able to
show efficacy, as measured by a reduc-
tion of a composite score covering the
core features of depression. 
core symptoms that might overlook, for
example, worsening of sleep, appetite or
even of suicidal thoughts. It is safer and
better practice of course to concentrate
on the core symptoms identified on the
DSM-IV diagnostic system or on the
MADRS to make sure that these symp-
toms have resolved satisfactorily and to
check on the scores on the scales to be
able to justify the status of remission.  
Remission in an important goal since
it is at this point that long-term treat-
ment begins. The aim of long-term treat-
ment is to consolidate remission and
prevent relapse in a period of continua-
tion treatment in all patients, and to
prevent recurrence in those with recur-
rent depression. It is necessary, in treat-
ing depression, whether in a primary
care or a specialist setting, to pay assid-
uous attention to checking on all these
core symptoms for adequate monitoring
of response, remission, and, most im-
portantly, sustained remission. 
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Would it be more relevant for GPs to
rely on core symptoms only for the diag-
nosis and the assessment of recovery
of depression?  
In order to diagnose MDD accord-ing to the DSM-IV, or for that
matter to diagnose depressive illness fol-
lowing the International Statistical Clas-
sification of Diseases and Health-Related
Problems, 10th Revision (ICD-10) sys-
tem, it is necessary to check on all of the
core diagnostic symptoms. Depression
is a disorder where the sufferer may have
some symptoms and not others, and it
is for this reason that the formulation of
the diagnostic system is that as well as
depressed mood or loss of interest there
should be evidence of the presence a to-
tal of 5 out of the 9 core symptoms at a
distressing or dysfunctional level for at
least 2 weeks. 
Monitoring the progress of the de-
pressed patients will require the tracking
of changes in the severity of these core
symptoms in terms, and it would be un-
wise to cut corners and ignore any of
them. The aim of treatment is not just
to achieve a response with reduction in
the severity of symptoms, but also to
treat the depressed individual adequately
to achieve remission, which is compati-
ble with the recovered state. Remission
is mostly defined by a low level of symp-
toms measured on the standard rating
scales with, for example a cutoff score of
11 or less on the MADRS or 7 or less on
the Hamilton scale. It would be difficult
to justify examining a truncated list of
those antidepressants that disrupt sleep
and appetite appear better than they re-
ally are. A good antidepressant should be
able to improve all the symptoms of de-
pression rather than just selected items.
Self-rating scales have been used and
have their place provided that scales
cover the core symptoms and are easily
understood. Their use is obviously limit-
ed in patients who have difficulty under-
standing or who are severely ill. They
have no place in assessing depression in
patients who are illiterate.
Although it is more reliable to inter-
view a patient face to face, there are many
occasions when this may not be possible.
It is quite possible to assess the core
symptoms of depression in telephone
interviews, either in a direct conversation
with the patient or indirectly via a voice
interactive computer-generated interview.
There may be some difficulty in assess-
ing certain behavioral symptoms, but
these interviews have nevertheless been
shown to be reliable and able to reflect
response or deterioration. The voice in-
teractive system has the advantage of
not being prone to the bias of the inter-
viewer; moreover, some sensitive infor-
mation may be more readily obtained 
by this means than in the face-to-face
interview where a patient is aware of the
stigma associated with mental illness.
Normal management of a patient should
include regular monitoring of progress,
but the need to come to the surgery for
this assessment is uneconomic and inef-
ficient and may contribute to discontin-
uation from therapy.
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L a dépression est une affection grave, sous-évaluée et sous-traitée. Une étude menée chez 78 000 adultes européens àmis en évidence l’existence d’une dépression chez 17 % des
sujets, dont 69 % n’étaient pas traités, alors que seuls 7 % de ceux
qui avaient un trouble dépressif majeur recevaient un antidé-
presseur. Cet échec pour détecter et traiter la dépression dans la
prise en charge primaire est dû à des facteurs propres à la fois au
patient et au médecin. S’y ajoute l’influence néfaste des com-
mentaires péjoratifs des médias et de l’aura négative dont est
toujours entachée la maladie mentale. Pourtant la dépression
peut être diagnostiquée de façon fiable et rapide, même par té-
léphone, par la réponse à des questions spécifiques, comme cela se
fait pour l’hypertension ou le diabète. Les médecins doivent être
attentifs aux plaintes concernant un mauvais sommeil, une anxié-
té ou une perte d’énergie. Le DSM-IV (Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition) exige la présence depuis
au moins 2 semaines d’une humeur dépressive ou d’une perte
d’intérêt atteignant un degré pénible ou handicapant conjoin-
tement à celle d’au moins cinq symptômes majeurs (troubles de
l’appétit, troubles du sommeil, troubles psychomoteurs, fatigue
ou baisse d’énergie, sensation de dévalorisation ou de culpabilité,
baisse de concentration et idées ou gestes suicidaires). Ces items
et l’échelle de dépression de Montgomery et Asberg sont tout à
fait concordants, malgré des méthodes d’interprétation radicale-
ment différentes. La réponse au traitement est évaluée au moyen
des mêmes items majeurs utilisés pour le diagnostic. L’efficacité
du traitement est définie par l’amélioration prolongée pendant
6 à 8 semaines des symptômes majeurs. La réponse au placebo
remplissant également cette définition chez certains patients, la
conduite des études cliniques s’en trouve compliquée, ce qui de-
vrait attirer l’attention des médecins généralistes sur l’intérêt
psychothérapeutique d’une évaluation constante et du réconfort
procuré par un suivi bienveillant.
SYMPTÔMES MAJEURS DE LA DÉPRESSION EN PRATIQUE CLINIQUE
input, the generation of multiple response alter-
natives, planning abilities, and self-evaluation.5,6
Parietal and parahippocampal activity has been
associated with anxiety,7 and medial frontal and
cingulate activity with cognitive performance and
emotional bias.8,9 A more complex ventral-dorsal
segregation of frontal lobe function has also been
described, with a positive correlation between ven-
tral prefrontal activity and anxiety/tension, and a
negative correlation between dorsolateral activity
and psychomotor and cognitive slowing.10
Cognitive activation studies: 
emotional processing
Studies of resting state patterns have been com-
plemented by activation experiments using PET
or functional magnetic resonance imaging (fMRI)
of specific cognitive and emotional processes in
healthy volunteers and depressed patients. Emo-
tional processing in depression is characterized by
Functional and structural neuroimaging offersan unrivalled window onto the neuroanato-my of depression. Positron emission tomog-
raphy (PET) studies of cerebral blood flow and glu-
cose metabolism have consistently characterized
major depressive disorder, whether primary or asso-
ciated with specific or diffuse brain lesions, as a sys-
tem-level illness affecting discrete, but functionally
integrated cortical, subcortical, and limbic path-
ways.1,2
Resting state studies
Brain metabolism and regional blood flow have
been measured in depressed subjects at rest (ie, in
the absence of specifically oriented mental activity),
in ventral and dorsal prefrontal cortex, anterior cin-
gulate, basal ganglia, amygdala, and hippocampus.
The best-replicated behavioral correlate of a resting
state abnormality is that of an inverse relationship
between prefrontal activity and depression sever-
ity.3 Specific neural network changes are associated
with symptomatic dimensions of depression that
have been grouped into affective, circadian-somat-
ic, cognitive, and motor behavioral subsystems to
allow easier evaluation of the mechanisms medi-
ating variation in normal behavior domains. Dorso-
lateral prefrontal cortex (DLPFC) activity has been
linked both to psychomotor speed and to executive
functions4 that include a set of cognitive processes
engaged in the integration of multimodal sensory
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F O C U S
F unctional brain imaging studies suggest that depressionis a system-level disorder affecting discrete, but function-ally linked, corticolimbic structures with abnormalities
in the anterior cingulate, lateral and medial prefrontal cortex,
amygdala, and hippocampus. Within this circuitry, abnormal
corticolimbic interactions underlie the characteristic cognitive
deficits and emotional impairment. Depression involves a cog-
nitive bias toward processing negative emotional information
congruent with the patient’s mood and worries, possibly reflect-
ing prolonged involuntary processing of emotional stimuli and
impaired modulation of emotional responses to negative stimuli.
Antidepressant treatment, whether with drugs or psychotherapy,
may help the brain to restore cognitive and emotional homeo-
stasis by improving connectivity in dysfunctional corticolimbic
pathways. Pretreatment increases in rostral anterior cingulate
and amygdalar activity predict clinical response to antidepressant
drugs. By combining structural and functional investigations,
brain imaging studies may help to generate novel antidepres-
sant treatments that regulate structural and functional plastic-
ity within the neural network regulating mood and affective be-
havior.
Medicographia. 2008;30:55-59. (see French abstract on page 59)
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to cognitive and emotional demands. Thus testing
depressed patients with a cognitive task they can
perform is more important than demonstrating
deficit in a task they cannot perform because how
they are doing is more informative for understand-
ing the pathophysiology of depression than what
they are doing.20 Recent behavioral and fMRI data
support this hypothesis. Depressed patients with
anhedonic features showed deficits in continuous
attentional tasks compared to depressed patients
with impulsive features.20 These deficits appeared
progressively during the task, displaying a time-
on-task effect consistent with previous findings in
normal anhedonic subjects, and suggesting that an-
hedonia trait and state are associated with a reduced
capacity to sustain cognitive effort.21
In a recent fMRI study,we compared 10 depressed
subjects and 10 normal controls in a verbal n-back
working memory task that required the n stimuli
to be maintained and updated each time a new
stimulus occurred.22 We manipulated the working
memory load across the experiment (1,2,3-back)
to increase cognitive demands. Having deliberate-
ly selected depressed patients who performed nor-
mally on the n-back task, we found no intergroup
difference in either performance or reaction times
at each level of complexity: both groups showed
bilateral activation of the DLPFC (Broca area [BA]
9/46), premotor and supplementary motor areas
(BA 6/8), Broca’s area, dorsal anterior cingulate
cortex (ACC), and parietal cortex. Task complexity
modulated activation in these regions. Depressed
patients showed greater DLPFC and dorsal ACC ac-
tivation in the n-back neural network than normal
controls. Of the three fMRI studies that have since
used an n-back or working memory task in de-
pressed patients, two have confirmed left DLPFC
hyperactivation versus normal controls.23-25
Earlier neuroimaging studies had shown simi-
larly aberrant DLPFC activation in depression.26,27
Thus the Stroop task, which measures the effect of
interference on performance of a color identifica-
tion task, revealed a shift in brain activation in de-
pressed patients to the left DLPFC, a region not re-
cruited for this task in healthy subjects, associated
with blunting of the expected ACC increase.26
The aberrant DLPFC and ACC activation associ-
ated with normal performance in depressed sub-
jects may reflect several problems: (i) an inefficient
task-related neural network reflecting difficulty in
organizing neural activity and an abnormal signal-
to-noise ratio indicative of dopaminergic dysfunc-
tion (Daniel R. Weinberger, National Institutes of
Health Neuroscience Center at Saint Elizabeth’s,
Washington, DC 20032, personal communication);
(ii) structural brain abnormalities within the work-
ing memory network; (iii) excessive subjective ef-
fort (volition) or task engagement; and (iv) difficul-
ty in inhibiting limbic structure activation during
a cognitive task, reflecting an inability to allocate
resources to the external world.22
In healthy subjects, ACC activation may reflect
the intentional amount of effort (volition) that a
subject uses in a task. The ACC also aids cognition
by detecting conflict and monitoring error during
bias toward the processing of negative stimuli,11 via
mechanisms that remain unelucidated. Mood dis-
orders may be associated with abnormalities in the
way emotional stimuli are perceived, interpreted,
and stored in memory. Depressed patients allocat-
ed more attention to sad than happy faces in a dot-
probe task, but because they showed no similar bias
toward other negative stimuli, such as angry faces,
they appeared not to have a general problem with
negative emotional stimuli per se.12 They interpret
emotionally neutral faces as sad,13 have a better
memory for negative stimuli, including words and
pictures, and show diminished responsiveness to
positive stimuli.
Several fMRI studies have evaluated the neural
correlates of impaired emotional processing in de-
pression with special focus on the amygdala, a me-
dial temporal structure involved in processing facial
expression, assigning valence and arousal to stim-
uli, and generating emotional responses to stimuli.
Presentation of sad faces prompted an increase in
amygdalar and ventral striatal activity which was
attenuated by treatment with the selective serotonin
reuptake inhibitor (SSRI) fluoxetine for 8 weeks.14
Amygdalar responses to negative emotional words
were abnormally sustained in depressed patients
compared to normal controls.15 This could be an
important neural correlate of rumination, a com-
mon clinical feature of major depressive episode.
Other fMRI studies in depression using emotional
words have shown reduced activation in frontotem-
poral and limbic regions in response to positive
stimuli.16,17
Depression and cognitive resources
Depression may not result only from selective re-
gional or pathway dysfunction, but also from fail-
ure of the remaining systems to maintain emo-
tional homeostasis in times of increased cognitive
demand.2 Cognitive or information-processing re-
sources are not unlimited, even in normal subjects,
and mental operations differ in their attentional or
cognitive requirements. Automatic processes run in
parallel, unrestricted by short-term memory capac-
ity, and require little or no cognitive effort, but they
require practice to develop, and are restricted to sit-
uations in which a given stimulus consistently in-
volves the same response. Controlled processes, on
the other hand, run in sequence, are restricted by
short-term memory capacity, are effortful, and im-
prove with minimal practice.18
Depression interferes with effortful cognitive pro-
cesses, leaving automatic processes intact in sever-
al domains, eg, learning, memory, problem-solving,
reading, and speed processing.19 The effortful-deficit
hypothesis in depression predicts impairment in ac-
tions requiring attentional and executive resources
such as complex goal-directed behaviors. We sug-
gest that deficits in depressed patients performing
an effortful task are preceded by increasing effort to
maintain a high performance level. Progressive ex-
haustion of cognitive resources precedes the deficits.
Cognitive resource depletion is the end product of
the failure by depressed patients to constantly adapt
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reported the normalization of many pretreatment
regional abnormalities, with brain metabolism and
blood flow ceasing to differ between patients and
controls. Improvement of frontal hypometabolism
is the best replicated finding.48,49 However, correc-
tion of frontal hypermetabolism has also been de-
scribed with venlafaxine and paroxetine.39,50 Post-
treatment changes in metabolic activity also occur
in brain regions that did not differ from controls at
baseline.41,51 Clinical heterogeneity, compensatory
processes, and treatment-specific effects may ac-
count for these divergent findings.
Studies comparing responders and nonrespon-
ders to a given treatment have identified the brain
changes specific to clinical response. In a study of
the time course of regional metabolic changes with
fluoxetine in unipolar depression, patients were
divided into responders (reduction >50% in the
Hamilton depression rating scale) and nonrespon-
ders after 6 weeks of treatment.37 At 1 week, both
groups had similar brain changes (brain stem and
hippocampal increases; posterior cingulate decrease)
and no clinical changes. At 6 weeks, clinical respon-
ders, but not nonresponders, developed specific
limbic and striatal decreases (subgenual cingulate,
hippocampus, insula, and pallidum), and brain stem
and dorsal cortical increases (prefrontal, parietal,
anterior, and posterior cingulate). These findings
were confirmed with venlafaxine and bupropion.14,47
The fact that depressed patients who respond to
placebo52 show the same brain changes as those who
respond to cognitive-behavioral therapy50 suggests
a final common pathway for the clinical remission
of depression achieved through both pharmacolog-
ic and non-pharmacologic treatments. However,
the presence of specific brainstem and hippocam-
pal changes in fluoxetine-treated patients supports
the hypothesis that both treatment-specific and re-
sponse-specific effects can be identified.53
In light of these differences between responders
and nonresponders, an obvious related question is
whether baseline regional activities predict treat-
ment outcome. Several studies have found that pre-
treatment metabolic activity in the rostral (pregen-
ual) cingulate uniquely distinguishes medication
responders from nonresponders.40,54,55 In an fMRI
study, amygdalar reactivity to emotional faces in
depressed patients predicted symptom reduction
after antidepressant treatment for 8 months.56 The
amygdalahas longbeen implicated inantidepressant
drug action via serotoninergic pathway inhibition.
Never-depressed volunteers receiving citalopram
20 mg/day for 1 week showed decreased amygdalar
responses to masked presentation of threat stim-
uli compared to volunteers receiving placebo, sug-
gesting that SSRIs modulate amygdalar responses
directly without elevating mood in normal sub-
jects.57 Other studies by the same Oxford group have
shown that single or repeated dosing with rebox-
etine may enhance speed of categorization and
recognition of positive emotional words in normal
controls. This positive bias induced by an antide-
pressant without concomitant mood change points
to a cognitive effect via the modulation of limbic
network reactivity (medial prefrontal cortex, amyg-
information processing.28 It may contribute to ex-
ecutive processes via the on-line detection of pro-
cessing conflicts that impair performance.29 Dur-
ing the n-back task, depressed patients may need
to monitor putative errors and conflict more than
controls, which could account for the greater ACC
activation. This hypothesis finds support from a
recent event-related potential study showing that
depressed patients have abnormal error-related
component activation reflecting excessive error
monitoring.30 The dorsal ACC has strong connec-
tions with the DLPFC. ACC activation may signal to
the brain the need for controlled processing and
the DLPFC could be critical for this form of con-
trolled processing.
In healthy subjects, fMRI studies have shown that
increasing cognitive demand engages a pattern of
brain activation characterized by a balance between
increasing activity in cortical cognitive areas and
decreasing activity in limbic and paralimbic struc-
tures, eg, ventromedial prefrontal regions.31 Limbic
deactivation may represent a gating function aimed
at inhibiting emotional interference during cogni-
tive effort. In our n-back study, depressed patients
had more difficulties than normal controls in deac-
tivating the medial prefrontal cortex.22,24 Abnormal
corticolimbic interaction may subserve performance
decrements in effortful tasks in depression,22 as sug-
gested by the fMRI evidence, obtained at rest and
during activation, of imbalance in corticolimbic ac-
tivity and connectivity in depression.32,33
The mechanisms mediating “corticolimbic fail-
ure” in depression are unelucidated, but presum-
ably involve genetic factors as well as developmen-
tal insults and environmental stressors.34-36 In this
model of dynamic brain adaptation in depression,
foci of network dysfunction identified in the base-
line depressed state can be considered both as eti-
ological abnormalities and as sites of adaptive and
maladaptive compensatory processes.
Brain changes with 
antidepressant treatment
Treatments for depression can be similarly viewed
within this corticolimbic framework. Functional
neuroimaging can help to identify the pathways
mediating the changes in depression and treatment
response. Most such studies have assessed depressed
patients using PET or fMRI before and after treat-
ment for 6, 8, or 10 weeks, systematically assessing
the regional brain changes associated with clinical
response, and evaluating treatment-specific effects
and differences between responders and nonre-
sponders.
Study drugs have included SSRIs (eg, fluoxetine,37
paroxetine,38-40 and sertraline),41 tricyclics (eg, imi-
pramine),42 the serotonin norepinephrine reuptake
inhibitor venlafaxine,43-46 and the atypical antide-
pressant bupropion, a norepinephrine and dopamine
reuptake inhibitor.47 Changes have been reported in
several areas of the cortex (dorsolateral, medial, and
ventral prefrontal regions, and parietal region), lim-
bic system (cingulate, amygdala, insula), and sub-
cortex (caudate, thalamus). Almost all studies have
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tive and emotional studies are needed in remitters
and subjects at high risk to elucidate the neural cor-
relates of vulnerability to depression. Preliminary
studies with mood induction have emphasized the
role of the medial prefrontal cortex in this regard.60
However, long-term imaging studies are needed to
define the neural correlates of sustained remission.
Preliminary data and recent findings with deep
brain stimulation suggest that maintaining persis-
tent control of activity in the subgenual cingulate
cortex (Brodman area 25) may prevent relapse of
depression.61 Perhaps the most fundamental re-
quirement is for further clinical and experimental
in vivo and in vitro studies to identify the genetic
and environmental determinants of structural and
functional plasticity within the neural network reg-
ulating mood and affective behavior, and thus to
prepare the ground for the development of novel
antidepressant treatments. 
dala).58,59 This interpretation is consistent with the
well-known anxiolytic properties of SSRIs and the
emotional bias observed in depressed patients.
Summary and future direction
Abnormal corticolimbic balance and connectivity
may subserve cognitive deficits and emotional bias
in acute depression. Reciprocal corticolimbic inter-
action (cortical increases / limbic decreases) is crit-
ical for clinical remission, whatever the treatment
used. By improving connectivity in dysfunctional
corticolimbic pathways, antidepressants may help
the brain to restore cognitive and emotional home-
ostasis. Increased pretreatment activity in the ros-
tral anterior cingulate and amygdala may predict
clinical response to pharmacotherapy. The studies
we have discussed have described the short-term ef-
fects of antidepressants in acute depression. Cogni-
F O C U S
58 A functional brain imaging perspective in depression – FossatiMEDICOGRAPHIA, VOL 30, No. 1, 2008
REFERENCES
1. Drevets WC. Functional anatomical abnormalities
in limbic and prefrontal cortical structures in major
depression. Prog Brain Res. 2000;126:413-431.
2. Mayberg HS, Fossati P. Dysfunctional limbic-cor-
tical circuits in major depression: a functional neuro-
imaging perspective. In: Barch DM, ed. Cognitive and
Affective Neuroscience of Psychopathology. Oxford,
UK: Oxford University Press; In press.
3. Ketter TA, George MS, Kimbrell TA, et al. Func-
tional brain imaging, limbic function, and affective
disorders. Neuroscientist.1996;2:55-65.
4. Bench CJ, Friston KJ, Brown RG, et al. Regional
cerebral blood flow in depression measured by posi-
tron emission tomography: the relationship with clin-
ical dimensions. Psychol Med. 1993;23:579-590.
5. Stuss DT, Benson DF. Neuropsychological studies of
the frontal lobes. Psychol Bull.1984;95:3-28.
6. Fossati P, Ergis AM, Allilaire JF. [Executive func-
tioning in unipolar depression: a review]. Encéphale.
2002;28:97-107.
7. Osuch EA, Ketter TA, Kimbrell TA, et al. Regional
cerebral metabolism associated with anxiety symp-
toms in affective disorder patients. Biol Psychiatry.
2000;48:1020-1030.
8. Dolan RJ, Bench CJ, Brown RG, et al. Neuropsy-
chological dysfunction in depression: the relationship
to regional cerebral blood flow. Psychol Med. 1994;
24:849-857.
9. Elliott R, Rubinsztein JS, Sahakian BJ, Dolan RJ.
The neural basis of mood-congruent processing biases
in depression. Arch Gen Psychiatry.2002;59:597-604.
10. Brody AL, Saxena S, Mandelkern MA, et al. Brain
metabolic changes associated with symptom factor
improvement in major depressive disorder. Biol Psy-
chiatry. 2001;50:171-178.
11. Leppänen JM. Emotional information processing
in mood disorders: a review of behavioral and neuro-
imaging findings. Curr Opin Psychiatry. 2006;19:34-
39.
12. Gotlib IH, Krasnoperova E, Neubauer D, Joor-
man J. Attentional biases for negative interpersonal
stimuli in clinical depression. J Abnorm Psychol.2004;
113:127-135.
13. Leppänen JM, Milders M, Bell JS, et al. Depression
biases the recognition of neutral faces. Psychiatry Res.
2004;128:123-133.
14. Fu CH, Williams SC, Cleare AJ, et al. Attenuation
of the neural responses to sad faces in major depres-
sion by antidepressant treatment. Arch Gen Psychi-
atry. 2004;61:877-889.
15. Siegle GJ, Steinhauer SR, Thase ME, Stenger VA,
Carter CS. Can’t shake that feeling: event-related
fMRI assessment of sustained amygdala activity in re-
sponse to emotional information in depressed indi-
viduals. Biol Psychiatry. 2002;51:693-707.
16. Canli T, Sivers H, Thomason ME, Whitfield-Ga-
brieli S, Gabrieli JD, Gotlib IH. Brain activation to
normally increased contributions from subgenual cor-
tex and thalamus. Biol Psychiatry. In press.
34. Frank E, Thase ME. Natural history and preven-
tive treatment of recurrent mood disorders. Ann Rev
Med.1999;50:453-468.
35. Jacobs BL, Praag H, Gage FH. Adult brain neuro-
genesis and psychiatry: a novel theory of depression.
Mol Psychiatry. 2000;5:262-269.
36. Kendler KS, Thornton LM, Gardner CO. Genet-
ic risk, number of previous depressive episodes, and
stressful life events in predicting onset of major de-
pression. Am J Psychiatry. 2001;158:582-586.
37. Mayberg HS, Brannan SK, Mahurin RK, et al.
Regional metabolic effects of fluoxetine in major de-
pression: serial changes and relationship to clinical
response. Biol Psychiatry. 2000;48:830-843.
38. Smith GS, Reynolds CF, Pollock B, et al. Cerebral
glucose metabolic response to combined total sleep
deprivation and antidepressant treatment in geriatric
depression. Am J Psychiatry. 1999;156:683-689.
39. Brody AL, Saxena S, Stoessel P, et al. Regional
brain metabolic changes in patients with major de-
pression treated with either paroxetine or interper-
sonal therapy. Arch Gen Psychiatry.2001;58:631-640.
40. Kennedy SH, Evans K, Kruger S, et al. Changes
in regional glucose metabolism with PET following
paroxetine treatment for major depression. Am J Psy-
chiatry. 2001;158:899-905.
41. Buchsbaum MS, Wu J, Siegel BV, et al. Effect of
sertraline on regional metabolic rate in patients with
affective disorder. Biol Psychiatry. 1997;41:15-22.
42. Hurwitz TA, Clark C, Murphy E, Klonoff H, Martin
WR, Pate BD. Regional cerebral glucose metabolism
in major depressive disorder. Can J Psychiatry. 1990;
35:684-688.
43. Martin SD, Martin E, Rai SS, et al. Brain blood
flow changes in depressed patients treated with inter-
personal psychotherapy or venlafaxine hydrochloride.
Arch Gen Psychiatry. 2001;58:641-664.
44. Davidson RJ, Irwin W, Anderle MJ, Kalin NH. The
neural substrates of affective processing in depressed
patients treated with venlafaxine. Am J Psychiatry.
2003;160:64-75.
45. Davies J, Lloyd KR, Jones IK, Barnes A, Pilowsky
LS. Changes in regional cerebral blood flow with ven-
lafaxine in the treatment of major depression. Am J
Psychiatry. 2003;160:374-376.
46. Schaefer HS, Putnam KM, Benca RM, Davidson
RJ. Event-related functional magnetic resonance
imaging measures of neural activity to positive social
stimuli in pre- and post-treatment depression. Biol
Psychiatry. In press.
47. Little JT, Ketter TA, Kimbrell TA, et al. Bupropion
and venlafaxine responders differ in pretreatment re-
gional cerebral metabolism in unipolar depression.
Biol Psychiatry. 2005;57:220-228.
48. Baxter LR Jr, Schwartz JM, Phelps ME, et al. Re-
emotional words in depressed vs healthy subjects.
Neuroreport. 2004;15:2585-2588.
17. Epstein J, Pari H, Kocsis JH, et al. Lack of ventral
striatal response to positive stimuli in depressed ver-
sus normal subjects. Am J Psychiatry. 2006;163:1784-
1790.
18. Hasher L, Zacks RT. Automatic and effortful pro-
cesses in memory. J Exp Psychol Gen.1979;108:356-
389.
19. Hartlage S, Alloy LB, Vazquez C, Dykman B. Au-
tomatic and effortful processing in depression. Psy-
chol Bull.1993;113:247-278.
20. Jouvent R, Dubal S, Fossati P. The cost of pleasure.
In: Sebanz N, Prinz W, eds. Disorders of Volition.
Cambridge, Mass: MIT Press; 2006:307-325.
21. Dubal S, Jouvent R. Time-on-task effect in trait
anhedonia. Eur Psychiatry. 2004;19:285-291.
22. Harvey PO, Fossati P, Pochon JB, et al. Brain Re-
sources and cognitive effort in depression: a fMRI study
using the n-back task. Neuroimage.2005;26:860-869.
23. Matsuo K, Glahn DC, Peluso MA, Hatch JP. Pre-
frontal hyperactivation during working memory task
in untreated individuals with major depressive dis-
order. Mol Psychiatry. 2007;12:158-166.
24. Rose EJ, Simonotto E, Ebmeier KP. Limbic over-
activity in depression during preserved performance
on the n-back task. Neuroimage. 2006;29:203-215.
25. Walter H, Wolf RC, Spitzer M, Vasic N. Increased
left prefrontal activation in patients with unipolar de-
pression: an event-related, parametric, performance-
controlled fMRI study. J Affect Disord. In press.
26. George MS, Ketter TA, Post RM. Prefrontal cortex
dysfunction in clinical depression. Depression.1994;
2:59-72.
27. Videbech P, Ravnkilde B, Kristensen S, et al. The
Danish PET/depression project: poor verbal fluency
performance despite normal prefrontal activation in
patients with major depression. Psychiatry Res.2003;
123:49-63.
28. Ridderinkhof KR, Ullsperger M, Crone EA, Nieu-
wenhuis S. The role of the medial frontal cortex in
cognitive control. Science. 2004;306:443-447.
29. Carter CS, Botvinick MM, Cohen JD. The contri-
bution of the anterior cingulate cortex to executive
processes in cognition. Rev Neurosci.1999;10:49-57.
30. Chiu PH, Deldin PJ. Neural evidence for enhanced
error detection in major depressive disorder. Am J
Psychiatry. 2007;164:608-616.
31. Pochon JB, Levy R, Fossati P, et al. The neural sys-
tem that bridges reward and cognition in humans:
an fMRI study. PNAS. 2002;99:5669-5674.
32. Anand A, Li Y, Wang Y, et al. Activity and connec-
tivity of brain mood regulating circuit in depression:
a functional magnetic resonance study. Biol Psychia-
try. 2005;57:1079-1088.
33. Greicius MD, Flores BH, Menon V, et al. Resting-
state functional connectivity in major depression: ab-
F O C U S
59A functional brain imaging perspective in depression – Fossati MEDICOGRAPHIA, VOL 30, No. 1, 2008
APPORTS DE L’IMAGERIE CÉRÉBRALE FONCTIONNELLE À LA PHYSIOPATHOLOGIE DE LA DÉPRESSION
duction of prefrontal cortex glucose metabolism
common to three types of depression. Arch Gen Psy-
chiatry.1989;46:243-250.
49. Martinot JL, Hardy P, Feline A, et al. Left pre-
frontal glucose hypometabolism in the depressed
state: a confirmation. Am J Psychiatry.1990;147:1313-
1317.
50. Goldapple K, Segal Z, Garson C, et al. Modulation
of cortical-limbic pathways in major depression: treat-
ment-specific effects of cognitive behavior therapy.
Arch Gen Psychiatry. 2004;61:34-41.
51. Bench CJ, Frackowiak RS, Dolan RJ. Changes in
regional cerebral blood flow on recovery from depres-
sion. Psychol Med. 1995;25:247-251.
52. Mayberg HS, Silva JA, Brannan SK, et al. The
functional neuroanatomy of the placebo effect. Am
J Psychiatry. 2002;159:728-737.
cues. Biol Psychiatry. 2006;59:816-820.
58. Miskowiak K, Papadatou-Pastou M, Cowen PJ,
Goodwin GM, Norbury R, Harmer CJ. Single dose an-
tidepressant administration modulates the neural
processing of self-referent personality trait words. Biol
Psychiatry. In press.
59. Norbury R, Mackay CB, Cowen PJ, Goodwin GM,
Harmer CJ. The effects of reboxetine on emotional
processing in healthy volunteers: an fMRI study. Neu-
roimage. In press.
60. Keightley ML, Seminowicz DA, Bagby RM, Costa
PT, Fossati P, Mayberg HS. Personality influences lim-
bic-cortical interactions during sad mood induction.
Neuroimage. 2003;20:2031-2039.
61. Mayberg HS, Lozano AM, Voon V, et al. Deep brain
stimulation for treatment-resistant depression. Neu-
ron. 2005;45:651-660.
53. Mayberg HS. Modulating limbic-cortical circuits
in depression: targets of antidepressant treatments.
Semin Clin Neuropsychiatry. 2002;7:255-268.
54. Mayberg H, Brannan S, Mahurin R, et al. Cingu-
late function in depression: A potential predictor of
treatment response. Neuroreport.1997;8:1057-1061.
55. Pizzagalli D, Pascual-Marqui RD, Nitschke JB.
Anterior cingulate activity as a predictor of degree of
treatment response in major depression: evidence
from brain electrical tomography analysis. Am J Psy-
chiatry. 2001;158:405-415.
56. Canli T, Cooney RE, Goldin P, et al. Amygdala re-
activity to emotional faces predicts improvement in
major depression. Neuroreport. 2005;16:1267-1270.
57. Harmer CJ, Mackay CE, Reid CB, Cowen PJ,
Goodwin GM. Antidepressant drug treatment mod-
ifies the neural processing of nonconscious threat
L es études d’imagerie cérébrale fonctionnelle suggèrent quela dépression est une maladie impliquant de multiples sys-tèmes constitués par des structures corticolimbiques dis-
crètes mais fonctionnellement liées. On peut ainsi observer des
anomalies touchant le cingulum antérieur, le cortex préfrontal
latéral et médian, l’amygdale et l’hippocampe. Celles-ci sont à
l’origine des interactions corticolimbiques anormales qui sous-
tendent les déficits cognitifs et les biais émotionnels caractéris-
tiques de la dépression. Dans cette maladie, il existe en effet un
biais cognitif privilégiant le traitement des informations émo-
tionnelles négatives en résonance avec l’humeur altérée et les
soucis du patient. Ceci traduit probablement une prolongation
du traitement involontaire des stimuli émotionnels et l’altéra-
tion de la modulation des réponses émotionnelles aux stimuli
négatifs. Le traitement antidépresseur, médicamenteux ou psy-
chothérapeutique, contribuerait à restaurer l’homéostasie céré-
brale cognitive et émotionnelle en améliorant la connectivité des
voies corticolimbiques défaillantes. Une augmentation de l’acti-
vité dans le cingulum rostral antérieur et l’amygdale avant trai-
tement est prédictive de la réponse clinique aux traitements an-
tidépresseurs. Les études d’imagerie cérébrale, en associant les
explorations structurales et fonctionnelles, pourraient contribuer
à l’avènement de nouveaux traitements antidépresseurs régu-
lateurs de la plasticité structurale et fonctionnelle au sein du
réseau nerveux qui commande les comportements affectifs et de
l’humeur.

60 Psychoeducational interventions targeting the core symptoms of depression – CuijpersMEDICOGRAPHIA, VOL 30, No. 1, 2008
interventions are effective not only in adults with
depression, but also in the elderly,20 in postpartum
depression,21 and depression associated with gen-
eral medical disorders, including multiple sclero-
sis,22 stroke,23 and cancer.24
Psychoeducational approaches are an increasing-
ly important variant of psychological intervention.
Most are CBT-based. Not only is CBT the state of the
art approach to depression, as shown in dozens of
well-designed trials, but its techniques tend to be
very straightforward, targeted at current problems
and situations, and thus readily decomposable into
relatively easy steps, unlike most common psycho-
logical interventions, such as psychodynamic or
interpersonal therapies. Interventions focus on the
core symptoms of unipolar depression, namely, de-
pressed mood and anhedonia. The CBT techniques
used to act on these core symptoms include cog-
nitive restructuring and activity scheduling.
Psychoeducational intervention 
on the core symptoms of depression: 
the Coping With Depression course
By far the best studied psychoeducational treat-
ment for depression, widely used in the US, UK,
Netherlands, Germany, Finland, and Norway, is the
Coping With Depression course (CWD), originally
Depressive disorders have a high prevalence
1,2
and incidence,3 and are associated with huge
losses in quality of life for patients and their
relatives,4 high mortality rates,5,6 high service con-
sumption, and enormous economic costs.7,8 They
currently account for the world’s fourth largest dis-
ease burden, and are on track to become the largest
disease burden in high-income countries by 2030.9
Most depressive disorders respond satisfactorily
to drug therapy and/or psychological intervention.
Dozens of well-designed randomized controlled tri-
als bear out the efficacy of pharmacological treat-
ments,10 while other evidence indicates that elec-
troconvulsive therapy,11,12 bright light therapy,13 and
exercise14 may also be effective. Further randomized
trials testify to the efficacy of a broad spectrum of
psychological interventions, including cognitive
behavioral therapy (CBT),15,16 behavioral activation
treatments,17 marital therapy,18 problem-solving
therapy,19 and interpersonal psychotherapy.16 These
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D epressive disorders have a high prevalence and incidence,and are associated with a huge burden of disease and eco-nomic costs. Most respond satisfactorily to drug therapy
and/or psychological intervention, in particular to psychoedu-
cation. By far the best-studied example of this approach is the
Coping With Depression course (CWD). Widely used in several
countries, the CWD comprises 8 to 16 sessions, targets the core
symptoms of depressed mood and anhedonia, and can be deliv-
ered in individual, group, or guided self-help formats. It is a high-
ly structured cognitive-behavioral intervention based on social
learning theory. The therapist is essentially an instructor and par-
ticipants are students rather than patients; there is no tradition-
al psychotherapeutic relationship between the two. The CWD is
highly flexible and can be adapted to a variety of contents, target
populations, and goals, including the treatment of established dis-
ease, and primary and secondary prevention. Randomized stud-
ies have shown that it lowers the incidence of depressive disorders
in subthreshold depression, relieves existing depressive disorders,
and may also reduce the relapse rate. It is also more effective in
mild-to-moderate depression, in subjects with higher expectations
of its results, those receiving more social support, and those who
feel in control of their lives. Delivery over the Internet has many
advantages and is becoming increasingly common.
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
specific target behaviors, as well as more general
components (self-monitoring, contracting, pro-
gressive goal attainment) that are considered crit-
ical for successful CBT. 
 Flexibility of the Coping With Depression (CWD)
course
The CWD is highly flexible. Although originally de-
signed for use with adults aged between 20 and 55,
it is readily adaptable to the needs of specific target
populations and to different areas of mental health
care, in each case with appropriate modifications.
Thus, it has been examined in different age groups,
including adolescents34-36 (with the addition of con-
flict-solving skills and a less formal presentation),
and the elderly37-39 (for whom the materials have
been simplified). Variants have been developed for
minority groups,40,41 caregivers of the elderly,42 peo-
ple with chronic medical illness43 (for whom “mood
improvement” has replaced “depression” in all ma-
terials), women with postpartum depression,44 and
menopausal women.45 The CWD has also been used
to help smokers with a history of depression to stop
smoking.46 Treatment goals vary from the preven-
tion of new disease in subjects already showing
developed by Peter Lewinsohn at the Oregon Re-
search Institute in Eugene, Oregon.25 Its theoret-
ical basis is social learning theory, which views de-
pression as associated with a decrease in pleasant
and an increase in unpleasant person-environment
interactions. It sees the problems presented by de-
pressed individuals as cognitive and behavioral pat-
terns which can be unlearned or relearned. CWD
content is thus cognitive-behavioral, and designed
to train skills that can be used by the depressed in-
dividual to change these cognitive and behavioral
patterns. The modules focus on cognitive skills, re-
laxation, social skills, and how to increase the num-
ber of pleasant events (Table I).
The cognitive skills are based on Aaron Beck’s
cognitive therapy26 and Albert Ellis’ rational emo-
tive behavior therapy.27 Lewinsohn developed the
pleasant-events approach.28 Each part of the skills
training follows the same basic format. An impor-
tant characteristic is that therapists are more like
instructors and patients more like students. First,
for 1-2 weeks, the patient-students collect infor-
mation on the subject matter (negative thoughts,
pleasant/unpleasant events, stressful events, social
events). They then set a goal for what they want to
change, and develop a systematic plan to achieve
that goal. Lastly, they start working with the plan,
improving it, and determining whether it alleviates
the depression.
The original CWD comprised 12 sessions, plus
two boosters 1 and 6 months after completing the
course. Homework is a basic component. Patients
record their cognitions and behaviors, and work on
their self-change plans at home. The CWD regu-
larly stresses that the most important changes are
those that take place in everyday life.
The psychoeducational CWD is highly structured.
The patient-student works more or less indepen-
dently through a standardized psychological treat-
ment protocol that is book or Web-based. Although
treatments are mainly delivered in a group format,
individual29 and guided self-help formats29-31 are also
available, with Internet delivery coming increasing-
ly to the fore. Since there is no traditional psycho-
therapeutic relationship between the professional
delivering the intervention and the patient-student,
treatment-instruction can be delivered by a variety
of health care professionals, including psycholo-
gists, general practitioners, social workers, and
nurses. Experience has shown, however, that inten-
sive training is required to do so successfully.
Therapist-instructors may differ significantly
from one other in enthusiasm, clarity, warmth, and
group cohesiveness, as rated by their patient-stu-
dents, but there is no significant relationship be-
tween a range of instructor characteristics and
course effectiveness.32,33 This indicates that the CWD
is a psychological treatment for depression that can
be used outside the psychologist’s office, eg, in the
classroom.
A further characteristic setting the CWD apart
from other CBT interventions is the toolbox idea:
patient-students learn all the skills that help them
cope with their depression and that more or less fit
the theoretical model. These skills address several
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Content Cognitive behavioral therapy for depression in a psycho-
educational format 
Target population Patients with mild-to-moderate depression. Those with 
severe depression may also participate, but should be 
offered additional therapy
Number of sessions 8 to 16 (depending on goals and target population)
Exclusion criteria Minimal, to comply with the psychoeducational approach:
– Other severe mental disorder (bipolar disorder, suicidal 
behavior, addiction, psychosis)
– Severe hearing difficulties or visual handicap
NB: Medication and other psychotherapy are NOT  
exclusion criteria
Skills taught – Activity scheduling is a behavioral treatment teaching 
patients how to monitor their mood and daily activities,
and how to increase the number of pleasant activities
and positive interactions with their environment
– Cognitive restructuring views depression as caused by 
dysfunctional cognitions. Patients learn to identify their
dysfunctional cognitions related to depression. They 
record the situations in which the cognitions arise and 
work out how they can challenge and change them so 
that they no longer trigger depression
– Social skills training teaches skills that patients can use 
when dealing with others, including assertiveness train-
ing, communication skills, and conflict management
– Relaxation techniques have no proven effect on depression,
but are much appreciated by patients. Applied relaxation
is the most widely used technique. Patients learn to relax
before entering stressful situations
Theoretical basis Social learning theory
Some basics – Teacher/student rather than therapist/patient relationship
– Intervention focuses on the patient’s current life and how 
it can be changed in order to improve mood; early life ex-
periences and the patient’s character are never discussed
– Homework is very important (1/2 – 1 hour per day)
Table I. Outline
of the Coping With
Depression course.
studies used a waiting list control group. One study
examined outcome at 1 and 3 years’ follow-up52: the
relapse rate 60 weeks after completing the CWD was
54%. It was higher in subjects with a history of pre-
vious majordepressive episode, those in poor health,
those unsatisfied in important life areas, younger
subjects, and those more seriously depressed at the
outset. The relapse rate was similar to that in other
psychological and pharmacological treatments of
depression. However, another study conducted af-
ter successful inpatient treatment for major depres-
sive episode reported 14% relapse at 6 months in
patients receiving CWD after recovery versus 43%
in controls.53 Thus, experience with the CWD sug-
gests that CBT can be conducted in a psychoedu-
cational format while retaining both short-term
and long-term efficacy.
Multiple regression analyses using the post-test
Beck Depression Inventory (BDI) score as the de-
pendent variable and a series of other variables as
predictors have identified three significant effect
predictors of the CWD in adults54,55:
 Those with higher expectations of the course.
 Those receiving more social support.
 Those who feel in control of their lives.
Conversely, subjects with high pretest BDI scores
(severe disease) have high post-test scores. The fol-
lowing were unrelated to outcome: intelligence,
proportion of homework performed, introversion,
irrational thoughts, suicidality, alcohol or drug
abuse, and acceptance of the theoretical model of
the CWD. In adolescents, post-CWD improvement
is greater in those with more depressive symptoms
and lower in those with a depressive family history;
efficacy is also lower if the adolescents feel less co-
hesion in their CWD group.36,56
 Coping With Depression course: advantages, dis-
advantages and future prospects
The CWD is an effective and flexible intervention
that can be used in subthreshold depression to pre-
vent the onset of major depression, but also as a
some symptoms of major depression, but not yet
meeting full-blown criteria, through the regular
treatment of depressed patients, to the prevention
of relapse following successful treatment.
 Efficacy of the Coping With Depression course
Four studies have evaluated the prophylactic effica-
cy of the CWD in subjects with subthreshold depres-
sion, ie,withclinically relevantdepressive symptoms
not yet meeting the criteria for major depression
or dysthymia (Table II).31,47-49 Three concluded that
the CWD had a significant effect on the incidence
of major depression. However, it remains unclear
whether intervention prevented the onset of major
depression altogether or simply postponed it.
Several studies have assessed the therapeutic ef-
ficacy of the CWD in established depression. In a
meta-analysis of seven randomized controlled trials,
we calculated the mean standardized effect size as
0.62 (95% confidence interval: 0.44-0.85).50 This is
similar to that for other psychological16 and phar-
macological treatments.10 Several subsequent stud-
ies, including in elderly,38,39 postpartum depression,44
minority groups,41 and depressed patients in the
general population,51 have reached similar conclu-
sions, namely that the CWD is an effective treat-
ment of depressive disorders.
Several efficacy questions remain unanswered.
No study has compared the CWD to pharmacolog-
ical or other common psychological treatments,
such as standard cognitive therapy or interpersonal
therapy. Furthermore, most studies in the meta-
analysis used waiting list control groups. In a re-
cent randomized trial comparing the CWD to prob-
lem-solving treatment and a no-treatment control
group, the CWD was effective in the short term, but
less so than problem-solving therapy.51
Longer-term efficacy is less clear. The meta-anal-
ysis found the mean level of depressive symptoms
unchanged at 6 months’ follow-up.50 However, this
result was based on only six studies and no control
groups were available at 6 months because most
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First Effect on 
author, Target Inclusion Treat- Treatment Follow- DO incidence of 
year population Recruitment criteria ment N schedule up (%) MDD/dysthymia
Allart,  Adults Via local BDI 10 1. CBT 61 12  2 h CBT  6 mo 25.0 At 2 years: no 
200347 (18-65 y) media no MDD 2. TAU 41 group sessions 1 y, 2 y significant effect
Clarke, Adolescents Via health CESD >24 or 1   1. CBT 43 15 1 h CBT 1 y, 2 y Not At 1 year: 14.5% in
200148 (13-18 y) maintenance DSM IV criteria & 2. TAU 47 group sessions reported treatment group  
organization parent treated for MDD vs 25.7% in controls 
in past year, no MDD (P<0.05)
Clarke, Adolescents School CESD 24   1. CBT 55 153/4 h CBT 6 mo 1 y 17.3 At 1 year: 9.3% in
199549 (15 -16 y) screening no MDD 2. TAU 70 group sessions treatment group vs  
vs 28.8% in controls 
(P<0.01)
Willemse, Adults Primary 1 core symptom of DSM IV 1. CBT 107 Guided self-help 1 y 37.0 At 1 year: 12% in
200431 (18-65 y) care MDD + 1-3 other  2. TAU 109 CBT (self-help treatment group  
screening symptoms book + 6 brief vs 18% in controls 
but no MDD telephone contacts) (P<0.05)
Table II. Efficacy of the Coping With Depression course on the incidence of major depressive disorder in subjects with subthreshold depression.
Abbreviations: BDI, Beck Depression Inventory; CBT, cognitive behavioral therapy; CESD, Center for Epidemiologic Studies Depression Scale; DO, dropout rate; DSM-IV, Diag-
nostic and Statistical Manual of Mental Disorders, 4th ed; MDD, major depressive disorder; TAU, treatment as usual.
tivation by presenting a wide range of attractive au-
diovisual information with instructions given in
voices selected for their gender, age, language, and
accent; it can also be packaged in the client’s pre-
ferred game format, and can quickly and automat-
ically report progress and self-ratings.57 On the other
hand, patients may be unable to complete a self-help
intervention, which may result in a negative expe-
rience that could worsen a depressive episode. Nor
does everyone have ready access to the Internet. It
is not acceptable for all patients, and may miss sub-
tle nonverbal and verbal clues to client misunder-
standings.57 However, a 2007 meta-analysis of ran-
domized controlled trials of Internet-guided self-help
programs for mood and anxiety disorders found
these interventions to be highly effective when
backed by personal support (standardized effect size:
1.00).58 The Internet thus appears set to increase
the utility of the CWD as a psychoeducational in-
tervention in depression, whether for treatment or
primary and secondary prevention. 
treatment for major depression, and for relapse
prevention. However, in addition to the absence of
comparative efficacy studies and the issue of long-
term efficacy, several questions remain unanswered.
We do not know whether the CWD improves de-
pressed patients’ ability to concentrate at work. Nor
has its effects on relatives been seriously examined,
although clinical experience shows that most rela-
tives are happy that patients are encouraged to focus
on positive actions and are stimulated to change
their daily lives. However, a parallel intervention
targeting parents failed to improve CWD outcome
in depressed adolescents.35
The most recent positive development in psycho-
educational interventions for depression is Internet
delivery. It has many advantages: it saves therapist
time, abolishes the need to schedule therapist ap-
pointments, reduces the stigma of going to a ther-
apist, saves traveling time, lowers care costs, short-
ens waiting lists, allows patients to work at their
own pace, and can be programmed to enhance mo-
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L a prévalence et l’incidence des troubles dépressifs sontélevées, et associées à un lourd fardeau pathologique etéconomique. La plupart des troubles répondent de façon
satisfaisante au traitement et/ou aux mesures psychologiques, en
particulier à la psychoéducation. Le meilleur exemple de cette
approche est de loin la série de cours pratiques intitulée « S’Adap-
ter à la Dépression » (Coping With Depression [CWD]). Ces cours,
largement utilisés dans plusieurs pays, comprennent 8 à 16 ses-
sions qui ciblent les symptômes majeurs de la dépression et l’an-
hédonie. On peut participer à ces cours à titre individuel ou en
groupe ou encore« en solo », selon une approche par auto-sou-
tien guidé. Il s’agit d’une mesure cognitivo-comportementale
hautement structurée fondée sur une théorie d’apprentissage so-
cial où le médecin est essentiellement un éducateur et les par-
ticipants sont plutôt des étudiants que des patients ; il n’existe
aucune relation psychothérapeutique classique entre les deux.
Ces cours sont extrêmement flexibles et peuvent être adaptés à
un ensemble de contenus, de populations cibles et de buts y com-
pris au traitement de pathologies établies et en prévention pri-
maire et secondaire. Des études randomisées ont montré que
cette approche diminue l’incidence des troubles dépressifs dans
la dépression infraclinique, soulage les troubles dépressifs exis-
tants et peut aussi réduire le taux de rechute. Elle est aussi plus
efficace dans la dépression modérée à sévère, chez les sujets qui
en espèrent plus de résultats, qui reçoivent un soutien social plus
important et qui se sentent maîtres de leur vie. La dispensation de
ces cours par Internet présente de nombreux avantages et devient
de plus en plus pratiquée.

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ouis Pasteur (1822-1895), a chemist by training, introduced the laboratory into clinical medicine.
He was one of the first to understand the need to base medicine, and in particular the study of
infectious disease, on a rigorous experimental method. He was a contemporary and friend of Claude
Bernard, the founder of experimental medicine. Pasteur also understood that infection could be
prevented by clean technique (asepsis) and vaccination. But in a Third Republic where children
learned to think of France as having a universal mission by reciting Charlemagne’s words from the
contemporary play by Henri de Bornier: « Tout homme a deux pays, le sien et puis la France—Every
man has two countries, his own and France, » Pasteur’s vision stretched well beyond France. It made sense
only on a planetary scale. If there was to be vaccination, it had to be universal. Hence the need to have pro-
duction units, research centers, and outposts worldwide. The end of the 19th century was also the era that
saw the creation of the first major pharmaceutical companies.
The spirit of this turn-of-the-century age was militantly in favor of spreading scientific knowledge and
fighting distant disease such as plague, malaria, sleeping sickness, and leprosy. Bringing the gospel of
French science to the world was inscribed in the political ideology of the Third Republic. Colonial expan-
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cience has no country, or rather its country encompasses all humanity.” Driven by this convic-
tion, Louis Pasteur urged his students and colleagues, no sooner had they achieved the requisite
expertise, to disperse to the four corners of the earth and spread the benefits of French science in re-
sponse to the huge epidemic challenges of their time. In Paris in 1888, he opened the first Pasteur
Institute, a novel institution with a threefold remit, serving as a public health facility specializing
in rabies vaccination, an infectious disease research center, and a school of microbiological theory
and practice. All Pasteur Institutes that were subsequently set up abroad, in particular in the French
colonies from 1891 onwards, were assigned similar objectives. Institute scientists formed a community
that was inspired by a philosophy wholly oriented toward research and its practical applications, in par-
ticular teaching and the protection of populations threatened by epidemics. Eight Pasteur Institute staff
have received Nobel prizes in Medicine or Physiology since 1900. Yet the impetus behind the establishment
of many overseas Pasteur Institutes came from the adventurous fieldwork of individual investigators
wrestling with a particular problem of infection or epidemiology: Yersin with plague in Indochina, Nicolle
with typhus in Tunisia, Laveran with malaria in Algeria, Calmette with snake bites in Vietnam, and Jamot
with sleeping sickness in French Equatorial Africa. International Pasteur Institutes now number 30 mem-
ber institutions, all independent, but bound by a shared scientific philosophy and constituting a network
unique in the world.   
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sion and French diplomacy were shot through by a humanism inherited from the French Revolution, re-
vised and updated by the republican public health science of the late 19th century. It was in the name of
science that Pasteur’s disciples locked step with colonial expansionism in order to spread wide the benefits
of medical progress. The first Pasteur Institutes were set up in the humanitarian wake of French colonial
expansion and/or in countries which had formed close scientific ties with Pasteur and his earliest pupils.
Founding of the Pasteur Institute in Paris
The impetus came from Pasteur’s phenomenal success, in July 1885, in saving the life of 9-year-old Joseph
Meister after he’d been bitten by a rabid dog. This was followed by a second successful vaccination in
October the same year, performed on a 15-year-old shepherd with even more advanced disease. On the
strength of these achievements, on January 12, 1886, Pasteur felt able to write to the Count of Laubespin,
a generous philanthropist who had volunteered financial support for his research in the past: “My inten-
tion is (…) to establish a model institution in Paris without State aid, thanks to gifts and international
subscriptions. I’m confident that a single institution could suffice for France, but also for Europe, Russia,
and even North America.” 
On March 1, at the Academy of Sciences, Pasteur announced that it was urgent to establish a rabies in-
stitute, adding: “Clearly, in such an institute, we would need to train young scientists who would export
our techniques to these distant lands. We could undoubtedly do likewise for the various regions of Europe.”
A national and international subscription scheme was launched. It proved immensely successful with heads
of state, princes, and those of more modest means, whose names were printed in the French Republic’s
Official Journal. As a foundation in private law, the Pasteur Institute was directed to the public benefit by
the decree of June 4, 1887. A subscription of 2 million gold francs enabled it to buy an area of 10 000 m2
in rue Dutot in the 15th arrondissement of Paris.1-4 In January 1887, one of Pasteur’s old pupils, the biol-
ogist and chemist Émile Duclaux, founded the Annales de l’Institut Pasteur, a monthly microbiology jour-
nal designed to showcase the Institute’s work
and covering all aspects of the new discipline:
medicine, public health, biology, social as-
pects, and the industrial dimension.3
On November 18 the following year, at the
opening of the Pasteur Institute in Paris by
the President of the Republic, Sadi Carnot,
Pasteur proclaimed the Institute’s mission
as “at once a health center for treating rabies,
an infectious disease research center, and a
microbiology teaching center.” He filled the
five departments of the Institute with scien-
tists having a judicious mix of background
and scientific training: two graduates of pos-
sibly the most prestigious grande école, the
École Normale Supérieure, Émile Duclaux
in general microbiology, and Charles Cham-
The historic building of the Pasteur Institute, in Paris (1997). © Service Photo/
Institut Pasteur.
Antirabies vaccination at the “rabies barrier” at the vaccination room of the
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berland in the microbiology of public health; a biologist, Élie Metchnikoff in morphological microbiology;
and two physicians, Jacques-Joseph Grancher in rabies and Émile Roux in microbiological methods.2,3,5
The courses on offer established the Institute as a world center of microbiology teaching and a beacon of
Pasteurian research. It was also a production and distribution center for sera and vaccines. A steady flow
of donations enabled it to expand at regular intervals, building biochemistry laboratories, an infectious
diseases hospital (opened in 1900), and an outpatient wing.4,6,7
Émile Roux gave the first course, starting in March 1889. It attracted many French and foreign physi-
cians. Each session catered for 40 to 100 students and lasted 5 weeks, in facilities that were remarkably
well equipped for the period. The curriculum grew every year and was supplemented by practicals and spe-
cial lectures. After a gap during the First World War, the courses were
reinstated in 1922 by René Legroux and Julien Dumas. Roux was
appointed director of the Paris Pasteur Institute in 1904.4,6,7
Fieldwork and the founding of overseas Institutes
Enterprising fieldwork in Australia, China, Indochina, and North and
Sub-Saharan Africa produced some remarkable success stories. Al-
though only made possible by individuals blessed with resourceful-
ness and intellectual independence of the kind that drove Pasteur
himself, these successes also drew heavily upon the reputation of Pas-
teur the man, his research, his achievements, and the Paris Institute.
They included victories over anthrax and pleuropneumonia in Aus-
tralian cattle, over plague in China and Indochina, and over sleeping
sickness in French Equatorial Africa.
In November 1887, the physician Adrien Loir, Pasteur’s nephew,
tackled the epidemic of bovine infectious disease in New South Wales,
Australia. The particular threat was anthrax. Despite going off course
several times and underestimating the need to control the rabbit vectors, Loir and his two assistants man-
aged to develop an anthrax vaccine in the laboratories and production center that they set up in 1890 on
Rodd Island in Sydney Harbor. Several million head of cattle were vaccinated. Several years later, pleu-
ropneumonia was conquered in Queensland cattle in the same way. By July 1892, the Sydney Pasteur
Institute—considered the first of its kind overseas—was producing vaccines against anthrax, glanders,
and pleuropneumonia. A year later, how-
ever, Loir left Australia for “urgent personal
reasons.” Disagreements and power strug-
gles between the governors of the differ-
ent states were almost certainly responsible
for his departure. The Australian mission
foundered in under 2 years.3,7
No less than four Pasteur Institutes were
founded in the French protectorate of In-
dochina: Saigon (now Ho Chi Minh City)
in 1891, Nha Trang in 1895, Hanoi in 1925,
and Da Lat in 1936. With each Institute’s
departments dovetailing with one another,
the four institutions were headed by a single
director, beginning with Alexandre Yersin
in 1904. They had four main objectives: to
export rabies treatment throughout the Far
East; to produce smallpox vaccine locally (using young buffalo); to study (and if possible eradicate) plague;
and to counter the influence of German bacteriology which had already swept through Japan.
Albert Calmette founded the Pasteur Institute in Saigon in 1891 at the insistence of Pasteur and with the
support of the Under-Secretary of State for the Colonies Eugène Etienne. It was the first overseas French
institute of microbiology. In Saigon, Calmette met Alexandre Yersin; the friendship between Calmette,
Roux and Yersin was deep and lasting. The Saigon Institute produced enough smallpox vaccine to im-
munize all 20 million Indochinese, with supplies left over for nearby China, Macao, and Thailand. Calmette
also developed a subspecialty in snake venom antisera production. The Pasteur Institute of Nha Trang
opened in a thatched hut along the shoreline in 1895, with Yersin as its first director. The Swiss-French
Yersin, whose father died before he was born, started his medical studies in Lausanne and continued them
in Marburg, finishing in Paris in 1885. While at the Hôtel Dieu Hospital, autopsying a patient who’d died
Alexandre Yersin
(1863-1943) in front of





Adrien Loir (1862-1941), a nephew
of Louis Pasteur, headed the Pasteur
Institutes in Sydney, Tunis, and Bula-
wayo (Rhodesia). © Institut Pasteur.
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of rabies, Yersin cut his finger, and went straight to Pasteur’s laboratory in the rue d’Ulm, where he was
promptly vaccinated by Émile Roux. This was his induction into microbiology and the start of a long
friendship between the three men. In May 1894, Yersin went to Hong Kong at the request of the senator
Dr Alcide Treille to investigate the plague epidemic that was also threatening Indochina (it was responsi-
ble for 12 million deaths). He arrived on June 15 complete with culture media, microscope, and autoclave.
But the British had already called in the Japanese bacteriologist Shiba-saburo Kitasato, a graduate of the
German school of Pasteur’s personal enemy, Robert Koch. Kitasato’s British minders prevented Yersin
from taking any samples from the patients in the Kennedy Town Hospital where Kitasato had established
his laboratory. Whereas Kitasato was hunting for the plague bacilli—“small stumpy round-tipped rods”—
in the patients’ blood, Yersin sought them in the lymph nodes and buboes. On June 22, a week after his
arrival, Yersin inoculated two mice with homogenized lymph node from the leg of a Mr Olu Kuong, who’d
died in the night. From the animals’ spleens he was then able to isolate the organism that he named Pas-
teurella pestis in his master’s honor, but that since 1970 has been known as Yersinia pestis in his own
honor. In 1895, he returned to Paris to develop a plague antiserum with Roux and Calmette. He took it
back with him to Indochina, set up a manufacturing laboratory in Nha Trang, and trialled his product in
the plagues of Canton and Bombay. Yersin went on to establish Pasteur Institutes in Hanoi (1926) and
Da Lat (1936), laboratories in Hué (1922), Phnom Penh (1926), and Vientiane (1927), and a journal, the
Les Archives des Instituts Pasteur d’Indochine, in 1926.7-9
Eugène Jamot was a former military specialist in tropical diseases before being appointed director of the
Pasteur Institute in Brazzaville (Congo). He set sail for French Equatorial Africa (modern Gabon, Repub-
lic of the Congo, Central African Republic, and Chad) on July 13, 1914. In Cameroon, first-hand observa-
tion of the havoc, wreaked by sleeping sickness, determined him to overcome trypanosomiasis. Because
patients with advanced disease were unable to make their way to the nearest health center, he realized
that it was the duty of mobile health care teams to go to them, and specifically to examine every villager
living close to the watercourses infested by trypanosomes and the two main species of tsetse fly (Glossina
palpalis and G tachinoides). “Two conditions are needed for the disease to spread across a region and be-
Pasteur Institute in Ho Chi Minh City, Vietnam, founded in 1891
by Albert Calmette. © IP Ho Chi Minh-Ville / Institut Pasteur. 
Pasteur Institute in Dakar, Senegal, founded in 1923. 
© IP Dakar/Institut Pasteur. 
Hellenic Pasteur Institute in Athens, Greece (1995). 
© Institut Pasteur.
Pasteur Institute of Iran, at Tehran (1995). © IP Iran/
Institut Pasteur.
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come endemic,” wrote Jamot. “On the one hand, the patient acting as the viral reservoir, and on the other,
the insect vector.” His plan appeared absurdly ambitious: it was to protect villagers against trypanosomi-
asis by putting in place a policy that combined health education, training of nurses and administrators,
the setting up of mobile health care teams, and treatment of those already infected. Jamot’s public health
program was delivered by mobile teams operating within their defined sectors. On April 12, 1917, Jamot
received carte blanche from the Governor-General of French Equatorial Africa. Between August 1917 and
May 1919, with very modest resources, his mobile teams examined 90% of the population (89 743 inhab-
itants) over a territory of 100 000 km2. The results that Jamot presented to the Society of Exotic Pathology
were spectacular: decreases of 65% in mortality and 90% in infective risk. He defined the resources re-
quired to eradicate the disease: one European physician, three European technicians, and ten African
nurses for every 50 000 inhabitants. In March 1922, he settled in Ayos, Cameroon, where in 1925 he set
up a training center for doctors, technicians, and nurses.9-12
These are just some of the dedicated careers that distinguished the disciples of Louis Pasteur.
Different Institutes bound by a common philosopphy
Pasteur Institute scientists were undaunted in their conquest of new biomedical frontiers. Their aims, in
their own minds, were primarily to bring the benefits of French scientific progress to distant populations.
Pasteur Institutes were always established in exotic locations in response to some specific public health
and infectious problem. Thus, Albert Calmette’s mission was to protect the inhabitants of Indochina against
rabies and smallpox by vaccination; Adrien Loir’s task was to help Tunisian winegrowers to solve problems
The International Pasteur Institute Network – Régnier
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The 30 independent Pasteur Institutes total 10 000 staff in 5 continents:
 Africa: Tunisia (Tunis, 1893); Algeria (Algiers, 1894); Madagascar (Antananarivo, 1898); Morocco
(Casablanca, 1911); Senegal (Dakar, 1923); Cameroon (Yaoundé, 1959); Central African Republic
(Bangui, 1961); Ivory Coast (Abidjan, 1972); and Niger (Niamey, 1978).
 Americas: Canada (Laval, 1938); French Overseas Department of Guiana (Cayenne, 1940); French
Overseas Department of Guadeloupe (Pointe-à-Pitre, 1948); and Uruguay (Montevideo, 2006).
 Asia: Vietnam (Saigon/Ho Chi Minh City, 1891; Nha Trang, 1895; Hanoi, 1923); Cambodia (Phnom
Penh, 1913); Iran (Teheran, 1920); China (Hong Kong, 2002; Shanghai, 2004); and South Korea
(Seoul, 2003).
 Europe: France (Paris, 1887; Lille, 1898); Belgium (Brussels, 1901); Romania (Bucarest, 1901);
Greece (Athens, 1919), Russia (St. Petersburg, 1923); Bulgaria (Sofia, 1947); and Italy (Rome, 1976).
 Oceania: French Overseas Territory of New Caledonia (Noumea, 1954).
Four of the 30 are associate institutes: the Armand Frappier Institute at Laval in Quebec, the Can-
tacuzene Institute in Bucarest, the Cenci Bolognetti Foundation in Rome, and the Stephan Angeloff
Institute in Sofia.
The Pasteur Institute has also formed partnerships or associations with other foundations or insti-
tutes across the world:
 The Weizmann Institute in Rehovot (Israel), establishing in 1975 the Pasteur-Weizmann Council
devoted primarily to cancer research.
 The Pasteur Foundation of New York, a company in United States law founded in 1985 to raise funds
for the Pasteur Institute.
 The Canadian Louis Pasteur foundation set up in 1997 in Montreal and Toronto, which finances
research and grants for young Canadian scientists.
 AMSUD-Pasteur has been developing since 2002 scientific collaboration with Chile and the Mer-
cosur countries (those belonging to regional trade agreement between Brazil, Argentina, Uruguay,
and Paraguay), in particular by creating regional biotechnology centers.
 The Oswaldo Cruz foundation in Rio de Janeiro, Brazil, founded in 1902, and which has been ex-
changing research scientists and collaborating with the Paris Pasteur Institute since 2004;
 The Pasteur Association in Tokyo, which has been financing visits by Japanese researchers to
Paris since 2005.
relating to grape juice fermentation; Alexandre Yersin’s remit was to overcome human plague. These mis-
sions, which today we would call humanitarian, also advanced basic science in bacteriology, virology,
immunology, and more generally in medicine. Calmette discovered antivenom serotherapy, and it was by
treating typhus patients in the Institute set up by Adrien Loir in Tunis that Charles Nicolle unraveled the
role of lice in transmitting the disease.8,10
The Pasteur Institute International Network now comprises 30 institutions. Seven Institutes were found-
ed in Africa, Madagascar, and Indochina between 1887 and 1900, ten more in Africa, Indochina, Quebec,
Europe, and Russia between 1901 and 1940, and a further seven in Africa, Europe, and the French terri-
tories of America and Oceania between 1945 and 1980. Each is independent, with its own history, statutes,
specificities, research interests, and challenges.7 Some-
times it was at the express request of a foreign govern-
ment, such as in Athens, Teheran, or Shanghai, that
the Pasteur Institute was asked to set up a vaccination
and infectious disease research center. More rarely, the
initiative was private, as in St Petersburg, where the
Institute was founded in 1886 with the help of Adrien
Loir. But in most cases scientists from the Paris Insti-
tute on a mission abroad found themselves involved
with, and obliged to respond to, the health service needs
of the French overseas civil administration and armed
forces. Army doctors such as Jamot were crucially im-
portant in establishing and developing Pasteur Insti-
tutes in exotic locations abroad, many of which were
operated by men of exceptional caliber.7
The secret of the Network’s astonishing durability
lies on the one hand in the scrupulous independence
of individual institutes from religious or political ide-
ologies, and on the other in the bedrock of ongoing scientific research. The research remit was defined
back in 1891 with the creation of the first overseas Pasteur Institute in Saigon: to study the major infec-
tious and endemic diseases in the host country; to improve public health by eliminating epidemics through
pathogen identification, vaccination, and treatment; and to train scientists and create a research network
linked to the Pasteur Institute in Paris. To quote Pasteur: “Knowledge is humanity’s heritage.” 1,2,7
A shared passion for fieldwork united Pasteur scientists, from whatever background. In some cases they
returned again and again to a problem until it was satisfactorily solved. Thus, it was on the ground in
Hong Kong, in 1894 in the purest Pasteur tradition, that Yersin identified the plague bacillus. In his wake
came Paul-Louis Simond, on assignment in Bombay, where he elucidated the routes of transmission of
the disease. Later fieldwork by Marcel Baltazard, at the Pasteur Institute in Teheran in 1950, yielded a new
preservation method for the plague bacillus and a better understanding of pathogen cyclicity. Finally, it
was at the Pasteur Institute in Madagascar that the relationship between plague and changes in the vil-
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Jean Laigret (1894-1966), in his lab at the Pasteur Institute in Tunis,
ca 1935. He developed the first yellow fever vaccination in Dakar. 
© Institut Pasteur.
lage storage of rice was unraveled, and that Georges Girard and Jean-Marie Robic developed the first ef-
fective live attenuated vaccine in 1932. As for yellow fever, Jean Laigret, working at the Pasteur Institute
in Dakar in the 1930s, developed a vaccine that was to remain the only one of its kind for the next 30 years,
while at the Pasteur Institute in Algiers, Edmond Sergent, a settler Algerian from Philippeville (modern
Skikda), designed the country’s malaria prevention program in the 1920s.7-9
Some Pasteur scientists complemented their research by becoming anthropologists, ethnologists, or
sociologists in the belief that a better understanding of indigenous behavior with respect to infectious
diseases would inform their preventive strategies. A notable example was Army doctor Émile Marchoux in
his studies of yellow fever, typhoid, and malaria in Brazil and Sub-Saharan Africa in the early 1900s.7
The Pasteur Institute Network: a history that is written daily
Prior to 1970, Pasteur Institutes appeared isolated, without real contact with one another. Their only real
relationship seemed to be with the Pasteur Institute in Paris. Then in 1972, at the instigation of Pasteur
scientist Jacques Monod, winner of the Nobel Prize for Medicine in 1965, a council of Pasteur Institute
directors was established, with striking results. With its annual meeting and associated networking, the
council instilled an awareness into each member of their shared intellectual and human heritage and the
need to keep it healthy. At the same time, it gave rise to the concept of an international Pasteurian scien-
tific community. The name “Overseas Pasteur Institute” no longer seemed appropriate in this new con-
ceptual framework, and it was replaced in 1988 by that of “International Network of Pasteur Institutes and
Associate Institutes”  (RIIP, Réseau International des Instituts Pasteur)
In the 1980s, study groups were set up to incorporate all those within the community who were involved
in a particular line of research. Thus the virology group sprouted subgroups classified by their pathogen
of interest: arbovirus, polio enterovirus, human immunodeficiency lentivirus, human T-cell leukemia
virus, etc.
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Paris Pasteur Institute Center of Scientific Information (1995)
built thanks to a legacy from the Duchess of Windsor. © Dacbert,
J.-P. / Institut Pasteur.
The Paris Pasteur Institute’s collection of fungi (2001) the major-
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Virologist at the Pasteur Institute in Ho Chi Minh City carrying out
research work on the mutation of the H5N1 virus (2005). 
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In recent years, the multipartner regime has been formalized in a General Declaration of Scientific
Cooperation signed by all Institutes and, more recently, in a Network Charter, which determines the mem-
bership of each Institute within the Pasteurian community, with the statutory election to the Assembly
(the highest authority in the Paris Pasteur Institute) of twelve Institute directors chosen by their peers.
This reform reflects the determination of the Paris Institute to incorporate Network members in its ad-
ministration. 1991 saw the creation of the Calmette Fund, which awards training or exchange scholarships,
while an inter-State ranking commission independently monitors the careers of national researchers.
Functioning in a few Institutes only, this consultative commission could see its role expanded in response
to increased demand. The creation of a Network scientific committee to act as a think-tank for the Direc-
tor-General further enhances interaction both within the Network and between the Network and the Paris
Institute, while also promoting the Network’s potential. Various measures are also in the pipeline for ac-
celerating information exchange within the Network.
Above all, however, the Pasteur Institute Network is a collective enterprise driven by high-caliber in-
dividuals drawn from different cultures,but bound by the same faith in scientific method, and by a tra-
dition cemented on the one hand by the day-to-day problems encountered by scientists in their research
and on the other by the philosophy bequeathed to them by Pasteur himself. Still thriving after well over
a century of complete independence, the Network continues to be the world’s only such collective scien-
tific enterprise. 
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a science n’a pas de patrie, ou plutôt la patrie de la science embrasse l’humanité toute entière. »
Fort de ce principe, Louis Pasteur engagea rapidement ses élèves et ses collaborateurs à essaimer
à travers le monde pour répandre les bienfaits de la science française et pour répondre aux grands
défis épidémiques de son temps. Le premier Institut Pasteur fut inauguré à Paris en 1888. Cet
établissement d’un genre nouveau devait poursuivre trois missions: les soins et les vaccinations
contre la rage (dispensaire); les études sur les maladies infectieuses; l’enseignement de la micro-
biologie. Ces mêmes objectifs furent assignés à tous les Instituts Pasteur qui furent installés à l’étranger,
en particulier dans les colonies françaises, dès 1891. Les Pasteuriens formèrent une communauté scien-
tifique animée par une philosophie entièrement tournée vers la recherche, la diffusion des découvertes et
la protection sanitaire des populations soumises aux fléaux épidémiques. Huit chercheurs des Instituts
Pasteur ont reçu depuis 1900 le prix Nobel de Médecine ou de Physiologie. Pour autant, la fondation
d’Instituts Pasteur hors de France fut avant tout le fait d’aventures individuelles de Pasteuriens captivés
par la résolution d’une question infectieuse ou épidémiologique: Yersin en Indochine (la peste), Nicolle
en Tunisie (le typhus), Laveran en Algérie (le paludisme), Calmette (les morsures de serpent), et Jamot
en Afrique centrale (la maladie du sommeil). Aujourd’hui, le réseau des Instituts Pasteur rassemble une
trentaine d’établissements à travers le monde. Indépendants mais liés par une philosophie scientifique
commune, ces Instituts constituent un réseau unique au monde.
LE RÉSEAU INTERNATIONAL DE L’INSTITUT PASTEUR, 
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ne July Saturday in 1883, as the plane trees along the boulevard Saint-Germain in Paris strug-
gled to contain the blazing afternoon sun, a handful of men in suits and hats braved the heat
in the meeting rooms of the Saint-Simon Circle history society to learn more about an ambi-
tious new project being put forward by its two advocates: the diplomat Paul Cambon, the future
French ambassador in Madrid, Constantinople, and London, and Pierre Foncin, a geographer
with a passion for the high seas and international relations. Those seated around the table repre-
sented a broad secular and religious spectrum of what today we might call education stakeholders: the
former Minister of Education Paul Bert, two senior civil servants from the Ministries of Foreign Affairs
and Education, the apostolic missionary Father Charmetant, the Saint-Simon Circle’s treasurer, Alfred
Mayrargues, a Jew, and an academic, Paul Melon, a Protestant. This patchwork little group could have
had little idea that what it was bearing to the baptismal font has since grown into the world’s largest
cultural nongovernmental organization.
For these enlightened patriots the underlying agenda was to restore the international prestige of
France after the battering it had taken from the Prussians at Sedan in 1870. How? By setting up “a na-
tional association for propagating the French language in the colonies and abroad.”
A  T O U C H O F F R A N C E
uly 1883 saw the birth in Paris of “a national association for the propagation of the French lan-
guage in the colonies and abroad.” The Alliance Française, a cultural movement that enjoyed
a brilliant career in a 20th century scarred by the eclipse of humanism, is striding into the 21st
century in better health than ever and bursting with new projects. It functions according to three
principles that were spelled out at its inception and have remained astonishingly modern ever
since. The first, rooted in the period, was the idea of restoring French prestige, sorely undermined by
the defeat of 1870 in the Franco-Prussian war, using the peaceful weapons of language and culture, ie, by
cultural influence rather than by war. The second, virtually without precedent in France, was to rely on
a non-State association to conduct a policy of international influence. The third was to entrust the cultural
and linguistic promotion of France to foreigners. Alliances worldwide are associations in local law, head-
ed on a voluntary basis by local nationals with a love of French culture. The concept has proved extraor-
dinarily successful. From Canada to Tierra del Fuego, South Africa to the edge of the Artic Circle, Russia
to India, and China to Oceania, over 1000 Alliances now cater for 450 000 students and over 6 million
visitors to their cultural displays and events. A Foundation set up in 2007 underwrites the future of this
remarkable enterprise and helps to promote cultural diversity worldwide.   
Medicographia. 2008;30:73-83. (see French abstract on page 83)
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The ambition of using education to promote progress dovetailed quite naturally with the expansionist
drive that gripped France at the turn of the 19th century. There was, of course, much more to that drive
than the advancement of education, but education was its generous and humanist face, expressed in the
unabashed proclamation of civilizing pretensions, however politically incorrect these may sound to mod-
ern ears. But we have only to look at other cultures in other eras—Mesopotamia under Hammurabi, Greece
under Pericles, China under the Tang, Rome under Marcus Aurelius, or indeed France itself during the
Enlightenment—to realize that they too were similarly convinced of their moral, esthetic, and spiritu-
al excellence, and of the exemplary level of their so-
cial and political development. Comparison with such
peak periods in cultural achievement does not appear
unwarranted. French creativity had perhaps never been
as intense and wide-ranging as at this time in its his-
tory. In 1883, its greatest creators were in their prime:
Cézanne was 44, Monet 43, Zola, Renoir, Verlaine and
Fauré were approaching 40, while the young guard
was represented by no less than Gauguin, Van Gogh,
and Debussy. Rimbaud was in Harar, Ethiopia, while
his work was being published by Verlaine, Pasteur was
performing some of his most important work in Paris,
and Delamare-Deboutteville was inventing the mod-
ern automobile.
The history of the Alliance is interesting in that it
represents a sort of protohistory of French interna-
tional cultural policy. Until that time, cultural policy
was unofficial, conducted in only a few regions of the world, albeit with considerable influence, by a few
thousand missionaries representing a variety of religious persuasions, and accessorily, since its founding
in 1860, by the Alliance Israélite Universelle. What was special about the Alliance Française was that it
represented the emergence of a nondenominational institution inspired by scientists, writers, politicians,
and businessmen aiming to undertake concerted activity on a global scale.
Founding principles
From the outset, despite the radical differences in ideological context between that era and our own, there
were three founding principles that continue to make the venerable Alliance an astonishingly modern
institution, even by today’s standards.
The first such principle—surprising in a country that always expects so much from the State—was
the idea of relying on a non-State association for developing and implementing a policy of cultural and
educational influence abroad. The boldness of this initiative has always been the most striking feature of
the Alliance, but, depending on one’s degree of belief in the merits of central control, it has also been its
most admired and most contested feature, informing the Alliance’s ambiguous yet fruitful relationships
with the authorities throughout its long history.
The second principle was that of recruiting the charm of French culture to compensate for military
failure. The idea of erasing defeat on the battlefield through a combination of exhibitions, concerts, and
language courses was most unusual. How much suffering would countries had been spared had their bat-
tles been confined to quarrels between grammarians (however vicious these may be) or the fist-fights be-
tween Romantics and Classicists on the opening night of Victor Hugo’s Hernani?
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The third and probably most revolutionary principle was that
of Frenchmen entrusting the cultural and linguistic promotion
of their country to foreigners: as “free associations of free men,”
the various Alliances throughout the world are associations in
local law that are staffed and operated by local nationals with a
love of French language and culture.
Of all the major cultural organizations with an international
vocation—British Council, Goethe Institute, Cervantes Institute
and, more recently, Confucius Institute (all established at later
dates)—the Alliance Française is alone in operating according
to such a model. The Alliance is only French in France. Elsewhere
it is American, Bulgarian, Kenyan, or Korean. The Paris Alliance, which launched the basic idea of the in-
stitution and laid its foundations, provides long-term support, ensures consistency across the movement,
including compliance with its statutes, and helps to recruit staff seconded to the various Alliances by the
Ministry of Foreign Affairs.
From the outset, the founders excluded all sectarian and party bias and all political, religious, and ide-
ological commitment. They appealed to people of goodwill from across the opinion spectrum, to all those
enamored of the French language and concerned for its future—industrialists, merchants, shipowners,
chambers of commerce, learned societies, journalists, economists, and the like—in fact to all those inter-
ested in French expansion across the world under the exclusively peaceful guise of its language and culture.
These powerfully principled ambitions captured the immediate attention of some important public fig-
ures: the explorer Savorgnan de Brazza, Cardinal Lavigerie, the Egyptologist Gaston Maspero (founder
of the Cairo Museum), the medievalist Gaston Paris, the writers Ernest Renan and Hippolyte Taine, Gen-
eral Faidherbe, and Louis Pasteur. A board of directors was set up that included men from the most varied
backgrounds: diplomats and academics sat alongside archeologists (Salomon Reinach), historians (Ernest
Lavisse, Victor Duruy), geographers, magistrates, and publishers (Armand Colin), while religious figures
(Pastor Puaux, Chief Rabbi Zadoc Kahn) rubbed shoulders with
determined anticlericalists such as Paul Bert. The association was
registered on January 24, 1884, thereby officializing the birth of a
venture that was to extend to all five continents and survive all the
trials and tribulations of a particularly event-laden 20th century.
A dazzling debut
Active committees sprouted across France in response to public
lectures by academics such as Jean Jaurès (“the Alliance Française
can count on people flocking to it from every corner”) or the
economist Charles Gide, uncle of the writer. Jules Verne himself
set up an Alliance in Amiens, while the future head of government
Casimir-Périer founded another in Troyes. Membership applica-
tions flowed in from many countries, with committees being set
up in London, Barcelona, Tangiers, Fez, Tunis, Tokyo, Constan-
tinople, and Mexico City. But fastest of all off the mark was Mau-
ritius, known as Île de France before the British takeover: the Port Louis committee met as early as
September 1884, offering French lessons, granting scholarships, organizing concerts and celebrations,
and launching an annual French language competition that remains immensely successful to this day.
The association was registered as being of public benefit in 1886 and the Suez Canal engineer, Ferdinand
de Lesseps, became its chairman in 1887. Pierre Foncin, the first Secretary-General, was the effective ar-
chitect of the association. His first concern lay with the countries closest to home, the Maghreb, and Al-
geria in particular: “How many of the 20000 school age Muslim children are being educated in French?
6000. Is that worthy of a great nation?” The Alliance funded schools, distributed books, provided grants,
and set up its first courses for North-African adults. In Black Africa, the Alliance established thirteen
schools in Senegal. Local associations were set up on Réunion Island, in Madagascar, and even Zanzibar.
Others followed in the Eastern Mediterranean and Middle East (Greece, Turkey, Persia, and Egypt). The
Pierre Paul Cambon (1843-1924), who conceived the concept 
of the Alliance Française. A French diplomat, with postings in
Tunis, Madrid, Constantinople, and London, he signed with Lord
Lansdowne the Entente Cordiale convention between France 
and Britain in 1904 and helped resolve the Balkan Wars crisis 
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Alliance supported many French-speaking schools, regardless of denominational or nondenominational
status. It has always been very French in its commitment to secularism, remaining steadfastly neutral and
respectful in all matters pertaining to religious belief. In Asia, it was only natural for the Alliance to es-
tablish its first outposts in regions where France already had a stake, such as its renowned trading posts
in India (Pondicherry [now Puducherry], Karaikal, and Chandernagore [now Chandannagar]), and the
countries of Indochina. But associations were also set up in Canton, Peking, and Shanghai. The first Aus-
tralian committee met in Melbourne in 1890.
The Alliance appointed a General Director in Montreal in 1885. Pierre Foncin told Canadian deputy
minister Monsignor Lavelle: “Be sure to tell our brethren that from now on we shall no longer forget them
and that we love them with all our heart.” In the United States, Franco-American friendship societies ap-
plied to affiliate with the Alliance, which set up in New York and San Francisco.
In Latin America, which in the 20th century was to become the Alliance flagship, committees sprang up
in Mexico City (1885), Costa Rica, and Cuba (1886), but also in Caracas, Montevideo, Lima, Mendoza, and
Tucuman. The Rio de Janeiro Alliance was founded in 1886 and a local newspaper wrote: “we shall be see-
ing institutions on every side that regardless of nationality, age, sex, circumstances, resources, color, or
race will offer free tuition in the language in which the rights of man were first written.”
In 1889, the Alliance Française was present at the Universal Exhibition in Paris, where it was awarded
a Grand Prize, as well as three gold and five silver medals for the schools it was supporting. It should be
said that the Paris headquarters was supporting these schools with annual subsidies to the tune of over
100 000 gold francs. Such sums were raised by public lectures, balls, parties, lotteries, charity sales, and of
course banquets (in the finest restaurants—Ledoyen, Le Grand
Véfour, etc), and even by door-to-door collections. The regional
councils and Ministry of Foreign Affairs decided very early on to
support the undertaking, with the Ministry in particular prov-
ing the Alliance’s most faithful partner over the years, along
with the Ministry of Education. Beginning in 1894, a monthly
newspaper was published aimed at younger readers to inform
them about “other peoples, their customs and ways of life, the
progress they are making, the instructive examples they offer us,
and about their children and schools.” This concern for knowl-
edge about other cultures, and the taste for what today we term
cultural diversity, were fundamental to the Alliance Française
from the outset and probably one of the keys to its success.
In the years following, the Alliance developed the broad out-
lines of a thoroughly modern cultural policy. It devised lecture
tours and adult language courses, funded book publications
and scholarships for foreign speakers, and networked with lo-
cal individuals and organizations. As the historian François
Chaubet has written: “It will be difficult to reimburse at their
true value the drafts drawn by the apparatus of 20th century
cultural diplomacy on the operational methods developed by
the Alliance.”
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Poster advertising an “artistic and literary
matinee” in support of Madagascan schools,
organized in Paris by the Alliance Française
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“The bright flame of French thought”
Such was the Alliance’s expansion, both abroad and within France, that the association decided in 1913 to
treat itself to prestigious headquarters, purchased from the University of Paris, at 101 boulevard Raspail,
thanks to help from a number of publishers, including Armand Colin, Flammarion, and Hachette. Over
12000 students of French now pass through the building annually. It has a theater, auditorium, and gallery,
as well as a remarkable resource center and multimedia library.
After surviving the painful interlude of the First World War, the Alliance gained in strength, chaired or
operated by major political figures, including some future presidents of the Republic, such as Raymond
Poincaré (twice chairman of the Alliance), Paul Deschanel, and Paul Doumer. The schools subsidized by
the Paris headquarters or provincial committees were numbered in their hundreds. There were around
200 committees in the United States. In 1921 the new Soviet regime allowed the Moscow Alliance to re-
main open. Pupil numbers continued to grow in Alliances worldwide, whether in Mexico City, Buenos Aires,
Shanghai, or Sydney. New centers were set up in Czechoslovakia, Poland, Canada, Egypt, and Syria. In Paris,
leading figures came on board, including the sinologist Paul Pelliot, the sociologist Lucien Lévy-Bruhl, the
writer André Maurois, the lawyer Maurice Garçon, and General Gouraud. But the 1929 Crash had a severe
impact on the international network and encouraged the growth of nationalism, in particular in the coun-
tries that were established or reestablished after the World War. Pupil numbers in the various Alliances
declined, and financial difficulties rose to the fore.
The Roaring Twenties finally clouded over. Following the Munich agreement, the Paris headquarters
received a “sorrowful message” from the chairman of the federation of Czech Alliances, to which Georges
Duhamel, elected chairman in 1937, could respond only with embarrassed sympathy.
By 1940, the Germans had become masters of Paris. They ordered the closure of the Alliance, viewing
it as a potential hotbed of moral resistance, and dispatched its archives to Berlin, where they were care-
fully scrutinized, probably for political purposes. They were later confiscated by the victorious Russians
and shipped to Moscow, from where they were only repatriated to the Paris Alliance in October 2000. Al-
though severely depleted, they still contained handwritten letters by, among others, Marcel Proust and
Louis-Ferdinand Céline.
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THE CULTURAL DIVERSITY ISSUE
The advent of globalization has brought the issue of cultural identity and its future into much sharp-
er focus. This is not a new phenomenon, if we think back to the great empires of past millennia. But
the new communication techniques make today’s globalization different. Images, and the means by
which they are transmitted and displayed, have become universal, and they express, despite them-
selves, the primacy of economic dominion that shapes our era.
Attempts to preserve the greatest possible cultural diversity for the future give rise to a multiplic-
ity of issues relating to geopolitics, citizenship, artistic expression, economics, technology, and ecol-
ogy, to take but a few that arouse enormous tension.
It’s doubtful whether the market can be trusted to safeguard cultural and linguistic diversity, since
with a rationale of effective production at lower cost, it inevitably entails a degree of standardization.
Culture, on the other hand, more than any other “good,” has a symbolic dimension that greatly tran-
scends the use-value of goods or the contribution of cultural production to the gross domestic prod-
uct. That is why the United Nations Educational, Scientific, and Cultural Organization (UNESCO)
approved the Convention on the Protection and Promotion of the Diversity of Cultural Expressions
on October 20, 2005 by 148 votes to 4, and 4 abstentions. This was no mean victory. The Convention’s
purpose is important: it seeks to guarantee, in the cultural area, the freedom of States to define and
conduct policies that preserve the diversity of their cultural expression.
The Alliance Française sees as its vocation to campaign along the same lines. It is convinced that
the current situation, in which there is a virtually obligatory universal language, creates effective in-
feriority in intellectual and scientific discourse in all those who are not that language’s native speak-
ers. This could lead to a pernicious form of sterilization of research. The Alliance is convinced that
monoculturalism could ultimately prove highly detrimental to the capacity of innovation and that
it could also make life so monotonous that it would be scarcely worth living.
That is why the Alliance devotes so much energy to showcasing the cultures that host its many out-
posts: exhibitions and concerts in the host countries and Paris, publications, studies, backing for the
Maison des Cultures du Monde, week-long cultural festivals at the Paris headquarters, etc.
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Alliance Française centers in the world (2007). Tthe Alliance Française currently operates 1071 centers in 133 countries on all five continents.
Every year more than 450 000 students take language courses and 6 million persons attend cultural events organized by the Alliance Française.
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TODAY’S ALLIANCE FRANÇAISE NETWORK
Student numbers are growing by approximately 5% annually. Growth is highest in the major coun-
tries, such as China, India, the United States, Canada, Mexico, Russia, Brazil, Congo, South Africa, and
Angola, suggesting that French is far from a marginal demand.
Latin America, with 125000 students, is the world’s largest network, led by Brazil and Mexico, but
followed closely by Colombia, Peru, and Argentina. The largest Alliances are to be found in Lima,
Bogota, São Paolo, Mexico, Rio de Janeiro, Buenos Aires, Monterrey, and Quito. They are extremely
active on the cultural front, often bravely so, such as in Medellin, Colombia, where the Alliance puts
on classical music concerts in hospitals, orphanages, and shanty towns rocked with violence.
Europe is the second largest network, with 84563 students, but is to some extent the victim of the
monolingual bias in European Union institutions. In Central and Eastern Europe, since the fall of
the Berlin Wall, the Alliance has grown in strength, and has opened numerous branches in Russia, in
Nizhny Novgorod, Samara, Ekaterinburg, Rostov-on-Don (set up by the cellist, Mstislav Rostropovich),
Novosibirsk, and soon Irkutsk.
Asia, with 81810 students, is proving remarkably dynamic. India has the largest network (24 000
students), followed closely by China, where numbers are growing by 12% annually. The longest estab-
lished Alliances are in Hong Kong and Macao, but in the last 10 years others have been set up in
Shanghai, Canton, Beijing, Wuhan, Chengdu, Nanjing, Xi’an, Dalian, and Qingdao. Asia also has other
great Alliances to its credit, of course, such as in Singapore, Bangkok, and Seoul. The 31 Alliances in
Australia cater for 7600 students (a 16% increase). The French Film Festival organized by Sydney
and the French Festival in Adelaide are the two landmark events in the country-continent’s French
cultural calendar.
In Africa and the Indian Ocean, Madagascar heads the field (25317 students), followed, among oth-
ers, by Nigeria, South Africa, and Kenya. Numbers tend to be growing in all the anglophone countries
wanting to do business with francophone countries “in the neighbor’s language.”
Both great North American networks are showing significant expansion: Canada has 12860 students
and the United States over 20000, with major centers in Toronto, New York, and Miami. To consolidate
their futures, Alliances have embarked on a vast building movement, thanks to the French Ministry
of Foreign Affairs, which is generously topping up the investments made by the committees them-
selves. Building is currently going on in Madagascar, La Paz, Kampala, New Delhi, Miami, Lima, and
Bogota, and restoration works in Dublin, Rio, Bangkok, Karachi, and Trujillo, among other locations.
Following the closure of the Paris Alliance, the British federation agreed to a request from the Paris
board of directors to take over and manage the world network. It was a fine example of just how resilient
this large movement could be. General de Gaulle agreed to act as honorary chairman of a governing board
in London and congratulated the Alliance on having been “the first society to have rallied to the Free French
cause and placed its organization at its service.” This marked the start of de Gaulle’s unfailing benevolence
toward the institution. On October 30, 1943, in Algiers, General de Gaulle gave a magnificent speech to
mark the 60th anniversary of the founding of the Alliance française: “How was the bright flame of French
thought able to have acquired and maintained such sparkle, unless fed so liberally by other countries’
genius? I have drawn the conclusion once and for all that it is only by unfettered intellectual and moral
communication between ourselves and others that our cultural influence can expand to everyone’s ad-
vantage and conversely heighten our own worth.” He went on to add: “Organizing this communication
was the founding principle behind the Alliance Française; it remains its reason for being, and will be the
reason for the Alliance continuing with its work.”
Reconstruction
The Alliance faced tough challenges in recovering from the war years. Its coffers were empty, its archives
in Russian hands, and its network a shadow of its former self (pupil numbers were down to just 14000).
On top of which, its very existence was threatened at home by certain senior civil servants who dreamed
of replacing it with a State network more in line with French administrative tradition. Furthermore, French
prestige had been seriously undermined by defeat, occupation, and exclusion from the Big Three Yalta
Conference. The combined effect of these factors on an institution wholly given over to promoting the
influence and cultural signature of France was enough to make anyone despair. But the arrival of Marc
Blancpain as Secretary-General, first to chairman Georges Duhamel, then soon afterwards to Émile Hen-
riot, marked the start of an irresistible climb back from the brink. Marc Blancpain was a master builder.
His decades at the head of the institution (Secretary-General from 1944 to 1978, then chairman from 1978
to 1993, totaling half a century at the head of the organization) left a deep imprint on both the spirit and
practice of the Alliance in France and worldwide.
Under the Blancpain leadership, the Alliance instituted an energetic book policy, combined with the in-
troduction of new teaching methods. It developed its own textbook with a distinctive blue cover that became
known to thousands of students worldwide by the name of its author, Gaston Mauger. Alliances throughout
the world were strongly encouraged to invest in property as the only bulwark against the vicissitudes of his-
tory. The Paris headquarters were extended, but buildings also went up in Brazil, Chile, Peru, and Mexico
thanks to support from the Ministry of Foreign Affairs. New faces on the board of directors included the
psychiatrist Jean Delay, the then minister for Overseas Territories François Mitterrand, the philosopher Gas-
ton Berger, the physicist Louis Leprince-Ringuet, the poet and president of Senegal Léopold Sédar Senghor,
and Wilfrid Baumgartner, the then Governor of the Bank of France who subsequently, after leaving office
as Minister of Finance in 1962, was to prove a remarkable Alliance President until his death in 1978.
International activity and the Paris School expanded to such an extent that in 1952 a major building
program was undertaken to establish a hall of residence for around 100 students from the world over to
come and study French in Paris. This was supplemented by further new buildings on land purchased in 1961
to enable the School to cater for close on 30000 students annually. How many future celebrities on arriving
in Paris have since discovered their affinity for the French language thanks to the Alliance? Among our con-
temporaries they include the painter Zao Wou-Ki, the writers Hector Bianciotti and François Cheng, who
have both been elected to the French Academy, and Claudia Schiffer and Kenzo from the world of fashion.
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To mark the institution’s 75th anniversary, in December 1958, General de Gaulle gave a speech, this time
at the Paris headquarters, that included the since-famous phrase: “On ne résiste pas à l’Alliance Française”
(one cannot resist the Alliance Française). Modeled in language and sentiment on a celebrated maxim
by Victor Hugo on the superiority of ideas over armies, what de Gaulle had in mind was that the strength
of the Alliance lay at a level at which all resistance was futile. “For me,” he explained, “the Alliance Française
represents a permanent ambassador for what lies above and beyond politics. It transcends the mundane;
it operates above difficulties, divisions, and criticism. It is the ambassador of all that is modern in the ac-
tions of France.”
The three boom decades following the Second World War were good for the Alliance too. Its centers
became dotted over the five continents, thanks also to the new luster that France had started to acquire.
Politically committed intellectuals, daring architecture, and undisputed supremacy in the fashion world
leveraged the reexpansion of the Alliance, along with films and popular songs that somehow managed to
be hits both at home and across the world. In addition, Philippe Greffet, who was appointed secretary-gen-
eral in 1978, obtained enthusiastic backing from the Ministry of Foreign Affairs: as a result, in the 1980s,
the number of expatriates seconded to head local boards of directors increased to almost 500. This was an
opportunity for the young teachers concerned to discover multiple facets to their calling: they were just
as likely to have to equip a building or repair an aging roof as to plan lessons, recruit colleagues, set them-
selves a budget, manage staff, or advertise their Alliance’s events. They became transformed almost overnight
from civil servants into heads of small companies. Their other duties were to welcome visiting lecturers,
organize dinners, prepare shows and exhibitions, showcase films, and work on projects with local partners,
in every case with a great measure of freedom and unhampered by bureaucratic inertia. Most of those giv-
en such opportunities became disinclined ever to work under different conditions.
In 1982, partnered by the Ministry of Culture, the Alliance set up, at its Paris headquarters, the Maison
des Cultures du Monde, which for the last 25 years has been introducing the French public to the most
authentic and diverse expressions of artistic inspiration from around the world (www.mcm.asso.fr). At
the 1983 centenary attended by some 400 national and international delegates at the Comédie Française,
President Mitterrand paid tribute to “the Alliance Française, this exceedingly rare combination of exper-
imentation and tradition, which adds grandeur and beauty to our lives.”
What are the ingredients of the combination?
The several ingredients begin with the way in which the Alliance is organized. The network does not oper-
ate hierarchically. Perhaps the closest model is that of a neuronal network, ie, a constellation of elements
in continuous interaction, yet each remaining autonomous while freely attached to the network. This ex-
plains why all the Indian, Canadian, Brazilian, Chinese, or Ghanaian administrators, for example, feel them-
selves to be fully responsible for their local associations and why they probably put far more energy into
running them than they ever would on behalf of an employer or institution reporting to another State.
Among other ingredients is the Alliance’s unique capacity for integration. The very fact that it is an in-
stitution in local law operated by local citizens effectively involves each Alliance in the hopes and high points
of the host society, but also in its political and social hazards. There are any number of examples. During
the years of military repression in Latin America, when all intellectual and artistic activity was banned, the
Alliance was a haven for the intellectuals, students, and artists who were preparing their countries’ futures
and who, later, were to be generous in making their gratitude known. The serious economic crisis that
struck Argentina early this millennium did not spare the Buenos Aires Alliance, but it has since got back
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onto its feet, along with the country itself. Although the war in Afghanistan has led to the closure of the
Alliances in Pakistan, the premises and activities of those in Madagascar remained untouched through-
out the disturbances—in particular, the anti-French movements—that marked the last presidential elec-
tions in this country. Why? Because they were seen as Malagasy, not French. The same applied when France
fell out with the United States over the invasion of Iraq. The American Alliances were able to trade on their
home-grown patriotic legitimacy to curb local tempers and keep relations on an even keel for the future,
while in Paris the Alliance held high the torch of friendship between peoples, over and above transient
differences, however bitter these might be.
Integration is not an empty word. The readiness of the Alliances in the Indian Ocean to pitch in along-
side the local authorities after the tsunami in December 2004 gives an even better understanding of why
local populations can feel so strongly attached to “their” Alliances. Both the Bangkok and Colombo Al-
liances set up emergency reception centers for the stricken populations and coordinating centers for the
aid services. This shoulder-to-shoulder solidarity by an institution embedded in the surrounding social fab-
ric is without doubt one of the Alliance movement’s moral beauties, and perhaps its deepest raison d’être.
A final ingredient worth highlighting is the flexibility of the Alliance formula, its “off-road” capability.
Being apolitical and nondenominational, the Alliance can adapt to virtually any social environment: it can
set itself up in Vancouver just as readily as in Bangui in the Central African Republic, or as in Medellin, or
Ulan Bator; it’s as comfortable in the township of Soweto as in the swish sections of Washington or Boston,
or in the outskirts of Calcutta as in the port city of Rotterdam. Climatic extremes are no deterrent: the
southernmost Alliance outpost is in Ushuaia, in Tierra del Fuego, and its northernmost in Skellefteå, in
northern Sweden, at the edge of the Arctic Circle.
The Alliance’s current missions
During Jean Harzic’s term as Secretary-General from 1988 to 2001, and subsequently, commitment to the
Alliance ideals remained strong and it has continued to expand worldwide, despite a sharp decrease in
the resources earmarked for cultural activity outside France and a consequent drastic reduction in State
support. The traditional missions of the Alliance (French teaching, cultural exchange, and the provision
of documentary resources) still constitute the “hard core” of its activities, but they have adjusted to some
contemporary developments. The combination of a globalized economy, a job market that demands in-
creasingly qualified workers, a technological boom, and occupational nomadism has made “education
without borders” a reality. At the same time, it has turned foreign language teaching into a highly com-
petitive market, one in which French has the significant advantage of being perceived as stripped of any
imperialistic ambition. French is now seen as a language, perhaps the language, of culture and commu-
nication, not as a language of domination. The francophonia movement is becoming stronger, attracting
new members, and organizing itself along federal lines. The Organisation Internationale de la Franco-
phonie (OIF) receives some surprising membership applications, with the French-speaking population in
some member states amounting to no more than 1%. 
Motivations change with the changes in ways of life, the acceleration in communication, and the habit
of international travel for work or tourism. Courses and activities need to meet the urgent and specific
needs of people who travel more and more often, with less and less time at their disposal. Cultural ac-
tivities—whether plastic arts, theater, dance, concerts, or festivals—are often conducted with the sup-
port of the French embassies and Culturesfrance, an offshoot organization from the Ministries of For-
A  T O U C H O F F R A N C E

















eign Affairs and Culture for the international promotion of the arts
(www.culturesfrance.com). The flexible status of the Alliances, and
the fact that they are locally based, are a great advantage in simpli-
fying administrative procedures, bringing partners on board, and
ensuring better project penetration among the local population.
For a long time the Alliances provided only paper documentary
sources on France and French-speaking cultures. These were then
expanded to include film archives, until they have now mush-
roomed into full-fledged multimedia centers. At the same time,
culture is not confined to the theater, cinema, or dance. It also en-
compasses technology, research, and theory. If French is to remain
a living language in the era of the global village, it must be a vehi-
cle in which its users can portray their history and debate any issue
of contemporary concern, whether ecology, bioethics, multicul-
turalism, conservation, or the relationships between religion and
politics, and between public security and human rights. Over the
years the Alliance has developed a kind of practical genius for in-
ternational cooperation and a universal network of friends and sup-
porters. As such, it is being increasingly invited to take up where
the cultural activities of the embassies leave off, with an opera-
tional scope broadened to the entire field of cooperation.
Thus in Asmara, Eritrea, the Alliance subsidizes the publication of works on oral poetry and history;
it also supports studies on the Nara and Dahalik languages, and offers grants for master’s degrees at the
Sorbonne. In Zimbabwe, despite the shortage of fuel, foreign currency, and staple foods, the Alliance or-
ganizes music-making workshops between French and local musicians. In Nairobi, it helped stage a Victor
Hugo play in Swahili in the home of a French director, while in Ulan Bator the recently established Alliance
hosted a symposium with the local Academy of Sciences on European archeology. It was the Alliance,
which, with the Louvre and French National Library, brought restorers together from Ecuador, Bolivia,
Peru, and Venezuela for a seminar on restoration in the graphic arts. In Kingston, Jamaica, the Alliance
broadcasts Radio France 1 programs. In the Unites States, Alliances have hosted talks by the paleontolo-
gist Jean Clottes and the French Academician Hélène Carrère d’Encausse. Their Canadian counterparts
have organized debates on Islam and multiculturalism. The Washington Alliance has presented a festival
of films never shown in the United States, from Mauritania, Vietnam, Egypt, Morocco, France, and the
Lebanon. The movement can claim a long litany of locally significant achievements.
A new phase: the Alliance Française Foundation
In 1923 the celebrated grammarian André Thérive
published a book entitled “Le Français, Langue Morte
[French, a Dead Language].” He clearly wasn’t a latter-
day Nostradamus. Admittedly, once the country became
reconciled to its loss of cultural and diplomatic preem-
inence, a couple of decades went by in which French
sought to reposition itself. But perhaps now it is find-
ing that position as the embodiment of a cultural and
political alternative, a certain idea of quality of life, and
a novel approach to the environment. Just as Latin did
not displace Greek, which remained very much alive
as a language of culture and trade in Greece and Asia
Minor, so the French language, at the confluence of a
variety of African, Asian, and American cultures, can,
in the view of the Alliance Française, aim for a similar
mediator role.
Be that as it may, it is important for the linguistic
diversity battle to be joined, in particular by respected
institutions—no more so than in Europe itself where
the “maximin” principle threatens to become the norm
for communication within the Union’s institutions. This
concept from practical linguistics entails the maximiza-
tion of minimum competence, ie, when several people
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French across the world
 French is the mother tongue of 80 million people (the world’s
11th largest language group). It is the second language of 100
million speakers.
 250 million people are “occasional users of French.”
 82.5 million children and young adults are learning French or
studying in French outside France (total teachers: 900 000).
The Alliance Française
 The Alliance is present in 134 countries on all 5 continents. In
total there are 1074 Alliances and associated centers, 761 of
which teach 450 000 students.
 The network comprises over 8000 voluntary administrators,
and 11 000 staff, including 7 800 teachers. Receipts exceed 110
million euros, plus 3 million euros in local public funding, and
another 3 million euros from private contributions. A total of
206 Alliances own their premises, while 182 are accommodated
rent-free, generally by their local authority.
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Alliance Française Center in
Ziguinchor, Senegal. © Al-
liance Française. 
with different languages need to communicate, the language they choose must be that best known by the
member of the audience who knows it least. Under the maximin principle, in any political gathering com-
prising over 20 languages, convergence to a single one of them, English, appears inevitable.
Based on another linguistic concept, the Humboldt-Sapir-Whorf hypothesis, named after its main pro-
ponents, we have reason to believe that the structure of a language determines the way in which we see
the world. In other words, sharing a language means sharing a view of the world. It is therefore impor-
tant that ideas get an opportunity to be formulated in languages other than the dominant language, if
we are to escape what George Orwell, in his preface to Animal Farm, called “the gramophone mind.”
In this sense the Alliance Française con-
siders that its mission extends beyond sim-
ply expanding the influence of French lan-
guage and culture. It involves what the
literary historian Marc Fumaroli (1932-)
has defined as the French art of “untying
tongues and thawing hearts.” Its banner is
the “diversity” esthetic that Victor Segalen
(1878-1919), physician, poet, and sinolo-
gist, celebrated as essential to our devel-
opment.
Once it had launched the international
movement in 1883, the Paris Alliance was
essentially a provider of moral support, in
the absence of sufficient resources of its
own. However, in a world harboring fresh
communicational and organizational chal-
lenges, the Paris Alliance is facing increas-
ing demands to improve the coordination
and development of the network it spawned, upgrade the services on offer, enhance local staff training,
and support individual Alliances in their cultural undertakings and equipment requirements. It was there-
fore decided to establish an international foundation to provide individual Alliances with the requisite
intellectual, moral, and technical support for continuing their work. An additional remit of this founda-
tion, which comprises experts in association management and operational development alongside train-
ing and cultural affairs consultants, is to map out the broad directions to be taken by the Alliance move-
ment and to reflect the ambitions shared within this vast collective enterprise.
Such then is the portrait of the Alliance Française as it seeks to embody, under contemporary guise and
with renewed impetus, the grandiose ambitions expressed by its bearded and behatted founding fathers
one 19th century July afternoon in a little room on the boulevard Saint-Germain. 
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n juillet 1883 naît à Paris l’Alliance Française, « association nationale pour la propagation
de la langue française dans les colonies et à l’étranger », mouvement culturel qui connaîtra
une brillante carrière à travers un XXe siècle où faillit sombrer l’humanisme, et qui aborde
le XXIe en pleine prospérité, avec de nouveaux projets. Le mouvement repose sur trois principes
d’une surprenante modernité. Le premier consistait à l’époque à tenter de restaurer le prestige
de la France, entamé par la défaite de 1870, en empruntant les voies pacifiques de la langue et
de la culture. Le rayonnement culturel plutôt que la guerre, en somme. Le second principe, assez peu dans
la tradition française, est de miser sur une association non étatique pour mettre en œuvre une politique
d’influence internationale. Le troisième est de confier le rayonnement culturel et linguistique de la France
à des étrangers. En effet, les Alliances à travers le monde sont de droit local, dirigées bénévolement par
des nationaux qui ont l’amour de la culture française. La formule connaîtra un succès extraordinaire.
Du Canada à la Terre de Feu, de l’Afrique du Sud aux limites du cercle polaire, de la Russie à l’Inde, en
Chine comme en Océanie, plus d’un millier d’associations accueillent aujourd’hui plus de 450 000 étu-
diants, et plus de 6 millions de personnes aux manifestations culturelles qu’elles organisent. Une Fonda-
tion est créée en 2007 pour à la fois assurer l’avenir de cette entreprise exceptionnelle et contribuer à la
promotion de la diversité culturelle dans le monde.
L’ALLIANCE FRANÇAISE : PETITE HISTOIRE D’UNE GRANDE INSTITUTION
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Alliance Française Center in Nairobi,
Kenya. © Alliance Française. 
Building housing the Alliance Française Cen-
ter in Taibei, Taiwan. © Alliance Française.
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 Manuscripts should be provided on word-processor disks
(3.5-in, for IBM, IBM-compatible, or Apple computers) with
one (1) hard copy (text and figures) printed on one side of
standard-sized white bond paper, double-spaced, with 2.5-cm
margins. Pages must be numbered. Standard typed page =
25 lines of 75 characters (including spaces) double-spaced,
2.5-cm margins=a total of about 250 words per page.
 All texts should be submitted in English. In the case of
translations, the text in the original language should be in-
cluded.
 Provide black and white photograph(s) of author(s).
 On the title page, provide: a title (concise and informative);
full names of authors (first name, middle name initial, and
last name); highest academic degrees (in country-of-origin
language); affiliations (names of department[s] and institu-
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(no more than 50 letters and spaces), keywords (5-10); corre-
sponding author’s complete mailing address and telephone
No., fax No., and e-mail address; acknowledgments (on title
page, or at end of main text).
 Include an Abstract of 200-250 words (1 standard typed
page) for all texts except Editorials and replies to the Contro-
versial Question.
 Figures and Tables. Submit figures as two sets of clear
glossy prints. Figures should be of good quality or profession-
ally prepared, numbered according to their order, with proper
orientation indicated (eg, “top,” or “left”), and fully explicit
legends provided, not repetitive of text. All abbreviations used
should be explained in the legends. As figures and graphs may
need to be reduced or enlarged, all absolute values and statis-
tics should be provided. Illustrations will be reproduced in
full color only when clearly necessary, eg, images from nu-
clear medicine or histology. Provide each table on a separate
sheet, with title above and description below. All figures and
tables should be cited in the text, with distinct numbering for
figures and tables.
 Note that Editorials and Abstracts will be published in En-
glish and French. Translations into French will be provided
by the Publisher’s Editorial Department. 
 Include Headings using a consistent style for the various
levels of headings, to highlight key points and facilitate com-
prehension of the text. The Editorial Department reserves the
right to add or delete headings when necessary.
 Abbreviations should be used sparingly and expanded at
first mention. A list of selected abbreviations and acronyms
should be provided (or will be prepared by the Editorial De-
partment) where necessary. 
 Use Système International (SI) units.
 Use generic names of drugs.
 All references should be cited in the text and numbered
consecutively using superscript arabic numerals. Presenta-
tion of the references should be based on the Uniform Requi-
rements for Manuscripts Submitted to Biomedical Journals.
Ann Intern Med. 1997;126:36-47 (“Vancouver style”). The
author-date system of citation is NOT acceptable. In press ref-
erences are to be avoided. In the bibliography, titles of jour-
nals should be abbreviated according to the Index Medicus.
All authors should be listed up to six; if there are more, only
the first three should be listed, followed by “et al.” Where
necessary, references will be styled by the Editorial Depart-
ment to Medicographia copyediting requirements. Authors
bear total responsibility for the accuracy and completeness
of all references and for correct text citation. Example of style
for references:
1. Ouriel K, Geary K, Green RM, Geary JE, DeWeese JA. Factors
determining survival after ruptured abdominal aneurysm. J Vasc
Surg. 1990;11:493-496.
2. Darling RC, Brewster DC, Ottinger LW. Autopsy study of unop-
erated abdominal aortic aneurysms: the case for early resection.
Circulation. 1977;56(suppl II):II161-II164.
3. Schulman JL. Immunology of influenza. In: Kilbourne ED,
Alfade RT, eds. The Influenza Viruses and Influenza.Orlando, Fla:
Academic Press Inc; 1975:373-393.
Speci f ic  formats
 Editorial: 1500 words or 6 standard typed pages. No abstract
or illustrations should be included. A French translation of
the Editorial will be provided by the Editorial Department
and submitted to the author. 
 Replies to the Controversial Question: 500-750 words or
2 standard typed pages. References, if cited, should in no case
exceed 10. No abstract or illustrations should be included.
 Theme - Focus - Update - Interview - Touch of France: Ab-
stract: 250 words (1 standard typed page); main text: 3500
words (10 standard typed pages). References: their number
should not exceed 50. Illustrations (figures and tables): their
number should not exceed 5 unless clearly necessary.
Editor ia l  process ing
 Editorial style: All contributions to Medicographia will be
styled by the Editorial Department according to the specifi-
cations of the current edition of the American Medical Asso-
ciation Manual of Style, Williams & Wilkins.
 Page proofs and editorial queries will be sent to the cor-
responding author for approval and should be returned with-
in 5 days by fax AND express mail. If this deadline is not met,
changes made by the Editorial Department will be assumed
to be accepted by the author. Authors are responsible for all
statements made in their work, including changes made by
the Editorial Department and authorized by the author. Ar-
ticles and abstracts will be edited to required length or re-
turned to the author if specific requirements are not com-
plied with.
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 For reproduction of copyrighted work, it is the author’s re-
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authorizations with the manuscript.
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